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Dysregulation of normal cell function either via evasion of death signals or 
amplification of pro survival signals, is a tumorigenic defining characteristic. 
Chemotherapeutic agents therefore target these abnormal signaling pathways, in an 
attempt to induce death or at least, inhibit oncogenic proliferation. Unfortunately, 
tumors quickly acquire resistance to such drugs, thus explaining the interest in new 
compounds that could either induce death in these resistant phenotypes or sensitize 
them to current drug treatments. 
  
LY303511 (LY30) is an inactive analogue of the PI3K inhibitor LY294002 (LY29), 
frequently used in studies as a negative control to its active counterpart, LY29. Initial 
LY29 treatment in tumor cells resulted in intracellular generation of H2O2 that was 
thought to involve the pro survival PI3K-AKT axis. However, another PI3K inhibitor, 
wortmannin, was unable to trigger intracellular H2O2 production, suggesting that 
generation of intracellular H2O2 was specific to the LY29 compound alone. This 
observation was supported by further evidence demonstrating that LY30 treatment 
could also generate H2O2 in tumor cells. 
 
Further studies with LY30 showed that it was able to enhance sensitivity of prostate 
carcinoma cells to vincristine via its generation of intracellular H2O2 by augmenting 
caspase activation, leading to DNA fragmentation and eventual apoptosis. LY30’s 
novel PI3K-independent anti tumor activity implied that there were potential side 
effects associated with the use of LY29. It also further corroborated the role of H2O2 as 
an apoptotic effector, whereby H2O2-mediated alteration of the intracellular milieu 
could sensitize cells to drug-induced apoptosis. At the same time, the proven 
physiological significance of LY30’s (and LY29’s) ability to generate intracellular 
H2O2 in this system of drug sensitization could also account for the few reported PI3K 
independent effects of the LY compounds in current literature, given the ability of 
H2O2 to affect cellular physiology in a pleiotropic manner, thus providing a common 
link for these reported PI3K independent effects of both LY29 and LY30. 
 
Intriguingly, the activity of LY30 was not purely restricted to its generation of 
intracellular H2O2. LY30 could also sensitize cervical carcinoma cells to TRAIL 
mediated apoptosis via enhanced signaling of the TRAIL receptor, DR5, at the cell 
surface, resulting in enhanced Death Inducing Signaling Complex (DISC) assembly, 
increased caspase activation, as well as mitochondrial apoptotic events like cytochrome 
c and Smac/Diablo release, suggesting that LY30 may have more than one mode of 
action in the cell. The anti tumor activity of LY30 in these different apoptotic models 
also indicates further potential for other LY30 like small molecules in enhancing tumor 
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1. DEVELOPMENT OF ONCOGENECITY 
Life and death are flip sides of a coin, co existing side by side in equilibrium. When 
this equilibrium is thrown awry, cancer develops. The ability of a proto-oncogene 
involved in normal cell growth and proliferation, to switch to an oncogenic form 
thereby pushing cells into sustained proliferation or endowing them the property to 
resist death signals, confers onto it, its tumorigenicity. For example, a slight pro-
oxidant intracellular milieu is linked to genome instability (Morgan et al., 2002), 
implicated in survival signaling and inhibitory to death execution signals. These 
observations provide novel effector pathways of growth and cell fate regulation, 
which in turn, present novel avenues for intervention to bring oncogenesis under 
control. These processes are under multifactorial controls and involve the malfunction 
of cellular controls at the genetic and protein level. This has been elegantly 
demonstrated with growth regulating genes such as c-myc, h-ras, Akt/Protein Kinase 
B (PKB), c-jun and the bonafide tumor suppressor proteins, most notable being p53 
and Retinoblastoma (Rb), of which, the Akt oncogenic pathway will be subsequently 
reviewed in this thesis. To that end, recent observations have highlighted the critical 
intracellular microenvironment, in particular the cellular redox status as mediated by 
the reactive oxygen species (ROS), in regulating cell survival and death signaling and 
thereby playing a causative role in the process of cellular transformation. 
 
2. TYPES OF CELL DEATH 
 2
While hyperactivation of proliferative signals is a symptom of a (proto)oncogenic 
cell, we must not forget that evasion of the death signal is also an important 
component in the continued development of a normal cell to a cancerous one. It is no 
surprise therefore that the current literature abounds with studies on different types of 
cell death and how to induce them in tumour cells both at the in vitro and in vivo 
level. There are a variety of cell death types, which can be loosely classified as 
“programmed” and “non-programmed”. Programmed cell death processes include 
apoptosis and autophagy. An example of non-programmed cell death is necrosis. 
Apoptosis is a form of programmed cell death that cells undergo, through blebbing 
and shrinking (Hengartner, 2000), as opposed to the messier form of cell death, 
necrosis, where the cells swell and burst, releasing inflammatory cytokines into the 
surrounding milieu. In the intermediate states between life and death however, exists 




Necrosis, in comparison to apoptosis, appears to be an uncontrolled and pathological 
form of cell death. A necrotic phenotype often includes massive mitochondrial 
depolarization and depletion of intracellular ATP, disturbance of Ca2+ homeostasis, 
activation of DNA repair protein poly(ADP-ribose) polymerase (PARP), activation of 
nonapoptotic proteases and generation of ROS (Zong and Thompson, 2006).  
 
 3
2.1.1 The necrotic process 
Loss of function of the mitochondria electron transport chain in response to a necrotic 
stimulus disrupts ATP production, resulting in mitochondrial depolarization. This can 
also bring about a failure of the ATP-dependent ion pumps on the plasma membrane 
leading to the opening of a so-called death channel in the cytoplasmic membrane that 
is selectively permeable to anions. Opening of this death channel would then result in 
colloid osmotic forces and entry of cations that drive the plasma membrane swelling 
and eventual rupture and release of cellular contents into the extracellular milieu, 
triggering an acute inflammatory response characteristic of the necrotic process.  
 
Dysregulation of the intracellular ROS balance could result in necrotic levels of ROS 
in the cell. ROS can result in lipid oxidation, again bringing about a loss of integrity 
in the plasma membrane and other membrane organelles leading to an intracellular 
leak of proteases or a necrotic influx of Ca2+. ROS can also damage DNA by causing 
cleavage of DNA strands, DNA-protein cross-linking and oxidation of purines. This 
process is often mediated by the highly reactive hydroxyl radical. Although the DNA 
damage response of the cell includes apoptotic activation of p53, it can also result in 
hyperactivation of PARP, which catalyzes the synthesis of poly(ADP-ribose) 
polymers on histones and other chromatin-associated proteins in the vicinity of the 
DNA adduct (D'Amours et al., 1999). This process depletes cellular levels of β-
nicotinamide adenine dinucleotide (NAD) as it is the substrate for poly(ADP-
ribosyl)ation, thus, depleting the cellular levels of aerobic glycolysis dependent ATP, 
which is dependent on NAD.  In relation to this, a recent study (Zong et al., 2004) 
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shows that alkylating DNA damage stimulates a regulated form of necrotic cell death 
through PARP mediated depletion of intracellular cytosolic NAD levels. Increasingly, 
studies are starting to show that necrosis can be a regulated event involving many 
developmental, physiological and pathological scenarios. In the study by Zong et al., 
2004, cells using aerobic glycolysis to support their bioenergetics undergo rapid ATP 
depletion and death. In contrast, cells catabolizing nonglucose substrates to maintain 
oxidative phosphorylation are resistant to ATP depletion and death in response to 
PARP activation, due to their non-dependence on intracellular cytosolic NAD levels. 
This could also explain how DNA-damaging agents can selectively induce tumor cell 
death independent of p53 or Bcl-2 family protein; as most cancer cells maintain their 
ATP production through aerobic glycolysis, preferential depletion of cytosolic NAD 
through PARP activation would bring about a regulated form of cellular necrosis. 
 
2.2 Autophagy 
Autophagy is a cellular process that causes degradation of long-lived proteins and 
recycling of cellular components to ensure survival during starvation. During this 
process, the cytoplasmic contents are engulfed in a double-membraned structure 
referred to as the autophagosome, which then fuses with lysosomes, where the 
contents are delivered and degraded by lysosomal hydrolases (Lockshin and Zakeri, 
2004). The autophagy-related genes (ATG) found to regulate this process include 
Beclin1, which is required for autophagosome formation (Gozuacik and Kimchi, 
2004). Beclin 1 is part of the phosphotidylinositol-3-kinase (PI3K) class III lipid-
kinase complex that induces autophagy and activity of this complex is suppressed by 
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the binding of Beclin 1 to the anti apoptotic protein, Bcl2 (Liang et al., 1999). In fact, 
Beclin 1 was first discovered in a screen for Bcl2 binding partners (Liang et al., 
1998). The ability of Bcl2 to suppress autophagic process suggests cross talk between 
the apoptosis and autophagy signaling pathways. Indeed, components of the pro 
apoptotic pathway like Tumor Necrosis Factor (TNF) (Djavaheri-Mergny et al., 
2006), TNF Related Apoptosis Inducing Ligand (TRAIL) (Mills et al., 2004) and Fas 
Associated Death Domain (FADD) (Thorburn et al., 2005) have been shown to 
induce autophagy as well. A recent report has identified a novel coiled-coil UV 
irradiation resistance-associated gene (UVRAG) as a positive regulator of the 
Beclin1-PI(3)KC3 complex by associating with the Beclin1-Bcl-2-PI(3)KC3 
multiprotein complex, where UVRAG and Beclin1 interdependently induce 
autophagy (Liang et al., 2006). Autophagy has also been suggested as a way to 
conserve energy and nutrients under detrimental extracellular conditions (Lum et al., 
2005). In such cases, the mammalian target of rapamycin (mTOR), a downstream 
substrate of Akt activation, is suppressed, resulting in decreased cell growth and 
autophagy (Sarbassov dos et al., 2005). Further, activation of PI3K- Akt pro survival 
pathway in human colon cancer HT-29 cells has been shown to suppress autophagic 
sequestration. It would appear that well known signaling pathways regulating 
apoptosis would play a similar role in autophagy as well (Arico et al., 2001).  
 
Interestingly, a recent report (Yu et al., 2006) has also demonstrated that inhibition of 
caspases can cause selective autophagic degradation of intracellular catalase, leading 
to excessive ROS accumulation, lipid peroxidation and eventual autophagic-
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programmed cell death. Chemical inhibition of autophagy by chemical compounds or 
knocking down the expression of key autophagy proteins such as ATG7, ATG8, and 
the death inhibitory receptor interacting protein (RIP) blocks ROS accumulation and 
cell death suggesting a link between ROS and autophagy in non apoptotic 
programmed cell death.  
 
2.3 Mitotic catastrophe 
Mitotic catastrophe as previously mentioned, is not a form of cell death but rather, an 
irreversible trigger for death. It is due to aberrant segregation of chromomsomes 
during mitosis resulting in inhibition of cell cycle progression and activation of DNA 
repair machinery or checkpoints (Castedo et al., 2004). A deficient cell cycle 
checkpoint would result in death. Various chemotherapeutic drugs (vincristine, 
daunorubicin) act via induction of mitotic catastrophe by causing microtubule 
depolymerization, resulting in detachment of the kinetochores. The relative success of 
these agents in inducing mitotic catastrophe induced death in tumour cells can be 
accounted for by the lack of cell cycle checkpoints in these cells that resulted in their 
tumorigenesis in the first place. Mitotic catastrophe is regulated by various proteins 
especially the cell – cycle – specific kinases like the cyclin B1 dependent kinase 
(Cdk1), polo-like kinases and Aurora kinases, cell cycle check point proteins, 
survivin, p53, caspases and members of the Bcl-2 family. Activation of the 
Cdk1/cyclin B complex is necessary for cells to progress from the G2 to the M phase 
however its degradation by the anaphase promoting complex (APC) is necessary for 
entry into anaphase (Nigg, 2001). The tight spatiotemporal regulation of these cell 
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cycle specific kinases prevents aberrant mitotic entry before the completion of DNA 
replication. In fact, increased nuclear cyclin B1 has been found in numerous examples 
of pharmacologically or genetically induced mitotic catastrophe (Winters et al., 1998, 
Yoshikawa et al., 2001). Survivin, a member of the inhibitor of apoptosis protein 
(IAP) family, plays an interesting role at the interface of the mitotic checkpoint 
control and apoptosis suppression. As an IAP, it has been shown to inhibit caspases, a 
function that will be discussed in later sections in relation to apoptosis. However, it is 
also a substrate of Cdk1 and contributes to the spindle checkpoint as part of a 
complex with the cell cycle regulating aurora B kinase (Bolton et al., 2002). The 
survivin – aurora B complex is not an integral component of the spindle checkpoint, 
but it enables the cell to communicate lack of tension back to the attached 
microtubules, essential for chromosome biorientation, which is a prerequisite for 
proper chromosome segregation (Lens and Medema, 2003). Knock-down 
experiments in human cells also indicate that the function of this complex is required 
to correct improper microtubule-kinetochore interactions (Carvalho et al., 2003). 
  
2.4 Apoptosis 
Apoptosis is a form of programmed cell death where the cell essentially commits 
suicide. Its distinctive morphological characteristics are shrinking and blebbing of the 
cell membrane, followed by nuclear condensation or DNA fragmentation. Apoptosis 
plays an important role in embryonic development, tissue homeostasis and regulation 
of the immune response, just to name a few. More importantly, an avoidance of this 
cellular event is a crucial step in the development of cancer. (Kerr et al., 1972), were 
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the first to propose that apoptosis is a genetically controlled event. Caspases, which 
are intracellular cysteinyl aspartate specific proteases, also play a major role as 
effectors in the induction of apoptosis via proteosomal degradation of the cell and 
their specific functions will also be subsequently reviewed in later sections. Apoptosis 
has been classified into two forms of cell death, type I and II or the extrinsic (receptor 
mediated) and intrinsic (mitochondria mediated) pathway respectively (Danial and 
Korsmeyer, 2004), although these two forms of cell death are interchangeable and not 
mutually exclusive to each other (Figure 1).  
 
2.4.1 Death receptor mediated apoptosis – the extrinsic pathway 
Death receptor mediated apoptosis or the extrinsic apoptotic pathway, is initiated by 
the ligation of a death receptor by its ligand, subsequently followed by its 
oligomerization and assembly of the Death Inducing Signalling Complex (DISC). 
The DISC has been suggested to be a complex structure containing large numbers of 
receptors and adaptor proteins which have been visualized by microscopy in 
structures known as signaling protein oligomeric transduction structures (SPOTS). 
Here, caspase 8 has been suggested to be oligomerized in SPOTS and undergoes auto 
proteolytic cleavage and activation (Siegel et al., 2004). Death receptor signaling is 
mediated by the members of the Tumor Necrosis Factor (TNF) ligand and receptor  
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Figure 1: Extrinsic and intrinsic apoptotic signalling in the cell. The 
death receptor pathway (left) is usually triggered by ligands like CD95L 
and TRAIL while the mitochondrial pathway (right) is usually triggered 
in response to cytotoxic insult like DNA damage. These pathways 
converge at the level of caspase 3 activation which eventually results in 
the proteolytic degradation of the cell. (Hengartner, 2000)
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superfamily. The subsequent signaling events following death receptor ligation, that 
lead to the apoptotic death of a cell have been suggested to be dependent on it being 
either a type I or type II cell (Scaffidi et al., 1998). Upon death receptor ligation and 
assembly of the DISC, type I cells undergo sufficient activation of caspase 8 to 
induce a direct amplification of the caspase activation cascade that involve 
downstream caspases like caspase 3, caspase 6 and caspase 7. Cells that utilize 
primarily the extrinsic pathway upon death receptor activation are usually referred to 
as type I cells while in contrast, type II cells require activation of the intrinsic 
(mitochondria dependent) pathway to induce apoptosis upon ligation of the death 
receptor, usually via cleavage of the pro-apoptotic protein Bid to its truncated form 
(which can then be myristoylated and translocated to the mitochondria (Zha et al., 
2000)) by activated caspase 8 resulting in release of cytochrome c from the 
mitochondria and subsequent activation of caspase 9 and amplification of the caspase 
activation cascade downstream of the mitochondria. More notably, overexpression of 
the anti apoptotic protein Bcl2 can block apoptosis in type II cells but not in type I 
cells.  
 
Traditionally, various studies have classified cells as type I or type II depending on 
the extent of the involvement of the mitochondria in the cell undergoing apoptosis. 
The exact exclusive classification of cells as type I or type II however, has been 
debated over in recent years. Studies by other groups (Tafani et al., 2006) have 
demonstrated that the extrinsic death receptor mediated signaling in certain type I 
cells also involves a necessary mitochondrial alteration via the loss of mitchondrial 
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transmembrane potential and cytochrome c release, just as does the intrinsic pathway 
in type II cells and it is perhaps the rapidity of caspase 8 activation instead, that 
differs between these two cell types, with type I cells having a more rapid activation 
of caspase 8 and more extensive DISC formation upon death receptor ligation. 
 
2.4.1.1 TNF superfamily ligands and receptors 
TNF was first identified in 1975 as a serum factor that was able to kill cancer cells in 
mice (Carswell et al., 1975) but it was only in the last two decades that TNF-α was 
found to be but a representative member of a large family of cytokines involved in 
cellular proliferation and death. The TNF superfamily ligands predominantly are 
involved in modulation of the immune system and such ligands include CD40-L, LT-
β and RANKL (Ashkenazi, 2002). However there are other ligands that regulate 
apoptosis and these are most notably, the CD95-L and TRAIL.  
 
The extracellular carboxy-terminal region of many of the TNF-superfamily ligands is 
proteolytically processed into a soluble protein that is released to the extracellular 
space and this region, which has the most homology within the TNF family members, 
then binds to the cognate receptors. Among the TNF-Receptor superfamily members 
however, it is the extracellular amino terminal region that is the most similar within 
family members. This homologous region occurs mainly in cysteine rich domains 
(CRDs). The TNF-R extracellular region folds as a string of CRDs in tandem, with 
each CRD possessing an α-helical structure stabilized by disulphide bonds between 
cysteines. The basic signaling unit of the TNF-R superfamily is a three-receptor                              
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unit oligomer ligated by a trimeric molecule. This signaling unit basically functions 
as a transmembrane signal transducer activated upon ligand binding. In apoptosis, the 
death signal is transduced from the ligated receptor via the cytoplasmic portion of the 
receptor, known as a death domain (DD), which mediates recruitment of death 
domain-containing adapter molecules to the receptor signaling complex by interacting 
with other DD containing adaptor proteins to facilitate DISC formation (Orlinick and 
Chao, 1998). Receptors that do not possess a death domain are unable to transduce 
this signal and are known as decoy receptors. 
 
Eight death receptors belonging to the TNF receptor family have been identified to 
date and they include TNF-R1, Fas, DR3, TRAIL-R1 (DR4), TRAIL-R2 
(KILLER/DR5), DR6, NGFR and EDAR (Ashkenazi, 2002). Death receptors have an 
intracellular DD essential for transduction of the apoptotic signal. Here the focus is on 
the three most comprehensive pathways: the TNF/TNF-R, FAS-L/FAS and 
TRAIL/TRAIL-R pathways. 
 
2.4.1.1.1 TNF and TNF-Receptor 
While the initial discovery of TNF was based on its cytotoxic activity, it is now 
known that TNF can induce a variety of overlapping signals in cells, which include 
cell activation, proliferation, differentiation, NF-κB activation, and apoptosis. TNF is 
predominantly synthesized in activated macrophages (Renz et al., 1988) and has two 
receptors, TNF-R1 (with a DD) and TNF-R2 (without a DD). TNF and TNF-R1 have 
important functions in the endothelium, acting as an immunomodulator leading to the 
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secretion of platelet activating factor (PAF) as well as the transcription induction of 
pro-inflammatory cytokines like interleukin-1, 6 and –8 as well as leukocyte adhesion 
molecules (Lacasse and Rola-Pleszczynski, 1991). TNF-R1 and R2 are expressed 
ubiquitously with the exception of erythrocytes thus accounting for the widespread 
influence of TNF in various tissues.  
 
TNF-R1 directly interacts with an adaptor molecule, TRADD, via its DD. TRADD 
allows for differential signaling to take place via different interaction with different 
signaling intermediates thus deciding if the cell is to progress towards survival or 
death. For example, TRADD facilitates the interaction between TNF-R and FADD, 
inducing apoptosis in the cell via the FADD-caspase 8 apoptotic downstream 
signaling (Schneider-Brachert et al., 2004). Other secondary adaptors like receptor-
interacting protein 1 (RIP1), a serine-threonine kinase and TNF receptor-associated 
factor-2 (TRAF-2) can also be recruited by TRADD to activate NF-κB and JNK/AP-
1 survival pathways (Wajant and Scheurich, 2001). This appears to contradict data by 
other groups indicating that overexpression of RIP1 can also engage the death 
pathway (Meylan and Tschopp, 2005). The ability of RIP1 to trigger two opposing 
pathways appear to be dependent on the caspase 8 dependent, C-terminal cleavage 
product of RIP1 (generated upon induction of the death signal) which can block NF-
κB activation and promote cell death. The non-cleavable form of RIP1, which has the 
caspase targeted aspartate residue (Asp324) replaced by another amino acid, activates 




Apo-1/Fas or CD95, was the first member of the TNF receptor superfamily to be 
linked to apoptosis (Yonehara et al., 1989, Itoh et al., 1991, Trauth et al., 1989). It is a 
widely expressed glycosylated cell surface molecule of approximately 45 to 52kDa. It 
is a type I transmembrane receptor and can also occur in several soluble forms. It is 
widely expressed, predominantly in thymocytes and activated T cells and abundantly 
expressed in the liver, heart and kidney. 
 
CD95 mediated apoptosis is triggered by its natural ligand, CD95L. It was cloned 
from the cDNA of a killer cell and shown to be a 150 amino acid-containing TNF-
related type II transmembrane molecule (Itoh et al., 1991). It is only expressed in 
cytotoxic T cells and NK cells and in immune privileged sites like the retina and 
testes in the mouse. Its soluble form is inactive and generated through cleavage of the 
membrane form by a metalloproteinase (Schulze-Osthoff et al., 1998). 
 
Induction of CD 95 mediated apoptosis occurs through receptor ligation of the 
trimeric CD95L, which then triggers subsequent trimerization of the receptor itself. 
The death signal is then transduced via its DD, which recruits a DISC composed of 
FAS associated DD (FADD) and pro-caspase 8 or 10. FADD has two distinct 
domains, a DD able to interact with CD95 and a death effector domain (DED), which 
binds the DED of pro-caspase 8. This DED is essential for receptor mediated 
apoptotic signaling. The active caspase 8 can cleave downstream caspases like 
caspase 3 as well as indirectly activate caspase 6 as well, a characteristic of type I 
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cells. Classification of cells into type I and II as previously discussed, is dependent on 
the involvement of the intrinsic pathway, which will be discussed below.  
 
2.4.1.1.3 TRAIL 
Due to the widespread non-specificity of TNF in clinical trials, Genentech and 
Immunex researchers trawled the human genome database for sequences with 
homology to TNF in a bid to identify a more viable compound that could induce 
death receptor mediated apoptosis in tumour cells (Wiley et al., 1995, Pitti et al., 
1996). They found a protein that had a homology within two short but highly 
conserved sequence motifs characteristic for TNF family members. Due to its high 
protein sequence homology to CD95 and TNF, this compound was named Apo2 
ligand (APO2L) or TNF-related apoptosis-inducing ligand (TRAIL). It is a 281 amino 
acid-containing cytotoxic ligand integrated into the cytoplasmic membrane, although 
its soluble form also exists in small quantities. Apoptotic signaling is induced in a 
similar fashion to that of the CD95-CD95L system where TRAIL binds to its receptor 
as a homo trimeric molecule. 
 
Five receptors for TRAIL were subsequently identified, the two death receptors DR5 
and DR5, two decoy receptors DcR1 and DcR2 and a soluble receptor, 
osteoprotegerin (OPG) which can also bind to the osteoclast differentiation factor 
(ODF/OPGL/RANKL), another member of the TNF family. DR4 and 5 share 
significant homology in terms of gene structure, expression pattern and its 
downstream signaling. The mature DR4 protein is a 445 amino acid-containing Type 
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1 transmembrane receptor generated through the cleavage of a signal sequence of 23 
amino acids from a primary protein consisting of 463 amino acids. It has three 
cysteine rich repeats in the extracellular domain, derived from the N terminus of the 
protein. DR5 is a 411 amino acid containing protein that includes a 51 amino acid-
long signal peptide. It also has three cysteine rich repeats. One major difference 
between DR4 and DR5 however, is the capacity of p53 to induce DR5 transcription 
more widely in response to DNA damage in vitro and in vivo (Wen et al., 2000, Guan 
et al., 2001). 
 
2.4.1.1.3.1 Mechanisms and regulation of TRAIL induced apoptosis 
Transduction of the apoptotic signal through TRAIL death receptors, like CD95, 
follows the classical death receptor pathway in that the DISC is assembled via 
recruitment of FADD to the TRAIL receptor via its DD. Subsequent recruitment of 
caspase 8 or 10 by FADD via the DEDs then completes DISC assembly, resulting in 
Bid cleavage and translocation of truncated Bid to the mitochondria, following a 
series of classical mitochondrial apoptotic events for type II cells. In type I cells, 
activated caspase 8 directly activates caspase 3, leading to apoptosis. A recently 
identified adaptor protein, death-associated protein-3 (DAP-3) was also found to bind 
to the DD of the TRAIL death receptors via association with pro caspase8 and FADD 




Increasingly, studies have shown that events at the DISC are finely regulated by a 
host of proteins like the cellular-FLICE-like inhibitory protein (cFLIP) and the 
distribution of the death receptors on the cell surface itself. The short form of cFLIP 
(cFLIPs) shares homology to caspase 9 and caspase 10 but does not possess their 
protease activity. cFLIPs is able to bind to DISC in place of the initiator caspases thus 
blocking caspase activation (Bin et al., 2002). Over expression of cFLIPs as an 
explanation for tumour cell resistance to TRAIL however, remains controversial, as 
some studies have demonstrated that there is no clear correlation between the two.  
 
The TRAIL death receptors are p53-regulated genes induced by DNA damage. 
However, TRAIL death receptors can also be upregulated in the absence of p53 
activation. Both DR4 and DR5 have differential responses to TRAIL treatment. 
Although TRAIL can induce apoptosis through both receptors, at physiological 
conditions, it binds with a higher affinity to DR5 (Truneh et al., 2000). In addition, 
both death receptors have different cross-linking requirements. DR4 binds to both 
cross linked (e.g. membrane bound) and non-cross linked (e.g. soluble) TRAIL, while 
DR5 only tranduces the apoptotic signal in response to ligation of cross-linked 
soluble TRAIL. Transport of TRAIL death receptors to the surface is also an 
important factor in modulating TRAIL sensitivity. (Jin et al., 2004), demonstrated 
that TRAIL-resistant SW480 human colon adenocarcinoma cells had impaired DISC 
formation due to defective transport of DR4 to the surface following prolonged 
exposure to TRAIL in culture. The resistant clones could be resensitized to TRAIL by 
pretreatment with the glycosylation inhibitor tunicamycin, via increased cell surface 
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expression of DR4 and KILLER/DR5. This suggests that tumor cells may become 
resistant to TRAIL through regulation of the death receptor cell surface transport 
(deficient surface expression of DR4 and subsequent impairment of DISC formation 
in this case) and the ability of tunicamycin to revert the resistant phenotype suggests 
that glycosylation might be involved in the transport of death receptors to the cell 
surface in this study. 
 
2.4.2 Mitochondrial dependent apoptosis – the intrinsic pathway 
The intrinsic pathway typically involves the mitochondria directly without any 
involvement of death receptor ligation. While acting as the major respiratory 
powerhouse of the cell, the mitochondria can also be a major initiator of cell death for 
both death receptor dependent and independent apoptosis, although death receptor 
mediated apoptosis can proceed in the absence of mitochondrial activation in Type I 
cells. Mitochondrial dependent apoptosis can be initiated by stimuli like irradiation, 
reactive oxygen species or chemotherapeutic compounds (e.g. vincristine, 
daunorubicin, etoposide etc), that results in loss of mitochondrial transmembrane 
potential, allowing for the release of apoptogenic factors such as cytochrome c and 
apoptosis inducing factor (AIF) from the inner mitochondrial membrane space, 
followed by the formation of the apoptosome with caspase 9, cytochrome c and Apaf-
1 (Hail, 2005). This then activates the caspase cascade, which includes caspase 3 
activation, causing eventual DNA fragmentation of the cell. The mitochondrial 
transmembrane potential can be compromised in various ways, for example through 
the translocation of pro apoptotic proteins like Bax to the mitochondria which then 
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induces opening of the mitochondrial permeability transition pore and subsequent loss 
of mitochondrial transmembrane potential.  
 
2.4.2.1 Permeabilization of the mitochondria 
Mitochondria membrane permeabilization (MMP) plays an important role in the 
effector mechanisms of type II intrinsic apoptosis. It can occur via outer or inner 
MMP. Mitochondrial outer membrane permeabilization (MOMP) generally involves 
the Bcl2 family, which can promote or inhibit apoptosis accordingly (Lucken-
Ardjomande and Martinou, 2005). Inner mitochondrial permeabilization involves the 
permeability transition pore complex (PTPC). Basic components of the large, high 
conductance PTPC include the voltage dependant anion channel (VDAC), the outer 
membrane protein, adenine nucleotide translocator (ANT) and cyclophilin-D (Green 
and Kroemer, 2004). These proteins are hypothesized to interact at specialized 
contact sites between the mitochondria outer and inner membranes to form the PTPC 
structure together with other constituent proteins that could include creatine and 
adenylate kinases. Normally, the PTPC is in a closed conformation, however, various 
factors, including the external stimuli discussed above like reactive oxygen species 
can cause the PTPC to adopt an open conformation resulting in the entry of water and 
solutes which then cause swelling of the mitochondria and physical rupture of the 
outer mitochondrial membrane. Again, the various mechanisms by which MMP occur 
are not exclusive to each other, in fact, MOMP can be mediated both by the PTPC 
and the pore forming function of pro apoptotic Bcl2 family members, Bax or Bak 
(Suzuki et al., 2000). Interestingly however, release of apoptotgenic factors like 
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cytochrome c release from the mitochondria has also been shown to occur 
independently of MMP, suggesting that cytochrome c release from the mitochondria 
could occur without any major distruption of the mitochondria transmembrane 
potential (Garrido et al., 2006). 
 
2.4.3 Regulation of apoptosis 
The apoptotic process is a complex one, regulated by multifactorial pathways, either 
by alteration of pro/anti apoptotic gene-protein expression or changes in the 
intracellular milieu, just to name a few. The different ways by which apoptosis is 
regulated are by no means, exclusive to each other, in fact they are often dependent 
on each other, reflecting an increasingly complex and dynamic model that is 
apoptosis. Here, the Bcl2 family and the role of caspases in apoptotic regulation are 
discussed, as well as how alteration of the intracellular milieu by ROS can regulate 
apoptosis. 
 
2.4.3.1 Bcl2 family 
As mentioned earlier, over expression of the anti apoptotic Bcl2 protein can block 
apoptosis in type II cells. Over expression of the antiapoptotic Bcl2 family members 
is a common oncogenic phenotype and this was first discovered when the B-cell 
lymphoma 2 (Bcl2) gene, linked to an immunoglobulin locus by chromosome 
translocation in follicular lymphoma (Korsmeyer, 1999), was found to inhibit cell 
death, rather than promote proliferation, further cementing the notion that impairment 
of apoptosis is a crucial step in oncogenesis.  
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The Bcl2 family is a large one, consisting of pro apoptotic and anti apoptotic 
members sharing homology in any of the four common Bcl2 homology (BH) domains 
(BH1 to 4) (Figure 2). In addition to Bcl2, the other anti apoptotic proteins from this 
family include BclxL, Bclw, A1 and Mcl1 (Cory and Adams, 2002). These anti 
apoptotic proteins contain all four BH domains. Proteins like Bcl2, BclxL and Bclw 
contain a hydrophobic carboxy terminal domain that targets them to the cytoplasmic 
face of three intracellular membranes: the outer mitochondrial membrane (OMM), the 
endoplasmic reticulum (ER) and the nuclear envelope. Bcl2 and BclxL are usually 
shown to associate with the OMM, protecting its integrity and preventing the release 
of apoptogenic proteins from the mitochondria. Bcl2 is also a known modulator of ER 
calcium homeostasis in ER stress induced apoptosis (Foyouzi-Youssefi et al., 2000). 
Bclw has been found to be expressed in invasive glioma, Sertoli cells and diploid 
male germ cells. In fact, mice mutant for Bclw display progressive and nearly 
complete testicular degradation (Ross et al., 1998). Mcl-1 is an anti-apoptotic protein 
that is particularly important for the development of hematological and biliary 
malignancies (Minagawa et al., 2005) while A1 has been shown to be involved in the 
immune response, where for example, A1 expression can induce pre-T cell survival 
by inhibiting activation of caspase 3 (Mandal et al., 2005). A1 was also first 
discovered to be essential for inhibition of certain types of neutrophil apoptosis as  
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Figure 2: Three subfamilies of Bcl2-related proteins. The Bcl2 
family is divided into the pro survival Bcl2 family, the pro 
apoptotic Bax and the BH3-only family, each sharing homology in 
any of the four common BH domains. (Cory and Adams, 2002)
 23
peripheral blood neutrophils of A1 knock out mice underwent more extensive 
spontaneous apoptosis as compared to the wild type (Hamasaki et al., 1998). 
 
The proapoptotic Bcl2 family members can be subdivided into the Bax family, 
consisting of the BH1, BH2 and BH3 domains, and the BH3-only family. The Bax 
family consists of Bax, Bak and Bok. Bax and Bak induce outer membrane 
permeabilization and result in the release of proapoptotic factors like cytochrome c, 
from the mitochondria. Under normal conditions, Bax is retained in the cytoplasm in 
an inactive conformation with various proteins like the 14-3-3 proteins and the heat 
shock protein (Tsuruta et al., 2004, Kirchhoff et al., 2002). Upon an apoptotic trigger, 
it undergoes a conformational change, exposing its N terminal and translocates to the 
OMM where both Bax and Bak oligomerize to bring about MOMP. In the absence of 
death signal, VDAC2 can also interact with the inactive form of Bak to keep it in 
check at the mitochondrion (Cheng et al., 2003). Activation of the death signal can 
displace this interaction and Bak can also undergo homodimerization, to further 
compromise mitochondrial integrity.  Both Bax and Bak can also reside in the ER and 
partially control apoptosis by regulating ER calcium levels. An interesting function of 
Bak in the ER has recently been described (Klee and Pimentel-Muinos, 2005). When 
coexpressed with Bcl-XL, Bak induces dramatic conformational alterations and 
swelling of reticular cisternae. Interestingly, Bax was shown to completely lack this 
potential, indicating that the two multidomain homologues may not always carry out a 
completely overlapping range of cellular activities. While Bax and Bak are widely 
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distributed, Bok has restricted distribution in the reproductive tissues and is not 
widely studied although it has been suggested to be cell cycle regulated. 
 
The BH3-only family members with the exception of Bid (as mentioned in previous 
sections), usually act by binding to and neutralizing their anti apoptotic members of 
the Bcl2 family. The BH3-only family members include Bim, Bad, Bmf, Noxa and 
Puma. The high resolution 3D visualization of a Bim BH3 fragment bound to BclxL 
is a clear example of the interaction of the BH3-only family members with their anti 
apoptotic relatives (Liu et al., 2003). However, this pairing is selective for some BH3-
only members. While Bim and Puma bind all five pro survival proteins, Bad and Bmf 
bind only Bcl2, Bclxl and Bclw, and Noxa binds only Mcl-1 and A1 (Willis and 
Adams, 2005).  
 
2.4.3.2 Caspases and IAPs 
Caspases are cysteine aspartate proteases involved in the apoptotic break down of the 
cell and their inhibitors, the inhibitor of apoptotic proteins (IAPs). The roles of 
caspases have been previously mentioned in relation to extrinsic and intrinsic death 
signaling. Caspases exist in the cell as zymogens that get activated by oligomerization 
or processing. A phylogenetically distinct class of caspases (caspase 1, 4, 5, 11, 12) 
are involved in the inflammatory response via the proteolytic processing of the 
inflammatory cytokine precursors of interleukin 1β (IL 1β) and IL 18 (Martinon and 
Tschopp, 2004). Caspase 2, 8, 9 and 10 are the initiator caspases involved in 
apoptosis. Caspases are activated through protein-protein interactions via their DEDs 
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(as previously mentioned for caspase 8 in apoptotic receptor signaling) or caspase-
recruitment domains (CARDs) (Siegel, 2006). Upstream initiator caspases like 
caspase 8 or 9, which are involved in death receptor and mitochondria dependent 
apoptosis respectively, contain long prodomains and get activated via 
oligomerization, thus usually resulting in autoprocessing of the caspase. The 
functions of caspase 8 and 9 in receptor and mitochondria dependent apoptosis has 
been discussed earlier in relation to the roles that they play in the two apoptotic 
pathways, however, the role of other effector caspases, like caspase 2, as an initiator 
or an effector caspase still remains controversial as while it bears sequence homology 
to initiators like caspase 9, its cleavage specificity is closer to the effector caspases 
(caspase 3 and 7). A role for caspase 2 as an upstream initiator of mitochondrial 
permeabilization in response to cytotoxic insult like DNA damage has been proposed 
in recent years (Lassus et al., 2002), however other studies have shown that 
procaspase-2 is recruited to the CD95 DISC in human T- and B-cell lines but 
apparently not in the role of an initiator caspase as it was unable to initiate apoptosis 
in the corresponding caspase 8 deficient cell lines (Lavrik et al., 2006). Studies have 
shown that activation of caspase-2 occurs in a high molecular weight complex that 
contains the death domain-containing protein p53 inducible protein with a DD 
(PIDD), and the adaptor protein RIP associated CED homologous protein with DD 
(RAIDD). The association with PIDD suggests a link between p53 and caspase 2, in 
fact, p53 has been shown to be fundamental for caspase 2 activation in 5FU-induced 
apoptosis (Vakifahmetoglu et al., 2006), however the exact relationship between the 
two, be it at the transcriptional or post translational level, is still not clearly 
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delineated. Suppression of caspase 2 in the same system however, resulted in an 
upregulation of p53, suggestive perhaps of a bi directional regulatory relationship. 
 
Effector caspases (e.g. caspase 3, 6 and 7) contain a short prodomain, and are 
activated by proteolytic processing by an upstream caspase. Caspase 3 cleaves the 
inhibitor of caspase-activated DNase (ICAD) at two positions and inactivates its 
inhibitory effect on caspase-activated Dnase (CAD), allowing CAD to degrade 
chromosomal DNA in nucleosomal units, a distinctive apoptotic hallmark (Nagata, 
2000). Cell free systems containing only the single effector caspase (caspase 3, 6 or 
7) under study show that caspase-3 appears to be the primary executioner caspase, as 
in addition to ICAD, it is also necessary for cytochrome c/dATP-inducible cleavage 
of fodrin, gelsolin, U1 small nuclear ribonucleoprotein, RIP, X-linked inhibitor of 
apoptosis protein (XIAP), signal transducer and activator of transcription-1 (STAT1), 
topoisomerase I, vimentin, Rb, and lamin B but not for cleavage of PARP or lamin A 
(Slee et al., 2001). Although caspase-6 is known to cleave nuclear lamin A, which 
when present, must be cleaved in order for the chromosomal DNA to undergo 
complete condensation during apoptotic execution, caspase 6 depletion in the cell free 
system had minimal effect on the induction of apoptosis, as with caspase 7, despite its 
similarity in cleavage specificity and function to caspase 3. Double knock out mice 
lacking in both caspase 3 and 7 however, has been shown by (Lakhani et al., 2006), to 
die immediately after birth with defects in cardiac development. Fibroblasts lacking 
both caspases were highly resistant to both mitochondrial and death receptor-
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mediated apoptosis, with maintenance of mitochondrial membrane integrity, and 
defective nuclear translocation of apoptosis-inducing factor (AIF).  
 
The inhibitors of apoptotic proteins (IAPs) family are characterized by their 
baculoviral IAP repeat (BIR) motifs. Their BIR domains enable them to directly bind 
to, and inhibit caspases. However, the RING domain can bring about the 
ubiquitinylation and degradation of caspases (Vaux and Silke, 2005). One widely 
characterized IAP is the X-chromosome-linked IAP (XIAP), which can bind to the 
oligomerization induced autoprocessed form of procaspase 9 and caspase 3, although 
further feedback processing of caspase 9 by the downstream caspase 3 renders this 
form of caspase 9 insensitive to XIAP inhibition. The caspase inhibitory nature of the 
IAPs however can be blocked through protein-protein interaction with the second 
mitochondria-derived activator of caspases (Smac), normally sequestered in the 
mitochondria in healthy cells but upon cytotoxic insult and a loss of mitochondrial 
membrane intergrity, can be released into the cytosol to bind to and inactivate the 
IAPs. This can result in the eventual ubiquitin mediated proteosomal degradation of 
the IAPs, allowing for apoptosis to proceed.  
 
2.4.3.3 Regulation of death receptor apoptosis by ROS 
While regulation of death receptor mediated apoptosis involves a host of proteins 
either at the initiator or effector level, we must keep in mind that the intracellular 
milieu also plays an important role in the regulation of all cellular processes, 
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including death receptor mediated apoptosis. Here, ROS-mediated alteration of the 
intracellular milieu in regulation of the apoptotic process is discussed. 
 
CD95 upregulation has been shown to occur in the presence of ROS generation and a 
similar observation has been made with the TRAIL death receptors, either with 
exogenous addition of ROS like H2O2 or compounds that generate intracellular ROS. 
When used in conjunction with ROS generating compounds like arsenic trioxide, 
redox sensitive transcription factors like NFκB are activated to promote transcription 
of CD95 (Woo et al., 2004). ROS have also been shown to be required for 
apoptosome formation in Fas-stimulated Jurkat cells via oxidation of Apaf1 and 
subsequent activation of caspase 9 and 3 (Sato et al., 2004). ROS induced by cisplatin 
and UV irradiation also promotes clustering of CD95 at the surface, which could be 
abolished by treatment with antioxidants (Huang et al., 2003). Induction of receptor-
mediated apoptosis, either by CD95 or TRAIL, in some systems also requires the 
intermediacy of intracellular ROS as an apoptotic effector. Interestingly, the PI3K-
Akt pathway, in addition to its normal prosurvival role, has recently been shown to 
play an apoptotic role in CD95-mediated cell death through a mechanism that 
involves transcriptional activation of CD95 (Lu et al., 2006). This process also 
appears to be dependent on the generation of ROS upon CD95 treatment as 
scavenging of ROS with antioxidants abolished PI3K-Akt signaling. It has also been 
shown that mitochondrial derived ROS through uncoupling of oxidative 
phosphorylation via the use of carbonyl cyanide m-chlorophenylhydrazone (CCCP), 
resulted in TRAIL induced mitochondrial release of Smac/DIABLO and inactivation 
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of XIAP through caspase-9-independent activation of caspase 3 (Izeradjene et al., 
2005). At the same time, generation of ROS upon TRAIL induction has been shown 
to induce caspase activity. TRAIL mediated ROS accumulation has also been linked 
to activation of p38 MAPkinase that can then mediate the apoptotic pathway (Lee et 
al., 2002). Sodium nitroprusside, an NO donor has also been shown to enhanced 
TRAIL mediated apoptosis via the generation of ROS in a mitochondria dependent 
fashion (Lee et al., 2001). 
 
While the majority of current literature seems to indicate that ROS plays a sensitizing 
role or a direct inducing one in receptor mediated apoptosis, on the flip side, it should 
also be noted that studies have demonstrated the inhibitory effect of other types of 
ROS on receptor mediated apoptosis. The superoxide anion has been implicated in 
the prevention of CD95 mediated apoptosis either via increase of intracellular 
superoxide levels with chemicals or activation of superoxide producing oncogenes 
like Ras. In fact, in transgenic mice overexpressing SOD, CD95 expression was 
inhibited (Chen et al., 2005). Another separate study showed that pretreatment with 
H2O2 attenuated CD95 mediated apoptosis in Jurkat human leukemic T cells via the 
upregulation of Bfl-1, an antiapoptotic member of the Bcl2 family (Kim et al., 
2005b). The redox sensitive NF-κb transcription factor was also involved in this 
process which suggested that this could be a survival mechanism of cells exposed to 
phagocyte derived ROS.  
 
2.4.3.4 Regulation of mitochondria dependent pathway by ROS 
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In addition to regulation by pro and anti apoptotic proteins, the mitochondria 
dependent pathway has been increasingly shown to be dependent on the redox status 
of the intracellular milieu. 
 
Considering how the mitochondria are a major source of intracellular ROS, it is 
therefore no surprise that ROS would play a major role in regulating mitochondria 
dependent apoptosis. External ROS generating stimuli like drugs and UV irradiation 
could generate intracellular ROS, which could then result in release of cytochrome c 
due to disruption of the mitochondrial transmembrane potential. However, ROS can 
also be generated from disruption of the mitochondrial electron transport chain itself, 
to exert oxidative damage in the cell (Jezek and Hlavata, 2005). Exogenous addition 
of H2O2 to tumour cells has been shown to result in cytosolic acidification which is 
then responsible for the direct translocation of Bax to the mitochondria, an 
observation which is also consistent in drug induced apoptosis of tumour cells 
(Ahmad et al., 2004b). In fact, mitochondrial translocation of Bax has been shown to 
trigger an additional increase in mitochondrial H2O2 production, reinforcing the 
apoptotic signal. Oxidation of caspases on their catalytic cysteine residues renders 
them ineffective as they function optimally in a reducing intracellular environment. 
The ability of moderate amounts of H2O2 to induce cytosolic acidification provides 
optimal caspase activation to further enhance the death signal. Over expression of 
Bcl2 in tumour cells was also able to confer resistance onto cytosolic acidification 
mediated apoptotic signaling. Interestingly, reduction of the intracellular superoxide 
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levels could sensitize these Bcl2 overexpressing tumour cells to receptor and drug 
induced apoptosis, independently of the mitochondria (Clement et al., 2003). 
 
Several other reports have provided new insight into the role of ROS in mediated 
mitochondria dependent apoptosis. AIF contributes to mitochondrial complex I 
activity and thus maintains the superoxide levels in the cell. AIF deficient tumour cell 
lines and knockout mice displayed a loss of tumorigenicity indicating that AIF-
mediated resistance to chemotherapeutic stress involves ROS and probably 
mitochondrial complex I as well (Urbano et al., 2005). AIF maintains the transformed 
state of colon cancer cells through its NADH oxidase activity, by mechanisms that 
involve complex I function suggesting a role for AIF as a novel type of cancer drug 
target.  
 
The p53 up-regulated modulator of apoptosis (PUMA) has also been shown to induce 
apoptosis, in part, through the BAX-dependent generation of superoxide and 
hydrogen peroxide (Liu et al., 2005). Such overproduction of ROS and oxidative 
stress, subsequently induced proteosome-wise alterations, such as degradation of 
stathmin, a cytosolic phosphoprotein involved in depolymerization of microtubules. 
This eventually resulted in apoptotic disorganization of the cell microtubule network. 
 
3. ACTIVATION OF PRO SURVIVAL SIGNALS IN ONCOGENECITY 
 
3.1 Oncogenes and oncoproteins 
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An oncogene is a gene that has been altered from its original form (the proto 
oncogene) in such a manner that it confers onto the cell a proliferative advantage and 
the ability to resist normal death signaling, thus resulting in its unabated formation 
into a tumor. An oncoprotein, similarly, is a transcription product of the oncogene 
that is directly involved in ensuring the superior survival capability of the cell, either 
by enhancing proliferation or resisting death signaling. The plethora of 
oncogenes/proteins contributing to cellular transformation and tumorigenesis could be 
loosely classified into growth factors, growth factor receptors, anti apoptotic proteins, 
pro survival kinases and transcription factors. One such signaling pathway crucial to 
the development of oncogenesis is the phosphatidylinositol-3-kinase (PI3K) network 
which has in the last ten years, been implicated in the activation of a variety of cell 
survival pathways. The genomic aberrations of this pathway, which include 
amplification, mutation and rearrangement, occur more frequently in human cancer 
than any other pathway, with the exception of the p53 and retinoblastoma pathways, 
thus underlining its importance as a therapeutic target for anti cancer strategies 
(Hennessy et al., 2005).  
 
3.1.1 PI3K 
The PI3K family comprises of both lipid and serine/threonine protein kinases 
included among which are the phosphatidylinositol kinases as well as the related 
DNA-dependent protein, ataxia telangiectasia mutated (ATM), and ataxia 
telangiectasia and Rad3 related (ATR) kinases (Fruman et al., 1998). They are 
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categorized into three classes; I to III with class I PI3Ks being the most widely 
studied and further subclassified into A and B.  
 
Class IA PI3Ks comprise of an adaptor/regulatory (either p85 or p55) and a p110 
catalytic subunit. There are three known isoforms of Class IA p110 
(p110α/p110β/p110δ), which contain an amino-terminal p85/p55-interacting region. 
There are seven known p85/p55 subunits generated by alternative splicing of three 
genes (p85α/p85β/p55γ), which can bind all isoforms of p110 (Vivanco and Sawyers, 
2002). Class IB PI3Ks consist of p110γ and a regulatory subunit p101. which is 
unrelated to p85, and are activated either directly by G-protein coupled receptors or 
indirectly by other receptors.  All class I PI3Ks possess intrinsic protein kinase 
activity where p110 autophosphorylation can subsequently phosphorylate p85 and 
downregulate activity of the complex. 
 
(Jimenez et al., 1998), were the first to describe the cloning and characterization of 
p65-PI3K, a mutant of the regulatory subunit of PI3K, which includes the initial 571 
residues of the wild type p85alpha-protein linked to a region conserved in the eph 
tyrosine kinase receptor family. This mutation, obtained from a transformed cell, 
unlike previously engineered mutations of the regulatory subunit, was demonstrated 
to induce the constitutive activation of PI3K and contribute to cellular transformation.  
 
3.1.2 PI3K-Akt signaling in cancer 
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AKT or Protein Kinase B, is a serine/threonine protein kinase originally discovered as 
a cellular homologue of the weakly transforming v-Akt oncogene (Bellacosa et al., 
1991). The Akt8 retrovirus was isolated from a spontaneous thymoma from the AKR 
strain of mice and it was demonstrated to uniquely transform only mink lung cells 
(CCL64) in culture, while virus inoculated into newborn mice was shown to be 
oncogenic (Staal and Hartley, 1988). Concurrent studies by several groups later 
showed that Akt was downstream of PI3K activation (Burgering and Coffer, 1995, 
Franke et al., 1995, Kohn et al., 1995). These studies were based primarily on the fact 
that chemical inhibition of PI3K could block Akt activation and growth factor 
receptor point mutations that prevent the activation of PI3K could also inhibit Akt. 
Akt has also been shown to be amplified and overexpressed in a variety of breast, 
ovarian, pancreatic and gastric carcinomas, an observation suggestive of its 
involvement in carcinogenesis.  
 
Akt has three isoforms (Akt 1, Akt2 and Akt3) and is also a member of the AGC 
family of kinases (Franke et al., 2003). Its dysregulation has often been implicated in 
oncogenesis, and interest in the regulation of AKT is due to its ability to initiate pro 
survival pathways involved in cell growth, proliferation, glucose metabolism, genome 
stability and neo-vascularization (Figure 3), as well as its constitutive activation in a 




Figure 3: The PI3K-Akt pathway. Upon activation of PI3K by the 
receptor protein tyrosine kinases, PI3K catalyzes the conversion of 
PIP2 to PIP3, allowing for increased recruitment of Akt to the 
membrane by PIP3, for phosphorylation and activation by PDK1. Once 
activated, Akt mediates the activtion and inhbition of various cellular 
targets promoting cellular growth and survival. 
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Activation of AKT occurs through a phosphorylation process at the plasma 
membrane by the phosphoinositide - dependent kinase 1 (PDK) at Thr 308 of its 
activation loop followed by phosphorylation at Ser 473 in the C terminal hydrophobic 
motif by a kinase (often referred to as PDK-2), whose identity is currently under 
study (Scheid and Woodgett, 2003). The Akt activation process also depends on its 
pleckstrin homologoy (PH) domain, which mediates its plasma membrane 
translocation. Recruitment of Akt to the plasma membrane for activation is dependent 
on the pool of phosphatidylinositol diphosphate (PIP2) and phosphatidylinositol 
triphosphate (PIP3) in the cell. PI3K mediates the conversion of PIP2 to PIP3. Both 
PIP2 and PIP3 bind to the Akt PH domain, resulting in a conformational change in 
Akt, which enables phosphorylation and activation by PDK1 at the plasma 
membrane. (Klippel et al., 1997), first described the direct mechanism of Akt 
activation by PI3K involving the binding of PIP2 to the Akt PH domain. This 
pathway is negatively regulated by the tumour suppressor PTEN, a dual-specificity 
protein and lipid phosphatase that reduces intracellular levels of PIP3 by facilitating 
conversion to PIP2. This in turn blocks the PI3K/Akt pathway by suppressing its 
recruitment to the plasma membrane for activation. 
 
3.1.3 Akt at the crossroads of oncogenic and tumour suppressor networks 
Activation of Akt at the plasma membrane is only the first step, as it stands at the 
crossroads of oncogenic and tumour suppressor signaling networks. Akt activates a 
myriad of pro survival signaling pathways of which many are involved in apoptosis 
inhibition, cell metabolism, translation, growth and proliferation. Akt phosphorylation 
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inactivates several proapoptotic factors including the pro-apoptotic Bcl-2 member 
BAD, procaspase-9, and Forkhead (FKHR) transcription factors which mediate the 
expression of critical apoptotic genes such as the Fas ligand (CD95L/Apo1L) (Brazil 
et al., 2002). Akt also phosphorylates and activates IκB kinase (IKK), which in turn 
positively regulates NF-κB via the inactivation of IκB (inhibitor of NF-κB) and its 
proteosomal degradation, eventually resulting in translocation of NF-κB to the 
nucleus and transcription of antiapoptotic genes. Another antiapoptoic effect of Akt is 
reflected in its ability to phosphorylate Mdm2, allowing it to enter the nucleus and 
downregulate p53, thus antagonizing p53-mediated cell cycle apoptotic 
checkpoints(Gottlieb et al., 2002). 
 
Glycogen synthase kinase 3β (GSK3β) is another Akt substrate and is inactivated 
upon phosphorylation by Akt, thus preventing cyclin D1 degradation. Akt can also 
directly antagonize cell cycle inhibitors p21waf1 and p27kip1. At the same time, 
activation of mammalian target of rapamycin (mTOR) kinases by Akt-mediated 
phosphorylation can also increase translation of cyclin D1, D3 and E transcripts 
(Ruggero and Sonenberg, 2005). mTOR mediates cell growth and proliferation by 
regulating ribosomal biogenesis and protein translation. It can also regulate response 
to nutrients by restricting cell cycle progression in the presence of suboptimal growth 
conditions. 
 
4. ROLE OF ROS IN DEVELOPMENT OF ONCOGENECITY 
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4.1 Types of ROS 
Having discussed the role of ROS in alteration of the intracellular milieu in regulation 
of apoptosis, it should not be forgotten that they can play a role in the induction of 
oncogenesis itself. There are many types of ROS and they can be loosely classified as 
free oxygen radicals and non radical ROS. Free oxygen radicals may be defined as 
any chemical species capable of independent existence that contains one or more 
unpaired electrons. Examples of free oxygen radicals include the superoxide anion, 
the peroxy radical, singlet oxygen and hydroxyl radical, while nonradical ROS 
include molecules like hydrogen peroxide (H2O2). The long held opinion has been 
that any form of oxidative stress is detrimental to a cell, however research in the 
recent years have shown that the relationship of ROS with the tumour cell is much 
more complex than previously believed. 
 
4.2 Intracellular sources of ROS 
A main source of intracellular ROS is the mitochondria, where an estimated 2% of 
the total oxygen consumed leaks as partially reduced free oxygen radicals (Jezek and 
Hlavata, 2005). Tumour cells respire actively and continuously generate ROS during 
this process, via “leaking” of electrons from the electron transport chain localized at 
the mitochondrial inner membrane. At the NADH dehydrogenase (complex I) and the 
ubiquinone cytochrome b (complex III) intersection, electrons may leak out of the 
electron transport chain to partially reduce oxygen to generate superoxide and H2O2, 
which in the presence of iron, can produce the hydroxyl radical. Studies with canine 
heart tissue show that the inhibition of electron transport at the sites of complex I and 
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complex III in the normal submitochondrial particles resulted in a significant 
production of O2-. (Ide et al., 1999). As major sources of ROS production, 
mitochondria also could be major targets of ROS attack (from this localized 
production of ROS), given the short half life of ROS, thus further impairing the 
function of the electron transport chain and accelerating more O2-. production within 
the mitochondria. Superoxide can be converted to H2O2 in the mitochondria by 
manganese superoxide dismutase. While MnSOD is localized to the mitochondria, the 
other forms of dismutases, Cu/ZnSOD is found in the cytosol as well as in the 
extracellular space. O2-. can reduce Fe3+ to Fe2+, to catalyze the Fenton reaction in the 
generation of the highly damaging OH from H2O2 in a superoxide-assisted Fenton 
reaction. 
 
The small GTPase Rac-NADPH oxidase system, well characterized in neutrophils 
and macrophages, is another intracellular source of superoxide, as with other oxidase 
systems in the cell like the xanthine oxidase complex. The NADPH oxidase system in 
resting neutrophils consists of unassembled cytosolic (p40phox, p47phox, p67phox) and 
membrane components. Following receptor stimulation of neutrophils, these cytosolic 
components translocate to plasma or phagosome membranes where they associate 
with flavocytochrome b558 and Rap1A to form the active oxidase. Flavocytochrome 
b558 serves as the electron transporter that generates superoxide from oxygen and 
NADPH, resulting in the “respiratory burst” frequently observed in neutrophils and 
macrophages (Mizrahi et al., 2006). 
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O2-. can also be produced by other oxidase systems in the cell, with one such example 
being the xanthine oxidase system. Xanthine oxidase generates superoxide by 
converting hypoxanthine into xanthine and xanthine into uric acid. The enzyme is 
derived from xanthine dehydrogenase by proteolytic cleavage. Under normal 
conditions, xanthine oxidase accounts for only a minor proportion of total ROS 
production. However, ROS production by xanthine oxidase has been observed in 
TNF-treated endothelial cells and has also been implicated as a major source of 
oxidative stress under certain disease conditions such as ischemia and reperfusion 
(Zhang et al., 2006). 
 
4.3 Evidence of the prooxidant state in oncogenesis 
Studies have shown that tumour cells exist in a slightly prooxidant state favourable 
towards their continued oncogenic existence. The evidence for a role of prooxidant 
state in oncogenesis was first reviewed by (Cerutti, 1985), where clastogenic factors 
from serum of patients with ataxia telangiectasia and Bloom’s syndrome (hereditary 
diseases characterized by increased cancer incidence and spontaneous chromosomal 
breakage, a step to the induction of oncogenesis) were shown to be able to break 
chromosomes in test cultures of lymphocytes from healthy donors. This however 
could be inhibited by CuZn superoxide dismutase (SOD), indicating the intermediacy 
of O2-. in the clastogenic process. Furthermore, it was also shown that high oxygen 
tensions could increase the transformation frequency of irradiated mouse embryonic 
cells, suggesting that oxygen could promote radiation mediated transformation of 
mouse embryonic fibroblasts. The prooxidant state as caused by different agents like 
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hyperbaric oxygen, radiation, xenobiotic metabolites and fenton-type reagents, 
modulators of the cytochrome p-450 electron transport chain, peroxisome 
proliferators, inhibitors of the antioxidant defense and membrane-active agents like 
PMA, can cause chromosomal damage as a step to the induction of oncogenesis. 
Characteristic DNA lesions include single and double strand breaks, apurinic and 
apyrimidinic sites and products of the 5.6-dihydroxydihydrothymine type. The ability 
of antioxidants to suppress the clastogenic effect of these agents indicate the 
intermediacy of active oxygen in inducing the pro oxidant state. It was also suggested 
that the prooxidant states may regulate expression of genes related to growth and 
differentiation of initiated cells by causing structural genetic changes to the 
chromosomal DNA, although active oxygen may also participate in epigenetic 
mechanisms that result in altered gene expression. Poly(ADPribose) synthetase is 
stimulated by (possible oxygen induced) DNA strand breaks. The subsequent 
polyADP-ribosylation of chromosomal proteins would then play a role in the 
modulation of gene expression. 
 
4.3.1 Role of O2-.  in oncogenesis 
The observation that superoxide anion contributes to the continued oncogenic 
proliferation of the tumour cell was demonstrated in early studies showing that 
exogenous addition of superoxide, accompanied by an increase in intracellular pH, 
can stimulate a growth response in human fibroblasts, Balb/3T3 cells and mouse 
epidermal cells (JB6) through the induction of early growth response genes like c-fos 
and c-jun (Burdon, 1995). In contrast, exogenous addition of superoxide dismutase to 
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the growth medium of hamster and rat fibroblasts and HeLa cells resulted in a 
depressed rate of cell proliferation (Burdon et al., 1990). Growth of NIH3T3 mouse 
fibroblasts have also been shown to be inhibited by overexpression of manganese 
superoxide disumutase (MnSOD) as these cells had decreased cell growth correlated 
with an increase in ROS in S phase of the cell cycle and a decrease in glutathione in 
mitosis suggesting that specific levels of cellular redox status are necessary for cells 
to successfully progress through the various phases of the cell cycle (Li and Oberley, 
1998). A later study also demonstrated that overexpression of MnSOD in androgen 
independent prostate carcinoma PC-3 cells inhibited their proliferative ability via an 
increase in cell doubling time, reduced anchorage-independent growth in soft agar 
compared to wild type PC-3 cells, and reduced growth rate of PC-3 tumor xenografts 
in athymic nude mice (Venkataraman et al., 2005). The proportion of MnSOD 
overexpressing PC-3 cells in the G1 cell cycle phase was also increased, suggestive of 
a reduction in proliferation through a retardation in the G1-S transition. In fact, 
current studies showing the effectivness of SOD in counteracting oncogenesis suggest 
that it is O2-. that is implicated in the disease process by enhancing proliferation and 
cell cycle progression, and not H2O2, the product of O2-. dismutation. SOD mimetics 
have also been shown to successfully reduce in vivo tumor growth in mice when 
treated in synergy with cytotoxic drugs as shown by (Laurent et al., 2005), where 
cotreatment of oxaliplatin in association with either one of the three SOD mimetics 
manganese(III)tetrakis(4-benzoic acid) porphyrin, copper(II)(3,5-
diisopropylsalicylate)2, or manganese dipyridoxyl diphosphate resulted in smaller 
tumor volume for all 3 mimetics than those treated with oxaliplatin alone. 
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The NADPH oxidase system, also found in other non-inflammatory cells, is a critical 
intracellular source of superoxide. In fact, inhibition of the NADPH oxidase complex 
by diphenyleneiodonium (DPI) has been shown to sensitize Bcl-2 overexpressing 
tumour cells to receptor and drug induced apoptosis independently of the 
mitochondria (Clement et al., 2003). Interestingly, another study has shown that at 
high concentrations DPI can inhibit the mitochondrial respiratory chain resulting in 
high amounts of superoxide production, which lead to apoptotic cell death suggesting 
again that it is a homeostatic maintenance of the intracellular redox state that 
determines the cell’s fate in response to oxidative stress (Li et al., 2003). 
 
Various studies have increasingly pointed to the low levels of the superoxide anion as 
a mediator for the induction and maintenance of oncogenesis via the evasion of cell 
death. In fact, the superoxide anion has been shown to be a natural inhibitor of Fas-
mediated cell death through the use of phorbol esters, which elevate the intracellular 
superoxide levels via PKC-mediated NADPH oxidase activation (Clement and 
Stamenkovic, 1996). The inhibitor of Cu/Zn SOD, diethyldithiocarbamate (DDC), 
also increased intracellular levels of superoxide, conferring resistance to Fas-
mediated cell death in human melanoma cells.  
 
Given that cancer cells are nearly always low in both MnSOD and Cu/ZnSOD 
activity, the role of O2-. in cancer is also further evidenced by the ability of the SODs 
to inhibit cancer progression. This was first suggested by (Oberley and Buettner, 
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1979), where normalization of the SOD levels in cancer cells should be able to at 
least partially revert the cancer phenotype. Since then, many studies have shown the 
potential of SODs as a tumor suppressor. While both forms of SOD have been 
implicated in the role of tumor suppressor, more studies appear to implicate MnSOD 
in inhibiting oncogenic proliferation. However, a recent study by (Weydert et al., 
2006), demonstrated that in vitro overexpression of MnSOD or CuZnSOD decreased 
not only breast cancer cell growth but also clonogenic survival in a dose- and 
transgene-dependent manner. Tumors overexpressing MnSOD or CuZnSOD 
displayed decreased xenograft growth in vivo compared to controls. This first direct 
comparison of MnSOD to CuZnSOD overexpression indicated that CuZnSOD and 
MnSOD were similarly effective at suppressing cancer cell growth. Overexpression 
of MnSOD in a variety of systems, both in vitro and in vivo, has also been shown to 
suppress both AP-1 and NF-κB activation (Oberley, 2005). MnSOD can also 
suppress accumulation of hypoxia inducible factor 1 (HIF1), a transcription factor 
involved in promoting tumor growth under hypoxic conditions, in breast carcinoma 
MCF7 cells under hypoxic conditions (1% and 4% O2) (Wang et al., 2005). This 
MnSOD suppression appeared to be biphasic, with accumulation of HIF1 occurring 
again at high levels of MnSOD activity. The accumulation of HIF1 was abolished 
with the co expression of mitochondria H2O2 removing antioxidants, suggesting that 
restabilization of HIF1 observed under high levels of MnSOD activity is probably due 
to H2O2, most likely produced from MnSOD. 
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In a separate study, activation of the RacGTPase, a downstream effector of the 
oncogenic p21ras has also been shown to inhibit apoptosis in tumour cells via 
intracellular superoxide production (Pervaiz et al., 2001). Low doses of resveratrol, a 
phenolic grape-derived compound, has also been shown to produce intracellular 
superoxide and confer resistance to drug induced cell death onto tumour cells. 
Inhibition of the NADPH oxidase complex by DPI can reverse this resveratrol-
mediated resistance (Ahmad et al., 2004a). 
 
4.4 Oxidative stress-induced necrotic death 
Any alteration of the prooxidant tumor promoting state towards a more reducing one 
may cause the cell to enter apoptosis or alternatively, an overwhelming intracellular 
production of oxidative stress would result in oxidative DNA, lipid and protein 
damage leading to necrotic cell death. This form of cell death is often associated with 
the highly reactive hydroxyl radical. OH mediated DNA damage generates a variety 
of products as it attacks DNA bases, deoxyribose sugar and can also cause DNA 
protein cross linking. For example, it can add on to guanine at carbon positions 4, 5 or 
8 in the purine ring. Addition of C8 produces a C8 OH-adduct radical that can be 
reduced to 8-hydroxy-7,8-dihydroguanine (8OH-dG) (Halliwell, 1999). OH can 
fragment the deoxyribose sugar with the formation of carbon centered radicals that 
rapidly convert to sugar peroxyl radicals in the presence of O2. These can undergo a 
series of reactions, including disproportionation, rearrangement, elimination of water 
and C-C bond fragmentation to yield a variety of carbonyl products. DNA protein 
cross linking occurs when nuclear proteins are attacked by OH to give protein-derived 
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radicals which can cross link to base derived radicals if they meet in chromatin, 
giving rise to DNA-protein cross links (e.g. thymine to tyrosine) that interfere with 
chromatin unfolding, DNA repair, replication and transcription. 
 
4.5 Role of H2O2 in modulating the tumor phenotype 
Additionally, studies have also shown that similar to O2-., low exogenous amounts of 
H2O2 can stimulate the growth of cultured cells, through the tyrosine phosphorylation 
of several growth factor receptors in the absence of growth factor stimulation, and 
overwhelming amounts of H2O2 can also result in necrotic cell death (Burdon, 1995). 
Increasingly, studies have shown that intermediate amounts of H2O2 can also play a 
role in determining cell fate. As reviewed earlier, studies have shown that 
intracellular generation of H2O2 upon cytotoxic insult can lead to a more reducing 
intracellular milieu which would tip the cell towards apoptosis via intracellular 
acidification and translocation of Bax to the mitochondria, creating a 
survival/apoptotic homeostatic balance mediated by these respective forms of 
oxidative and reducing stress (Ahmad et al., 2004b, Pervaiz and Clement, 2002). In 
addition to its role as apoptotic effector molecule, H2O2 has also been shown to be 
able to sensitize tumor cells to apoptosis in chemotherapeutic drug models utilizing 
death triggers like TNFα and TRAIL (Lee et al., 2001, Han et al., 2006). 
 
4.6 Role of ROS in modulating the PI3K-Akt pathway 
While subtle elevations of the intracellular superoxide levels confer onto tumour cells 
a resistance to various apoptotic signals, this pro oxidant state can also directly induce 
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a pro survival phenotype, for example via activation of the PI3K-Akt prosurvival 
pathway. As with H2O2, small increases in the intracellular superoxide levels through 
the use of chemicals like DDC, result in increased proliferation in cultured cells. This 
proliferative effect is also observed in tumour cells with constitutive activation of the 
Rac GTPase complex. Exposure of cultured cells to UV irradiation has been shown to 
result in H2O2 production (Huang et al., 2002). This ensuing production of H2O2 then 
directly phosphorylates and activates Akt. Exogenous addition of H2O2 has been 
shown to increase tyrosine phosphorylation of tyrosine kinase receptors in the 
absence of growth factor binding and subsequently activate its downstream signaling 
targets like Akt (Esposito et al., 2003). PTEN, the negative regulator of the PI3K-Akt 
pathway, contains a cysteine residue in its active site that requires reducing conditions 
for its phosphatase activity. Various studies have shown that this cysteine residue is 
sensitive to oxidation and under conditions of oxidative stress, PTEN is inactivated, 
suggesting a physiological mechanism of regulation for PTEN not only by oxidative 
stress, but by also ROS produced in other cellular circumstances, like stimulation of 
cells by growth factors (Kwon et al., 2004). In fact, H2O2 produced in response to 
stimulation of cells with epidermal growth factor or platelet-derived growth factor has 
been shown to transiently inactivate PTEN via its oxidation. (Leslie et al., 2003), 
were the first to show direct evidence for the oxidative inactivation of PTEN in cells, 
by both exogenous and endogenously produced oxidants in PTEN expressing 
U97MG glioblastoma cells and RAW264.7 macrophage cells respectively while (Cho 
et al., 2004), proposed that the inactivation of protein tyrosine phosphatases like 
PTEN occurred through the formation of a disulfide bond between two cysteines, one 
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in the active site and the other nearby, during oxidation by exogenous or endogenous 
ROS like H2O2. Such oxidative stress – mediated inactivation of PTEN resulted in an 
increase in the cytosolic pools of PIP3 that can recruit Akt to the membrane for 
activation and tranduction of pro survival/proliferative signals. Additionally, PTEN 
has also been shown to be sensitive to mitochondria derived H2O2 (via the 
overexpression of MnSOD) in endothelial cells (Connor et al., 2005), promoting the 
angiogenic phenotype through PTEN oxidation and inactivation by mitochondria 
derived H2O2. 
 
At the same time, conflicting reports have also linked the PI3K-Akt pathway to the 
generation of ROS, which could further contribute to the pro oxidant state of the 
tumorigenic cells, thus enhancing its proliferative ability. For example, Akt has been 
shown to directly interact with and phosphorylate the NADPH oxidase component 
p47phox in neutrophils (Chen et al., 2003), which acts as an adaptor protein that 
assembles the components of the functional NADPH complex. This suggests that 
during neutrophil stimulation, the PI3K dependent respiratory burst and 
phosphorylation of NADPH oxidase component p47phox are both Akt mediated. 
 
5. CHEMOTHERAPEUTIC STRATEGY AND DESIGN 
The study of survival and death signaling pathways in cancer eventually coalesces 
towards the goal of eradicating the tumor phenotype. As such, efforts by various 
research groups in the design of chemotherapeutic strategies in relation to the survival 
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and death signaling pathways that have been discussed above will be reviewed in this 
section. 
 
5.1 Therapeutic targeting of the PI3K-Akt pathway 
The downstream effectors of the PI3K-Akt pathway are too many to be fully 
reviewed, however their role in promoting survival, growth and differentiation of the 
cell is generally undisputed. It is therefore not suprising that in contrast to the p53 
tumour suppressor pathways, the oncogenic activation of the PI3K-AKT pathway 
makes it an easier therapeutic target as it is usually easier to block its gain of function 
events than to replace a loss of function event as in the case of the p53 pathway in 
tumour cells (Hennessy et al., 2005). In light of the clinical success of tyrosine kinase 
inhibitors in like erlotinib, gefitinib and imatinib, it made sense that targeting the 
deactivation of the PI3K-AKT pathway to initiate pro apoptotic signals to counteract 
the oncogenic cancer phenotype might have some clinical relevance in treatment for 
cancer patients. 
 
5.1.1 PI3K inhibitors 
Spurred by the many studies implicating the PI3K-Akt pathway in the development 
and maintenance of oncogenesis, various PI3K inhibitors were thus developed to 




Two central compounds that have been widely used over the last decade in the study 
of PI3K inhibition are wortmannin and LY294002. Wortmannin is a fungal 
metabolite first isolated from Penicillium wortmanni and a potent inhibitor of type I 
PI3K (Schultz et al., 1995). It irreversibly inhibits PI3K activity by binding 
covalently to a conserved lysine residue (Lys 802) in the p110 catalytic subunit of the 
enzyme.  LY294002 (LY29) is a synthetic flavanoid derivative that reversibly 
competes with ATP for the ATP-binding site of PI3K (Vlahos et al., 1994). However, 
LY29 has a very short half life and is insoluble in aqueous solutions, as is 
wortmannin, although water-soluble wortmannin conjugates are being developed to 
circumvent this issue. Earlier studies have hailed LY29 as a more selective inhibitor 
of the PI3K-Akt pathway as compared to wortmannin that has been shown to target 
phospholipases C, D(Bonser et al., 1991), A2(Cross et al., 1995) as well as mitogen 
activated protein kinases (MAPKs)(Ferby et al., 1996). Interestingly, recent studies 
have shown that LY29 has non-specific effects of its own as well, for example, the 
inhibition of tumor cell proliferation via mTOR and non mTOR dependent 
mechanisms (Kristof et al., 2005), inhibition of lipopolysaccharide induced iNOS 
expression (Kim et al., 2005c) and monocyte chemoattractant protein-1 (MCP-1) 
expression (Choi et al., 2004) in macrophage cells and human umbilical vein 
endothelial cells respectively, both via inhibition of NF-kappaB activation and 
inhibition of K(V) currents in rat pancreatic cells via a direct mechanism (El-Kholy et 
al., 2003). These observations will be discussed in greater detail with relation to the 
results obtained in this thesis in the Discussion section. In this regard, in vivo studies 
of both PI3K inhibitors have shown that while they demonstrate anti tumour activity, 
 51
they are also associated with many unwanted side effects, which are probably due to 
their non selectivity as well as the fact that PI3K has many other important cellular 
targets with regards to neuronal, cardiovascular, immune and diabetes-related cell 
function. 
 
5.1.2 Akt inhibitors 
One approach in inhibiting Akt would be to target its PH domain and interfere with 
PIP3 binding thus disabling its membrane translocation. Phosphatidylinositol ether 
analogues (PIAs) were therefore designed with this in mind as they cannot be 
phosphorylated by PI3K (Gills and Dennis, 2004). Targeting of the PH domain by 
PIAs would also minimize non specificity observed with compounds that target the 
ATP-binding domain of Akt. More importantly, studies by various groups have 
shown that PIAs can selectively induce apoptosis in tumor cell lines with 
constitutively activated Akt, further corroborating the role of PIAs as effective Akt 
inhibitors (Castillo et al., 2004). However their role in vivo is as yet unknown and 
remains to be studied.  
 
In recent years, various other Akt inhibitors have been described. Perifosine is a novel 
orally bioavailable alkylphospholipid structurally resembling naturally occurring 
phospholipids that displays strong anti neoplastic effects both on its own (Hideshima 
et al., 2006) and in synergy with other cytotoxic agents like etoposide, anti-EGF 
receptor monoclonal antibody cetuximab, histone deacetylase inhibitors in various 
tumor cell lines like Jurkat and HL60 leukemia, multiple myeloma, MDA468 breast 
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cancer cells. However, it has been shown to be unable to enhance the radiosensitivity 
of human glioma cells (de la Pena et al., 2006). Perifosine inhibits Akt 
phosphorylation by reducing its membrane localization, possibly through interaction 
with its PH domain and is currently in phase II clinical trials (Knowling et al., 2006). 
Earlier studies have shown that perifosine can cause cell cycle arrest with induction 
of p21waf1/cip1 in a p53-independent fashion and its ability to inhibit Akt suggests that 
the PI3K-Akt pathway could contribute to the regulation of p21waf1/cip1expression 
(Cheng et al., 2005).  
 
Also of particular interest are a group of novel allosteric Akt kinase inhibitors that are 
PH domain dependent, displaying high specificity with respect to other kinases as 
well as within the Akt isozymes themselves (Barnett et al., 2005). However, 
maximum induction of apoptosis by isozyme-selective Akt inhibitors in several 
cancer cell lines was achieved with the Akt1/Akt2 dual inhibitor. These isoform 
specific inhibitors were only able to modestly induce apoptosis in tumour cells but 
could however produce optimal anti apoptotic effects when synergistically combined 
with other chemotherapeutic agents like TRAIL. 
 
The PI3K-Akt pathway remains an attractive target for anti cancer drug discovery 
mainly due to its role in the induction and maintenance of oncogenesis. PI3K/Akt 
signaling can be upregulated by many forms of cellular stress including heat shock, 
low pH, ultraviolet light, ischemia, hypoxia, hypoglycemia and oxidative stress. 
Stress induced PI3K/Akt upregulation is frequently viewed as a compensatory 
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protective mechanism that cells activate in an attempt to escape the death signal. The 
role of oxidative stress in PI3K/Akt signaling however is a controversial one as 
studies have shown that it could either activate or inhibit this pathway. At the same 
time, as previously mentioned, generation of reactive oxygen species (ROS) could 
also be a downstream by product of the activation of the PI3K-Akt pathway. 
 
5.2 Chemotherapeutic resistance to apoptosis in cancer 
Resistance to drug induced apoptosis is a major problem in cancer as cancer cells 
evolve to evade apoptotic signals that would normally allow these transformed cells 
to die naturally. Hence the search is on for ways and means to sensitize tumour cells 
to drug induced apoptosis as cancer cells evolve to develop resistance to many of the 
chemotherapeutic drugs already in use. 
 
5.2.1 Chemotherapeutic targets in death receptor mediated apoptosis 
The promise of CD95 as an antiapoptotic molecule has led to attempts to exploit it as 
a chemotherapeutic option. However, its toxic side effects in animals treated with 
CD95 agonistic antibodies included acute hepatotoxicity, which led to death by liver 
failure.  This resulted in the development of CD95L fusion proteins, which were only 
activated on the tumour cell surface, which displayed lesser systemic toxicity (Samel 
et al., 2003, Shiraishi et al., 2004). Another way of minimizing systemic toxicity in 
CD95 based chemotherapy could be via the use of adenoviral vectors with inducible 
or tissue-specific promoters (Shinoura et al., 2000). While initial studies show 
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promising results, limitations still exist in the form of inefficient target delivery and 
strong immunogenicity. 
 
The preferential cytotoxicity of TRAIL towards tumour cells with low toxicity in 
normal cells, promises new hope in the development of anti cancer strategies. 
However, the inevitable appearance of TRAIL resistant tumours has also resulted in a 
plethora of various studies with regards to enhancment of TRAIL mediated apoptosis, 
of which include receptor DR5 upregulation and oligomerization (Jung et al., 2005, 
Matsui et al., 2006), enhanced assembly of the DISC complex (Ramaswamy et al., 
2004), silencing or upregulation and activation of various pro/anti apoptotic TRAIL 
proteins like FLIP, FADD, Smac, caspase 8, IAPs and Bid (Chawla-Sarkar et al., 
2004). As with CD95, similar attempts have also been made, with varying results, to 
administer TRAIL as a chemotherapeutic option in vivo, with TRAIL fusion proteins, 
adenoviral encoded transmembrane TRAIL expression and TRAIL death receptor 
antibodies (Wajant et al., 2005).  
 
As with current tumour cell line studies, treatment with chemotherapy could also 
sensitize tumours to TRAIL treatment in vivo, suggesting a way to bypass the 
development to TRAIL resistance in tumours via the synergistic action of other 
chemotherapeutic compounds in restoring the previously deficient TRAIL signaling 
components, for example, via the upregulation of DR4 and DR5 receptor expression 




5.2.3 Chemotherapeutic targets in mitochondria dependent apoptotis 
Over expression of Bcl2 has long been shown to confer a protective effect on the 
mitochondrial death pathway. Bcl2 family of proteins is therefore a natural 
chemotherapeutic target with the development of compounds that inhibit the 
protective Bcl2 function. One such compound is HA14-1, the small molecule Bcl2 
inhibitor and inducer of oxidative stress, which has been documented to enhance 
apoptosis to sulindac (a non steroidal anti-inflammatory drug) and TRAIL in resistant 
colon carcinoma cell lines (Sinicrope and Penington, 2005). It has also been shown to 
be effective in vivo where in combination with etoposide, HA14-1 could reduce the 
formation of malignant glioma tumours in nude mice (Manero et al., 2006). Another 
approach that targets the anti apoptotic function of Bcl2 is via the use of antisense 
technology to down regulate its expression. G3139 is a phosphorothioate 
oligonucleotide that causes anti sense targeting of Bcl2 resulting in sensitization of 
cells to low concentrations of staurosporine and ceramide (Lebedeva and Stein, 
2001). It has also been shown be effective in vitro and in vivo, where Bcl-2 
downregulation by G3139, followed by the administration of rituximab is an efficient 
anti-tumour strategy associated with improved survival in lymphoma-bearing SCID 
mice (Ramanarayanan et al., 2004). Currently, clinical trials on G3139 for diverse 
tumors are underway in phase II and phase III. Alternatively, targeting of 
proapoptotic Bcl2 peptides to the mitochondria could be another strategy to bypass 
the tumorigenic overexpression of Bcl2, for example, via the use of recombinant Bax 
adenovirus to sensitize cells to apoptosis. 
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The ability of Smac/Diablo to inhibit the anti apoptotic effect of IAPs make it a viable 
target for chemotherapeutic design via amplification of the mitochondrial death 
events. Small molecule Smac mimetics have been shown to sensitize human gliomas 
in nude mice to TRAIL (Li et al., 2004). In the same way, adenoviral vectors 
encoding an anti sense XIAP cDNA could also sensitize chemoresistant ovarian 
carcinoma cell lines and increase radiation sensitivity of non small-cell lung 








This study originated from attempts to establish a link between ROS and the PI3K-
Akt pathway. Initial studies with a variety of tumor cell lines showed that inhibition 
of PI3K with the pharmacological inhibitor LY29, elevated the intracellular levels of 
H2O2 in the cell, suggesting a possible link between the PI3K-AKT pro survival axis 
and H2O2 in maintaining the life-death balance. Using a cell line with constitutively 
activated AKT, the LNCaP prostate carcinoma cell line, we then decided on the 
following study with other PI3K inhibitors to establish if the H2O2 generated was 
related to the PI3K-Akt axis and to prove if generation of such copious amounts of 
H2O2 could nudge the tumor cell towards cell death. Interestingly, our results showed 
that LY29 produced intracellular H2O2 while the other PI3K inhibitor wortmannin, 
did not. The inactive analogue of LY29, LY30 was also able to generate intracellular 
H2O2, and seeing how LY30 has been used as a negative control for LY29 in a variety 
of studies, we then set out to find if such H2O2 generated by LY30 was 
physiologically significant in a tumor cell model, based on the hypothesis that 
varying changes in the intracellular H2O2 levels could induce either apoptosis or 
necrosis. The specific aims of this study are to determine: 
 
• The significance of intracellular H2O2 generation by LY29 with regards to PI3K 
inhibition. 
• The physiological significance of LY30-mediated generation of intracellular 
H2O2, either on its own or in conjunction with other compounds. 
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MATERIAL AND METHODS 
 
In this study, the ability of LY30 to sensitize tumor cells to apoptosis in two different 
drug models were evaluated through various assays and the dependence of this 
system on the intracellular generation of H2O2 was also assessed, mainly via the 
transient transfection of human catalase into the cultured tumor cell lines. The 
materials and methods used in this study are summarized below: 
 
1. Cell lines  
The prostate cancer cell line LNCaP, cervical cancer cell line HeLa, colon carcinoma 
cell lines HCT116 and HT29 where obtained from American Type Culture Collection 
(Rockville, MD). The LNCaP cell line was grown in RPMI 1640 medium (Hyclone, 
Logan, Utah, USA) containing 10% FBS, 1% penicillin, 1% glutamine and 100μM 
sodium pyruvate at 37°C in an incubator with 5% CO2.  The HeLa cell line was 
grown in DMEM (Hyclone, Logan, Utah, USA) while HCT116 and HT29 were 
grown in McCoy’s 5A Medium (Invitrogen Life Technologies, Carlsbad, CA, USA), 
all of which were supplemented with 10% FBS, 1% penicillin, 1% glutamine and also 
kept at 37°C in an incubator with 5% CO2. 
 
2. Drugs used in studying the apoptotic effects of a combinatorial ROS 
generating chemotherapeutic system. 
The ability of the PI3K inhibitor LY29 and more importantly, its inactive analogue, 
LY30 to sensitize tumor cells to drug induced apoptosis independently of its ability to 
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inhibit PI3K and possibly via its role in generating H2O2 was a major discussion point 
in the first part of the study. The second part of the study showed that LY30 could 
also sensitize cells to TRAIL induced apoptosis in a non H2O2 dependent fashion. The 
following apoptosis-inducing drugs were used in the present study: vincristine 
(Sigma, St. Louis, MO), LY294002, LY303511 (both from Calbiochem, San Diego, 
CA and Alexis Biochemical, San Diego, CA) and TRAIL (Biomol Research 
Laboratories, Plymouth Meeting, PA). Other chemotherapeutic drugs like etoposide 
(Sigma, St. Louis, MO) and daunorubicin (Sigma, St. Louis, MO) were also used to 
compare the combinatorial efficacy of the LY compounds in the system with the drug 
of choice, vincristine and TRAIL. For all experiments, cells were first pre incubated 
for one hour with LY29 or LY30 before incubation with the chemotherapeutic drug 
of choice. To study the role of caspases in this model, cells were pretreated with 
either caspase inhibitors 2, 3, 8 or 9 (R&D systems, Minneapolis, MN, USA), or the 
pan caspase inhibitor zVAD – fmk (Alexis Biochemicals, San Diego, CA) for one 
hour before preincubation with LY29 or LY30, followed by either vincristine or 
TRAIL, depending on the cell line used. 
 
3. Cell viability assays 
The focus of this thesis centered on the ability of the novel compounds used to induce 
or enhance death in tumor cells and hence the crystal violet cell viability assay was 
used as quick and easy methods of assessing tumor cell viability and proliferation 
after drug treatment. While cell viability was an important parameter in assessing the 
effects of these compounds, more importantly, we had to also account for the colony 
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forming ability of these cells after drug treatment. This was done using a modified 
version of the crystal violet assay. 
 
3.1 Crystal violet cell viability assay 
In a typical survival assay, tumor cells (1-2.5×105 cells/well, depending on cell line 
used) plated in 24 well plates were incubated with the drug(s) of choice for a period 
of 18 to 48h depending on the experiment itself. Cytotoxicity was determined by the 
crystal violet assay. After drug exposure, cells were washed once with phosphate 
buffered saline (PBS) and 0.25ml of crystal violet solution (0.75% crystal violet in 
50% ethanol:distilled water with 1.75% formaldehyde and 0.25% NaCl) was added to 
each well and incubated for 15 min. The excess crystal violet solution was washed 
away with distilled water and the remaining crystals were dissolved in a 1% SDS in 
1X PBS solution. Viability was determined by absorbance at 595nm wavelength 
using an automated ELISA reader 
 
3.2 Colony forming assay 
Both LNCaP and HeLa cells (4000-8000) were first pretreated with LY29 or LY30, 
then treated with 0.02μM of vincristine and 20ng/ml TRAIL respectively for the 
indicated times. In cases where treatment with the drugs affected cell proliferation 
numbers, cell numbers were adjusted accordingly to take this into account when cells 
were plated. After treatment, cells were then washed and replated into 100mm culture 
dishes and left to form colonies over a period of 7 to 10 days. Culture dishes were 
stained with crystal violet and the number of colonies in a 2cm x 2cm grid (on the 
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culture plates) were scored to determine the colony forming ability of cells. Only 
colonies containing more the 50 cells were counted. 
 
4. Apoptotic assays 
While it was established that these novel compounds had some detrimental effect on 
tumour cell viability, it was also critical to determine what sort of death it was 
enhancing, for example, be it apoptotic or necrotic. DNA fragmentation is a hallmark 
of apoptosis where DNA is fragmented into nucleosomal units by endonucleases. 
Propidium iodide, a DNA dye, could pick up this apoptotic population of cells 
containing fragmented DNA and analysis by flow cytometry of such stained cells was 
used in this study. 
 
4.1 Analysis of DNA fragmentation by PI incorporation 
Cells were stained with PI: RNase A (10μg/ml PI and 250μg/ml RNase A, both from 
Sigma, St. Louis, MO) in 38mM sodium citrate solution (in 1x PBS), after 
permeabilization with 70% ethanol, and the stained cells were run on a flow 
cytometer (Beckman Coulter, USA) after which they were analyzed with the 
WinMDI software. At least 10000 events were acquired per sample. The apoptotic 
population of cells are reflected in the histograms as displaying hypodiploid DNA 
content. 
 
4.2 Determination of caspase activities 
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Caspase-2, caspase-3, caspase-8 and caspase-9 activities were determined using the 
fluorogenic peptide substrates, 40μM VDVAD-AMC, 40μM DEVD-AFC, 40μM 
IETD-AFC and 40μM LEHD-AFC, all from Alexis Biochemicals, San Diego, CA, 
respectively, as described previously by (Nicholson et al., 1995). Cell lysates and 
substrates were combined in a standard reaction buffer and real-time measurements of 
enzyme-catalyzed release of AMC or AFC were obtained using a Tecan Genios 
(Zurich, Switzerland) plate reader operating with Magellan software. Final 
fluorescence values obtained after 1h incubation at 37◦C were normalized against the 
protein concentration of samples and plotted as x fold increase in caspase activity 
over the untreated control. 
 
4.3 Analysis of mitochondrial transmembrane potential 
Loss of mitochondrial membrane potential was evaluated by the capacity of cells to 
uptake the potential-sensitive cationic fluorescent probe, 3, 3' 
dihexyloxacarbocyanine iodide (DIOC6, from Molecular Probes Eugene, OR, USA). 
In brief, cells were harvested after drug treatment then incubated with 40nM DIOC6 
in 37°C for 10min before they were washed and resuspended in culture medium. 
These cells were than analyzed by flow cytometry. CCCP (Sigma) is a membrane 
permeable proton ionophore that is always used as positive control for detection 
dissipation of ∆ψ in the study due to its ability to disrupt mitochondrial membrane-
potential. 
 
4.4 Detection of apoptotic related proteins by western blot analysis 
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Total cell lysates, mitochondrial and cytosolic fractions were obtained using standard 
procedures (see each related method). Protein concentration was determined using the 
Coumassie Blue reagent (Pierce, IL, USA) and samples were subjected to different 
concentrations of SDS-PAGE depending on the molecular weight of target proteins, 
followed by transfer to PVDF membranes. In brief, 6% gel was used for detecting p-
mTOR, mTOR, p70S6K, 8% gel used for detecting p-AKT and AKT 12% gel for 
XIAP, cIAP2, DR5, FADD, Caspase 8, Smac, p53 and 15% for detecting caspase-3, 
Smac, and cytochrome c. Immunoblotting was performed with the respective primary 
antibodies (see below), and visualized via enhanced chemiluminescence (Pierce, IL, 
USA). Equivalent protein loading was confirmed by re-probing of membranes with 
antibodies to β-actin or VDAC, as indicated.  
 
Antibodies list for western blot: Akt (Cell Signaling, Beverly, MA, USA), phospho 
Akt ser473 (Cell Signaling, Beverly, MA, USA), Bid (clone 7A3 Cell Signaling, 
Beverly, MA, USA), caspase 3 (BD Pharmingen, San Diego, CA, USA), caspase 8 
(clone 1C13, Cell Signaling), catalase (Calbiochem, Darmstadt, Germany), 
cytochrome c (clone 7H8.2C12, BD Pharmingen, San Diego, CA, USA), DR5 
(BioVision, Mountain View, CA, USA), FADD (clone A662; BD Transduction Labs, 
San Diego, CA, USA), GSK3α/β (Cell Signaling, Beverly, MA, USA), phospho 
GSK3α/β ser 21/9 (Cell Signaling, Beverly, MA, USA), p21 (Santa Cruz, Santa 
Cruz, CA, USA), p53 (BD Pharmingen, San Diego, CA, USA), mTOR (Clone 30, 
BD Transduction Laboratories, San Diego, CA, USA), phospho mTOR ser2481 (Cell 
Signaling, Beverly, MA, USA), p70S6K(clone 1A5, Cell Signaling, Beverly, MA, 
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USA), phospho p70S6K thr 389(Cell Signaling, Beverly, MA, USA), cIAP-2 (clone 
F30-2285, BD Pharmingen, San Diego, CA, USA), XIAP (clone 48, BD Pharmingen, 
San Diego, CA, USA), Smac (clone 7, BD Pharmingen, San Diego, CA, USA), β 
actin (Sigma Aldrich, St Louis, MO, USA). 
 
4.5 Cytochrome c and Smac release 
For isolation of mitochondria and cytosolic fractions, cells were incubated for 30min 
in extraction buffer A. Cells were then homogenized with a dounce homogenizer 30 
times after which the homogenates were centrifuged twice at 300g for 10min. 
Supernatants were collected and centrifuged at 12,000g for 20min. The supernatant 
thus obtained was the cytosolic fraction and the pellet recovered was enriched in 
mitochondria. The whole process was performed on ice. Samples were then denatured 
in RIPA lysis buffer and resolved on SDS-PAGE gels. Cytochrome c and Smac 
release were evaluated by Western blot through a comparison of the expression in 
cytosolic versus mitochondrial fractions. 
 
4.6 Assesment of DISC formation 
5 ×106 HeLa cells were seeded in 100mm petri dishes and treated with LY30 and 
TRAIL accordingly. After treatment, culture medium was removed and cells were 
washed twice with ice cold PBS and incubated for 30 min at 4◦C in cell lysis buffer 
on a rocker platform. Cells were then harvested and centrifuged at 12000 rpm for 
5min at 4◦C and the supernatant was collected, which were then precleared with 20μl 
Protein A (Sigma Aldrich, St Louis, MO, USA) before incubating overnight on a 
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rocker with rabbit polyclonal anti DR5 (BioVision, Mountain View, CA, USA) and 
40μl Protein A (Sigma, St Louis, MO). The complexes were washed four times in 
lysis buffer at 12000 rpm, 5min at 4◦C before boiling for 10min in 1x Lammelli 
loading buffer. The complexes were then electrophoresed on an acrylamide gel and 
immunoblotted with mouse anti caspase 8 (Cell Signaling Beverly, MA, USA) and 
mouse anti FADD (BD Tranduction Labs, San Diego, CA, USA). Protein blots were 
probed for equal loading with polyclonal goat anti DR5 (R&D Systems, Minneapolis, 
MN, USA). 
 
4.7 Assessment of DR5 oligomerization 
For assessment of DR5 oligomerization, the lysates were first precleared, then 
incubated overnight on a rocker with limiting and excess amounts of the same anti-
DR5 used for immunoprecipitation in analysis of DISC formation. The limiting 
(0.4μg) and excess amounts (5μg) of anti-DR5 were determined via a titration 
process where the limiting amount was determined by the highest amount of anti-
DR5 that was just not enough to be able to immunoprecipitate any DR5. The DR5 
complexes were immunoprecipitated with protein A beads and subsequently washed 
as with for analysis of DISC formation earlier. Lysates were then subjected to SDS-
PAGE and immunoblotted with goat anti-DR5. 
 
 
4.8 DR5 surface staining  
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1 ×105 HeLa cells were treated with LY30 and TRAIL accordingly then washed three 
times in PBS supplemented with 0.5% BSA. Subsequently, they were stained with 
phycoerythrin-conjugated mouse monoclonal anti-human DR5 or DR4 (clone 71908 
and 69036 respectively; both from R&D systems, Minneapolis, MN, USA) for 45 
minutes at 4°C as per manufacturer’s instructions before washing and resuspension in 
PBS for flow analysis using 488 wavelength laser excitation. As an isotype control 
for analysis, cells were also separately treated with PE-labeled mouse IgG antibody, 
also from R&D systems, Minneapolis, MN, USA. 
 
5. Detection of intracellular H2O2 levels.  
Intracellular concentration of H2O2 was determined by staining with the redox 
sensitive dye 5-(and-6)-chloromethyl-2’,7’-dichlorofluorescin diacetate (CM-
H2DCFDA; Molecular Probes, Eugene, OR, USA), which becomes fluorescent when 
oxidized by H2O2 and its free radical products.  After harvesting, cells were washed 
once with PBS, loaded with 5μM CM-H2DCFDA at 37oC for 15 minutes, and 
analyzed by flow cytometry using an excitation wavelength of 488nm.  At least 
10,000 events were analyzed.  
 
6. Non-radioactive Akt/PKB immunoprecipitation kinase activity assay: 
Determination of the Akt/PKB kinase activity was done via the AKT kinase assay kit 
(Cell Signaling, Beverly, MA, USA). 3 ×106 LNCaP cells were plated in a 100mm 
petri dish and treated with the indicated compounds for the various amounts of time 
after which the culture medium was removed and the cells washed once with ice cold 
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PBS. 1ml of cell lysis buffer was added to each plate and allowed to incubate for 
10min. Cells were then scraped off the plates and immobilized Akt monoclonal 
antibody was used to immunoprecipitate Akt from cell extracts. Then, an in vitro 
kinase assay was performed using GSK-3 fusion protein as a substrate. 
Phosphorylation of GSK-3 was measured by Western blotting, using a phospho-GSK-
3α/β (Ser21/9) antibody (Cell Signaling, Beverly, MA, USA). 
 
7. Molecular approaches 
 
7.1 Amplification of pzeoSV-catalase 
The pzeoSV-h-catalse was a generous gift from Dr. J.D. Lambeth, Emory University 
School of Medicine, Atlanta. Cells were first transformed with the plasmid (both the 
empty vector and the one containing the catalase construct) on zeocin (25μg/ml) 
containing agar plates. Colonies were then picked out and used for mini and maxi 
culture as per manufacturer’s instructions from Nuclebond, Clontech Laboratories, 
CA, USA followed by maxi prep (Nucleobond, Clontech Laboratories, CA, USA) to 
obtain amplified amounts of the DNA which were then subject to restriction enzyme 
analysis to check for integrity of the maxi prep. The DNA was then purified with high 
salt and ethanol before dissolving in sterile water for use for transient transfection. 
 
7.2 Transient transfection of pzeoSV-catalase 
Cells were transiently transfected with the pzeoSV plasmid vector with the 1.6kb 
human catalase cDNA cloned into the HindIII sites. Briefly, the pzeoSV-h-cat was 
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transfected into cells using the SuperFect Transfection reagent from Qiagen GMBH 
(Germany) as per manufacturer’s instructions. Overexpression of human catalase 
occurred at usually around 24-48h after transfection and decreased to basal levels 
subsequently. Cells transfected with the empty vector pzeoSV were used as controls. 
Expression of human catalase protein was detected using human anti-catalase 
antibody (Calbiochem, Darmstadt, Germany), which recognizes the 60-65 kDa 
catalase subunit in cell lysates. 
 
Appendix: Buffers used in the study 
 
RIPA Lysis Buffer: 
50mM Tris HCL ph7.5, 150mM NaCl, 1% v/v Nonidet P40, 1%v/v deoxycholic acid, 
0.1%v/v SDS, 1mM EDTA. Before use, protease inhibitors (1mM PMSF, 10μg/ml 
Aprotinine, 20μg/ml Pepstatin A, 10μg/ml Leupeptine, 1mM NaF, 1mM Na3VO4) 
were added. 
 
Cell lysis buffer for immunoprecipitation experiments: 
30mM Tris-Hcl pH 7.5, 150mM NaCl, 2mM EDTA, 10% glycerol, 1% Triton X 
supplemented with protease inhibitors 1mM PMSF, 10mg/ml Aprotinine, 20mg/ml 
Pepstatine A and 10mg/ml Leupeptine 
 
2X Reaction Buffer for caspase substrates: 
20mM Hepes, 4mM EDTA, 20mM KCL and 3mM MgCl2 in distilled water. 
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Buffer for making SDS-Page gel: 
Separating gel preparation (0.375M Tris, pH 8.8) 
 
Percentage of gel 15% 12% 10% 7.5% 5% 
dH2O (ml) 2.35 3.35 4.02 4.85 5.68 
1.5M Tris pH 8.8 (ml) 2.5 2.5 2.5 2.5 2.5 
10%SDS 100μl 100μl 100μl 100μl 100μl 
30% Acrylamide/Bis (ml) 5 4 3.33 2.5 1.67 
10% APS 50μl 50μl 50μl 50μl 50μl 
TEMED 5μl 5μl 5μl 5μl 5μl 
Total volume 10 10 10 10 10 
Linear separating range (KD) 12-43  16-68 36-94 57-212 
 




  dH2O (ml) 7.29 
  1.0M Tris pH 6.8 (ml) 1.25 
  10%SDS 100μl 
  30% Acrylamide/Bis (ml) 1.3 
  10% APS 50μl 
  TEMED 5μl 
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  Total volume 10ml 
 
Running buffer for SDS-Page gel: 10X (2L) 
Tris-base 60g, glysine 288g, SDS 20g, top to 2L with dH2O. 
 
Transfer buffer for western blot: 1X (5L) 
Tris-base 12.1g, glycine 57.84g, methanol 1L, top to 5L with dH2O. 
 
Lammeli loading buffer: 5X (10ml) 
Tris-Hcl pH 6.8  3.1ml (1M), SDS 1g (10%), glycerol 2ml (20%), beta-Me 2.5ml 
(25%), BPB 0.01g (0.1%), top to 10ml with 2.4ml dH2O. 
 
Buffer A for detection of  cytochrome c and Smac release: 
50mM PIPES-KOH pH7.4, 220mM mannitol, 68mM sucrose, 50mM KCl, 5mM 
EGTA, 2mM MgCl2, 1mM DTT. Before use, protease inhibitors (1mM PMSF, 
10μg/ml Aprotinine, 20μg/ml Pepstatin A, 10μg/ml Leupeptine, 1mM NaF, 1mM  




1. LY294002 AND LY303511 PRODUCE HYDROGEN PEROXIDE 
INDEPENDENT OF INHIBITION OF THE PI3K-AKT AXIS IN TUMOR 
CELLS. 
 
1.1 LY294002 triggers hydrogen peroxide production in tumor cells. 
In order to determine the relevance of ROS, in particular, H2O2, on the PI3K-Akt 
axis, a variety of tumor cell lines, T24 (human bladder carcinoma), HL60 (human 
leukemia), CEM (human leukemia) and LNCaP (human prostate carcinoma) were 
incubated with the PI3K inhibitor, LY29 (25 μM), for 1h and stained with DCFH-
DA, a redox sensitive dye, which is oxidized by H2O2. The oxidized product can be 
detected by the shift in fluorescence and by fluorescent-activated cell sorting (FACS) 
using a flow cytometer. Incubation of LNCaP cells, a prostate carcinoma cell line 
expressing hyperactivation of Akt due to a functionally inactive PTEN, with LY29 
(25 μM) for 1 hour (concentration commonly used in assays for the inhibition of 
PI3K) resulted in a significant increase in DCFH-DA fluorescence (Figure 4), which 
could be reversed in the presence of 1,000 units/ml of the H2O2 scavenger, catalase, 
thus indicating intracellular H2O2 production upon inhibition of PI3K. More 
importantly, this effect was not exclusive to LNCaP cells as evidenced by the similar 
effect of LY29 on HL60, CEM and T24 cells (Figure 4). Given that the 
mitochondrion is one of the main sources of intracellular ROS, attempts were made to 

















Figure 4: LY29 triggers intracellular H2O2 production in tumor cells. 
Tumor cells (1x106) from a variety of cell lines were treated with 25μM of 
LY29 for 1h in the presence or absence of 1000U/ml of catalase.  Cells were 
loaded with the H2O2 sensitive probe DCFH-DA (5μM) for 15 min and 
intracellular H2O2 was determined by the shift in DCFH-DA fluorescence as 
detected by flow cytometry. 
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intracellular H2O2. Interestingly, overexpression of Bcl2 did not inhibit the generation 
of intracellular H2O2 upon exposure to LY29 for 1h (CEM-Bcl-2; Figure 4).  
 
1.2 LY294002-induced hydrogen peroxide production is independent of its 
phosphoinositide 3-kinase-Akt inhibitory activity in LNCaP cells. 
It would seem to appear that it was the inhibition of PI3K by LY29 that resulted in 
generation of intracellular H2O2, suggesting a direct correlation between intracellular 
H2O2 levels and PI3K activity. In order to further study this, the LNCaP cell line was 
used as a model cell line, as these cells possess a functionally inactive PTEN, 
resulting in constitutive hyperactivation of the intracellular PI3K-Akt axis. LNCaP 
prostate cancer cells were first incubated with increasing concentrations of LY29 (1-
25 μM) for 1h and its concurrent effects on PI3K-Akt activation (as assessed by its 
phosphorylation status and activity) and intracellular H2O2 production were assessed. 
Akt activation as assessed in this manner, was then used as a read out for inhibition of 
PI3K activity by LY29. As expected, treatment with concentrations of LY29 in 
excess of 5 μM for 1h effectively blocked PI3K activity as evidenced by the 
inhibition of Akt phosphorylation and activity in LNCaP cells, assayed by Western 
blot analysis with the phospho-Akt (ser 473) antibody and by the ability of the 
phosphorylated Akt to phosphorylate its substrate GSK-3α/β (Figure 5A) in an Akt 
immunoprecipitation kinase activity assay. Intriguingly, LY29 was able to trigger 
intracellular H2O2 production at a concentration (1μM; Figure 5B) that did not affect 
Akt phosphorylation status or its ability to phosphorylate GSK-3α/β. This suggested 
that LY29-induced H2O2 production was independent of its inhibitory effect on  
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Figure 5: LY29-induced H2O2 production is independent of its 
PI3K-AKT inhibitory activity in LNCaP cells. (A) LY29 
dephosphorylates and deactivates AKT in a dose dependent manner. 
1.5 to 2 x106 LNCaP cells were incubated with varying doses of LY29 
for 1h and cell lysates were obtained for analysis of the AKT
phosphorylation status. In a similar experiment, 3 x106 LNCaP cells 
were incubated with similar doses of LY29 for 1h after which the
AKT immunoprecipitation kinase activity assay was performed on 
these cell lystates. Total AKT and total GSK bands indicated equal 
loading of protein for analysis of the AKT phosphorylation status and 
activity respectively. (B) LNCaP cells (0.8x106) were treated with 
1μM of LY29 for 1h in the presence or absence of 1000U/ml of 
catalase and assayed for the amount of intracellular H2O2 generated.
Medium
Catalase
Catalase + LY29 (1μM)
LY29 (1μM)
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intracellular PI3K activity, which was further corroborated by the inability of 
wortmannin, another commonly used PI3K inhibitor, to generate intracellular H2O2 
(Figure 6B) at doses that effectively inhibited Akt phosphorylation (10nM to 200nM) 
(Figure 6A). In fact, incubation of LNCaP cells with wortmannin actually reduced the 
levels of H2O2 in the cell (Figure6B). While the data at this point in time is not 
sufficient to explain this observation, it could be attributed to wortmannin’s ability to 
non specifically inhibit mitogen activated protein kinases (MAPKs) and 
phopsholipase D, as previously discussed in the Introduction, which might have a 
negative effect on the intracellular H2O2 levels. 
 
1.3 LY303511 (LY30), a LY294002 analogue that does not inhibit PI3K, is 
also able to produce intracellular H2O2 
To provide further evidence that the ability of LY29 to produce intracellular H2O2 
was not linked to its PI3K inhibitory effect, an analogue of LY29 (i.e., LY30), which 
has a high degree of structural similarity with LY29 (Figure 7A) but lacks the ability 
to inhibit the PI3K enzyme (Figure 7C) was investigated. LY30 differs from LY29 by 
an amine substitution for morpholino oxygen, thus reducing its ability to inhibit PI3K 
at its ATP binding site. Indeed, similar to the results obtained with LY29, incubation 
of LNCaP cells for 1 hour with varying concentrations of LY30 (1-25 μM) resulted in 
a significant increase in intracellular H2O2 (Figure 7B). 
 
1.4 Both LY29 and LY30 sensitize LNCaP cells to drug-induced apoptosis 





























Figure 6: Wortmannin inhibits PI3K, but has no effect on 
intracellular H2O2 production in LNCaP cells (A) LNCaP cells (1.5 to 
2 x106) were incubated with varying concentrations of wortmannin 
(10nM to 200nM) for 1h and cell lysates were obtained for western blot 
analysis of the AKT phosphorylation status. (B) LNCaP cells (0.8x106) 
were treated with varying doses of wortmannin (10nM to 200nM) for 1h. 
Cells were then loaded with DCFH-DA (5μM) for 15min. and 















Figure 7: LY30, a LY29 analogue, also produces H2O2 in LNCaP cells. 
(A) Structures of both LY29 and LY30. (B) LNCaP cells (0.8x106) were 
treated with varying doses (from 1μM to 25μM) of LY30 for 1h in the 
presence or absence of 1000U/ml of catalase. Cells were then loaded with 
DCFH-DA (5μM) for 15min. and intracellular H2O2 was detected by flow 
cytometry. (C) 1.5 to 2 x106 LNCaP cells were incubated with 25μM of 
LY29 or LY30 for 1h and cell lysates were obtained for western blot analysis 
of the AKT phosphorylation status.
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While it has been established in this study that both LY29 and LY30 could trigger 
increases in intracellular H2O2, independent of inhibition of PI3K, this observation 
had no merit on its own, unless it could be proven that the intracellular H2O2 thus 
generated, was physiologically active in the tumor cell. As the PI3K-inactive LY29 
analogue, LY30, could also generate intracellular H2O2 but not inhibit PI3K, it could 
therefore be used to study the H2O2 dependent and PI3K independent activity of the 
LY compounds in the cell for a parallel comparison with the (known) anti tumor 
effects of LY29. However, most studies have used LY30 as a negative control in 
experiments looking at PI3K effects in cultured cells, tumor or otherwise. A few 
recent studies have indicated PI3K independent effects of both LY29 and LY30, but 
none with regards to the induction of apoptosis in tumor cells. While it has been fairly 
well established that neither LY29 nor its analogue, LY30, could on their own, 
directly induce apoptosis in tumor cells in a PI3K independent fashion, the ability of 
these compounds to sensitize tumor cells to drug induced apoptosis via their ability to 
generate intracellular H2O2 has not been conclusively excluded. Hence, a system was 
developed using LNCaP cells to study if these LY compounds (LY30 in particular) 
could sensitize tumor cells to drug induced apoptosis via the generation of 
intracellular H2O2. 
 
2. PRETREATMENT WITH LY29 AND LY30 REDUCES VIABILITY OF 
VINCRISTINE TREATED LNCAP CELLS 
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2.1 Vincristine treatment appeared to be the most susceptible to sensitization 
by the LY compounds via their ability to generate intracellular H2O2.   
In order to determine if there was any functional significance to the increase in 
intracellular H2O2 levels by the LY compounds, especially with regards to 
sensitization of tumor cells to drug induced apoptosis, LNCaP cells were first pre 
treated for 1h with 1000 units/ml catalase, followed by 1h treatment with 25μM 
LY29 or LY30, then followed by treatment for 18h with vincristine (1.5μM), 
etoposide (10μM) and daunorubicin (0.2μg/ml), before cell viability was assessed 
with crystal violet staining. This was the order in which drugs were added for all 
subsequent sensitization experiments in this study (catalase first if used, followed by 
LY29 or 30, then the drug of choice) and both catalase and the LY compounds were 
not washed off during the total course of treatment. Intriguingly, while LY29 could 
sensitize LNCaP cells to drug induced apoptosis as expected, due to its ability to 
inhibit PI3K; LY30 also appeared to be able to slightly enhance vincristine induced 
cell death in LNCaP cells (Figure 8A). This effect also appeared to be catalase 
sensitive, as a 1h pretreatment with 1000units/ml catalase before treatment with LY30 
could protect the LY20-vincristine treated cells slightly against loss of viability 
suggesting an involvement of H2O2 in the sensitization process. The increase in cell 
death by LY30 was not as pronounced for cells treated with etoposide and 
daunorubicin. At the same time, the activity of caspases 2, 3, 8 and 9 in LY29 or 
LY30-vincristine treated cells was assessed at 12 and 18h (Figure 8B – E). 






vincristine treated cells, cells treated with both LY30 and vincristine also 
demonstrated a slight increase in caspase 2 activity (Figure 8B).  
 
2.2 LNCaP cells treated with lower doses of vincristine are more easily 
sensitized to cell death by the LY compounds. 
As initial studies showed that vincristine treated cells appeared to be the most 
responsive to LY30 mediated sensitization, vincristine was therefore selected as the 
drug of choice in all subsequent LY29 and LY30 sensitizing experiments with 
LNCaP cells. However, the dose of vincristine that was currently used (1.5μM) 
appeared to be cytotoxic for a significant sensitizing effect of LY30 to be observed, a 
dose response curve for vincristine was established (Figure 9A). The experiments 
were repeated again at one tenth (0.1μM) of the original dose of vincristine used 
earlier, seeing how 0.1μM vincristine appeared to induced minimal loss of cell 
viability (less than 10%). Indeed, a lower dose of vincristine (0.1μM) resulted in a 
more enhanced sensitization to vincristine induced cell death by LY30 as evidenced 
by the loss of cell viability (Fig 9B). It also appeared that caspase 2 and 3 activities 
were enhanced in LY30-vincristine treated cells at the lower dose of 0.1μM (Figure 9 
C and D) as compared to the earlier experiment with the higher dose. However, as 
with the previous result with 1.5μM vincristine (Fig 8D and E), there did not seem to 
be any increase in caspase 8 and 9 activity with the LY30-vincristine (0.1μM) treated 
cells (Figure 9E and F), suggesting that it is perhaps caspase 2 and 3 that play a 








 2.3 Establishment of an ideal dose of vincristine used (0.02μM) for the 
optimal sensitization of LNCaP cells to vincristine induced cell death by the LY 
compounds. 
Having demonstrated that a markedly reduced dose of vincristine (0.1μM) could 
enhance LY30 mediated sensitization; an even lower dose of vincristine where almost 
no loss of cell viability was seen at 18h (0.02μM), was used in conjunction with the 
LY compounds in the sensitization studies, in order to observe an even more optimal 
sensitization to cell death. With the selection of the optimal nonlethal dose of 
vincristine (0.02μM), LNCaP cells were then subsequently treated for 18h with this 
dose (0.02 μM) of vincristine that did not, by itself, have any effect on tumor cell 
viability (Figure 9A). However, preincubation of cells with LY29 and LY30 for 1h 
significantly increased tumor cell sensitivity to 0.02 μM vincristine as indicated by 
the reduction in the viable cell fraction (Figure 10) by an extent that was not observed 
with the previous vincristine doses used. At the same time, cell viability experiments 
indicated that incubation of cells with LY29 or LY30 overnight for 18 hours alone, 
reduced cell viability by 40% and 15%, respectively, suggesting perhaps an 
antiproliferative effect of these compounds on the doubling rate of LNCaP cells as 
well (Figure 10), given that the doubling time of these cells is about 24h. This could 
be extrapolated to mean that proliferation of all of the LY29 treated cells was affected 
and proliferation of about 15% of LY30 treated cells were affected. This observation 
appears to be concurrent with the recent study on LY30 by (Kristof et al., 2005) 





3. LY30, LIKE LY29 CAN MARKEDLY ENHANCE APOTOSIS IN 
VINCRISTINE TREATED LNCAP CELLS AS WELL AS REDUCE THEIR 
COLONY FORMING ABILITY. 
  
3.1 LY30, like LY29, can enhance caspase activation in vincristine treated 
cells. 
In order to further determine what type of cell death the LY compounds (LY30 in 
particular) were sensitizing vincristine treated LNCaP cells to, assays to determine the 
presence of the classical apoptotic characteristics, caspase activation and DNA 
fragmentation, were carried out.  While treatment with 0.02μM vincristine alone did 
not induce any intracellular caspase activation, pretreatment of cells with LY29 or 
LY30 triggered significantly robust increases in caspase-2 and caspase-3 activities on 
subsequent exposure to the same concentration of vincristine over a time frame of 6 
to 18h (Figure 11A; p<0.01, and 11B; p<0.05). The involvement of caspases in this 
sensitization model was further evidenced by the use of the tetrapeptide inhibitors of 
caspase-2 (VDVAD-fmk), caspase-3 (DEVD-fmk), and the pan-caspase inhibitor 
(ZVAD-fmk) on the effect of cell viability of vincristine treated cells pretreated with 
the LY compounds. The cell viability studies were carried out over a time frame of 18 
and 48h (Figure12A and B). Addition of ZVAD-fmk was able to block LY-induced 
sensitization of LNCaP cells (by both LY29 and LY30) to drug induced apoptosis 
more effectively than the addition of caspase-2 or caspase-3 inhibitor alone, as seen 
most significantly in an increase in cell viability over a longer period of study at 48 






3.2 LY30, like LY29, can enhance DNA fragmentation in vincristine treated 
cells in a caspase dependent manner. 
Again, as an additional marker of apoptosis, analysis of fragmented DNA was also 
carried out (Figure 13 and 14). LNCaP cells incubated with 0.02μM vincristine were 
again preincubated in the presence or absence of LY29 or LY30 for 1h. Incubation 
with 0.02μM vincristine alone did not alter the cell cycle profile; however, addition of 
LY29 or LY30 to vincristine-treated cells increased the sub-G1 and G2/M fractions of 
these cells, albeit to different extents at 18 and 48h (Figure 14A and B respectively). 
Extent of DNA fragmentation is shown as a histogram where LY30 increased the 
amount of DNA fragmentation observed in vincristine-treated cells to levels similar 
to that observed with LY29 at 48h incubation (Figure 14B). In addition, caspase-3 
inhibitor (DEVD-fmk), and the pan-caspase inhibitor (ZVAD-fmk) reduced the 
amount of DNA fragmentation in LY-vincristine treated samples at 18 and 48h as 
shown in Figures 10A and B and the actual cell cycle profiles as obtained by 
propidium iodide staining (Figure 14A and B). Addition of caspase-2 inhibitor 
(VDVAD-fmk) however, did not appear to have a significant effect on the DNA 
fragmentation observed (Figure 13A and B) The pan-caspase inhibitor ZVAD-fmk 
reduced the extent of DNA fragmentation effectively as depicted in the representative 
cell cycle profiles (Figure 14A and B). The ability of ZVAD-fmk to almost 
completely attenuate the process of DNA fragmentation much more effectively than 
the presence of either caspase 2 or caspase 3 inhibtior alone suggests that it is 
probably the synergistic inhibition of caspases 2 and 3 by ZVAD-fmk that protected 





Figure 14: LY30 increases the extent of DNA fragmentation in 
vincristine treated cells in a caspase dependent manner. (A) and (B)  
The actual cell cycle profiles as analysed by flow cytometry of LNCaP 
cells treated for 18h to show the effect of ZVAD on cells treated with 





3.3 LY303511 inhibits colony-forming ability of LNCaP cells treated with 
vincristine.  
The ability to kill off tumor cells should not be the sole aim of any chemotherapeutic 
regimen, as it should also be supplemented by an ability to prevent regeneration of 
the tumor itself. In a cellular context, regeneration of the tumor cell is evidenced by 
the ability of a single tumor cell to divide and form colonies. While LY30, like LY29, 
could effectively sensitize LNCaP cells to vincristine-induced apoptosis, the ability of 
the tumor cells to form colonies again after drug treatment is also an important 
consideration, thus experiments to study the colony forming ability of LNCaP cells 
after treatment with LY29/30 and vincristine were set up. Here, not only could both 
LY29 and LY30 sensitize cells to vincristine-induced cell death, but they were also 
effective in reducing the colony-forming ability of LNCaP cells when co treated with 
vincristine (Figure 15). LNCaP cells were pretreated with LY29 or LY30 before 
treatment with 0.02μM vincristine for 18h. As both LY29 and LY30 had an effect on 
cell proliferation overnight, the cell numbers were adjusted accordingly to take that 
into consideration. The cells were then replated onto 100 mm culture plates and 
incubated for 8 to 14 days to allow colonies to form. Cells pretreated with LY29 or 
LY30 (before vincristine exposure) showed a significant reduction in the number of 
colonies formed compared with cells treated with vincristine alone (Figure 15B). It 
should be pointed out that treatment of tumor cells with LY30 alone for 18h did not 
seem to significantly reduce the colony-forming ability of cells; however, incubation 
for the same period with LY29 alone affected the colony-forming ability of LNCaP 
cells, suggesting an even stronger sensitizing effect of LY30, which unlike LY29, has  
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Figure 15: LY30 inhibits colony forming ability of cells treated
with vincristine. (A) LNCaP cells (4000-8000) were exposed to 
0.02μM vincristine for 18h in the presence or absence of a 1h 
pretreatment either with 25μM LY29 or LY30. The cells were 
then seeded in 100mm petri dishes and allowed to form colonies 
over 8 to 14 days, after which they were stained with crystal violet 
to show colony formation. Data shown is representative of 9 
independent experiments, each performed in triplicate. (B) 
Histogram shows extent of colony formation for 3 independent 
experiments, each performed in triplicate.
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no effect on the PI3K-Akt pathway. Also, the histogram showing extent of colony 
formation (Figure 15B) appeared to show that LY30 had a better colony forming 
efficiency as compared to medium alone, although the reverse was true in the picture 
of the colonies themselves (Figure 15A). Here, seeing how colonies consisting of 
more than 50 cells were scored, the medium dish had larger but fewer colonies as 
compared to LY30, where the colonies were relatively smaller but more numerous, 
hence the disparity in numbers against the actual picture itself  (108% for LY30 
compared to 100% for medium only).   
 
4. PI3K INDEPENDENT SENSITIZATION OF LNCAP CELLS TO 
VINCRISTINE INDUCED APOPTOSIS IS A H2O2 DEPENDENT PROCESS. 
 
4.1 Transfection with human catalase is able to scavenge the synergistic burst 
of intracellular H2O2 seen upon incubation of cells with LY30 and vincristine.  
Additionally, whereas a low nonlethal dose of vincristine (0.02μM) did not produce 
any detectable H2O2, preincubation of tumor cells with 25μM LY30 produced a 
significant burst of intracellular H2O2 as seen with a rightward shift in DCF 
fluorescence (Figure 16). Having shown that the LY compounds not only increased 
sensitivity to drug-induced apoptosis but also stimulated a significant increase in 
intracellular H2O2 production, we next asked if LY-induced increases in caspase-2 
and caspase-3 activities and cell sensitivity to drug-induced apoptosis were a result of 
intracellular H2O2 production. To do so, LNCaP cells were transiently transfected 
with a pzeoSV plasmid vector containing a 1.6-kb human catalase cDNA.  
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Figure 16: Preincubation with LY30 before 
treatment with vincristine results in a synergistic 
burst of intracellular H2O2. LNCaP cells (0.8x106) 
were treated with 0.02μM vincristine for 1h in the 
presence or absence of a 1h preincubation with 25μM 
LY30. Cells were then loaded with DCFH-DA (5μM) 




Overexpression of catalase was confirmed by Western blot analysis (Figure 17A). 
Cells overexpressing catalase showed a decrease in basal intracellular levels of H2O2 
and an ability to reduce the amount of intracellular H2O2 produced by LY30. 
However, cells overexpressing catalase could sometimes bypass the antioxidant 
effects of overexpressed intracellular catalase levels and achieve similar intracellular 
basal H2O2 levels as cells transfected with the empty vector (Figure 17B). 
Nevertheless, even in such catalase overexpressing cells with similar intracellular 
H2O2 levels as those transfected with the empty vector, there was no synergistic 
increase of intracellular H2O2 upon incubation with LY30 and vincristine (Figure 
17B), indicating the functionality of the transiently transfected catalase gene.  
 
4.2 Transfection with human catalase inhibits caspase activity and protects 
against the increase in apoptosis sensitivity induced by LY29 and LY30.  
While catalase overexpressing cells might display varying basal levels of H2O2, they 
were nonetheless protected against the LY30 mediated sensitization to vincristine, 
probably due to the scavenging effects by catalase on the LY30-vincristine mediated 
synergistic increase in H2O2 levels. When compared against vincristine treated cells, 
transient overexpression of catalase was able to protect the cells from sensitization by 
both LY29 and LY30 as measured by an increase in cell viability after an 18h 
incubation period using the crystal violet assay (Figure 18A). Caspase 2 and 3 
activation of these cells were also measured at the same time point (18h) and again, 
catalase overexpression could reduce activation of caspases 2 and 3 in both LY29-
vincristine and LY30-vincristine treated cells (Figure 18B). Interestingly, although  
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Figure 17: Transfection of human catalase into cells can scavenge the 
LY30-vincristine mediated synergistic increase in intracellular H2O2. 
(A) LNCaP cells were transiently transfected with human catalase and the 
empty zeocin vector. Overexpression of the catalase was detected by 
western blot analysis. Catalase overexpression resulted in similar or 
decreased basal levels of H2O2 in LNCaP cells assayed by DCFH-DA 
loading and flow cytometry. (B) LNCaP cells (0.8x106) transiently 
overexpressing catalase or an empty vector were treated with 0.02μM 
vincristine for 1h in the presence or absence of a 1h preincubation with 
25μM LY30. Cells were then loaded with DCFH-DA (5μM) for 15min. 













Figure 18: Transfection of human catalase into cells protects them 
by reducing the increase in caspase 2 and 3 activity in cells treated 
with vincristine and LY29 or LY30. (A) and (B) At 24h post-
transfection, 0.8×106 LNCaP cells were treated with LY30/29 and 
0.02μM vincristine as per previously. Activation of caspases and 
proliferation rate of these cells were then assayed 18h later as previously 





overexpression of catalase resulted in a greater reduction in caspase activity for the 
LY29-vincristine treated cells, the viability of these cells were restored to a lesser 
extent, as compared to LY30-vincristine treated cells, indicating that lowering of the 
intracellular H2O2 levels via overexpression of catalase was still not sufficient enough 
to override the PI3K inhibitory effect of LY29, thus explaining the persistent decrease 
in cell viability for LY29-vincristine treated cells. While the mechanism of LY29 (via 
its PI3K inhibitory activity) enhanced cell death has been extensively studied, the 
observation that LY30 can also enhance drug-induced apoptosis in tumor cells is a 
relatively new and unexplained phenomenon.  
 
4.3 Overexpression of catalase increases the stay of LY30-vincristine treated 
cells in G2/M cell cycle arrest. 
Having shown earlier that LY30-vincristine mediated apoptosis in LNCaP cells is 
brought about by caspase dependent DNA fragmentation of the cell, the cell cycle 
profiles of cells overexpressing catalase were thus analysed via propidium iodide 
staining (Figure 19A and B). Interestingly, overexpression of catalase resulted in 
LY30-vincristine treated LNCaP cells entering G2/M cell cycle arrest earlier after 
12h of treatment (Figure 16B). Cells transfected with the empty vector did not enter 
G2/M cell cycle arrest at this time (12h); instead, some of these cells appeared to 
proceed directly into the apoptotic sub G1 fraction. Entry into significant apoptosis 
was also delayed in catalase overexpressing cells as shown by the increase in the G1 
fractions of these cells at 36 to 48h before proceeding into apoptosis (Figure 19B). 





Figure 19: Catalase overexpression could allow LNCaP cells to enter 
and stay in cell cycle arrest for a longer time in vincristine-LY30 
treated cells. (A) and (B) The actual cell cycle profiles as analysed by 
flow cytometry of LNCaP cells (0.8×106 ) treated for 12 – 48h to show 
the effect of empty vector/catalase transfection on cells treated with 
0.02μM vincristine and LY30 as per previously. Data shown is 
representative of at least three independent experiments.
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parallel its active counterpart, LY29, albeit at a slower rate, by first inducing G2/M 
cell cycle arrest, followed by apoptotic degradation of the cell via DNA 
fragmentation.  
 
4.4 Upregulation of p53 expression is observed in LY30-vincristine treated 
catalase overexpressing cells – concomitant with their entry into G2/M cell cycle 
arrest.  
Preliminary analysis of common proteins involved in G2/M cell cycle arrest like p53 
and p21, revealed that singular treatment with LY30 could upregulate p21 after a 12-
18h incubation period (lanes 2 and 3 in Figure 20A). However, cells incubated with 
both LY30 and vincristine demonstrated reduced levels of p21 at 12 and 18h (lane 6 
and 7 in Figure 20A) compared to cells treated with either drug alone (lanes 2 to 5 in 
Figure 20A). p53 levels were also synergistically increased in cells treated with both 
LY30 and vincristine at 18h (lane 7 in Figure 20A) compared to cells treated with 
LY30 and vincristine alone (lanes 3 and 5 in Figure 20A), concomitant with their 
state of G2/M arrest at 18h (Figure 14C). It would appear that the intracellular levels 
of p53 was only synergistically increased in LY30-vincristine treated cells arrested in 
the G2/M phase but a similar pattern was not observed with p21. In fact, single agent 
treatment (either LY30 or vincristine) resulted in an upregulation of p21 levels, 
however, co-treatment with both compounds resulted in a reduction of p21 levels 
back to those seen in untreated cells, suggesting that p21 levels were only upregulated 
in “pre arrest” cells singularly treated with either LY30 or vincristine. Having 
observed that catalase overexpressing cells entered G2/M cell cycle arrest earlier than 
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the empty vector transfected ones, the expression profiles of p53 and p21 in these 
cells were also similarly analyzed at 12h, when the catalase overexpressing cells were 
arrested in the G2/M phase but not the cells transfected with the empty vector. 
Indeed, there was an upregulation of p53 levels in LY30-vincristine treated catalase 
overexpressing cells (when compared against the lower β actin levels), concomitant 
with their entry into G2/M cell cycle arrest (lane 8, Figure 20B). There was no change 
in p21 levels in LY30-vincristine treated cells for either the catalase or empty vector 
transfected cells, however, in the vector transfected cells singly treated with LY30, 
there appeared to be an upregulation of p21 levels (lane 2, Figure 20B), again, 
perhaps again, suggestive of a “pre arrest” state in these cells as these cells have not 
yet entered G2/M cell cycle arrest. 
 
Having shown that the formerly inactive analogue of LY29, LY30 was able to 
sensitize LNCaP cells to sub lethal doses of vincristine, the next step was to 
establish if LY30 could behave similarly in other apoptotic models, for example, 
receptor mediated apoptosis, with one such example being the TRAIL induced 
receptor mediated apoptosis model. The current interest in small molecule 
compounds that could sensitize tumor cells to TRAIL induced apoptosis arose as a 
result of the frequently observed TRAIL resistant phenotype in tumor cells as well 
as reports of non specific TRAIL mediated toxicity. This prompted the question if 
LY30, as a cell-permeable small molecule compound, could also behave similarly 
as a sensitizer in the settings of TRAIL-induced apoptosis, by improving the 
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Figure 20: Catalase overexpression could alter expression levels of 
p53 and p21 in vincristine-LY30 treated cells. (A) LNCaP cells were 
treated for 12 – 18h with vincristine and LY30 as per previously to show 
the expression profiles of p53 and p21 analyzed via Western Blot. (B) 
The effect of empty vector/catalase transfection on the expression profiles 
of p53 and p21 of LNCaP cells (0.8×106 ) similarly treated with 
vincristine and LY30 was analyzed via Western Blot. 
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as well as possibly reversing the TRAIL resistant tumor phenotype with this new 
and improved drug efficacy. In order to test the hypothesis that LY30 could also 
behave as a sensitizer in TRAIL mediated apoptosis, a TRAIL responsive tumor 
cell line, the cervical carcinoma cell line HeLa, was first selected to be used as a 
model cell line for the initial study. 
 
5. LY30 CAN SENSITIZE CERVICAL CARCINOMA HELA CELLS TO 
TRAIL INDUCED APOPTOSIS AND INHIBIT TUMOR COLONY 
FORMATION 
                                                                                                                                                                        
5.1 Pre-incubation with LY30 increases TRAIL sensitivity via a reduction in 
cell viability. 
A dose response curve for TRAIL was first established for HeLa cells by evaluating 
the effect of increasing concentrations (20-100ng/ml) of TRAIL on cell viability for 
18h. HeLa cells responded to TRAIL exposure in a dose dependent manner with the 
LD50 of approximately 50ng/ml, but with relatively modest effect on cell viability 
(<20%) at concentrations of 20ng/ml or below (Figure 21A).  Therefore, in all 
subsequent experiments, a concentration of 20ng/ml of TRAIL was used to assess the 
death amplifying activity of LY30. HeLa cells were then subsequently incubated with 
LY30 at the same dose (25μM) used in the LY30-vincristine study with LNCaP cells 
for 1h, followed by treatment with 20ng/ml TRAIL for 18h. All subsequent 
experiments with LY30 and TRAIL were performed in this manner, with no washing 
off of the drugs after addition. Indeed, results show that pre-incubation of HeLa cells 
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with LY30 for 1h followed by treatment with 20ng/ml of TRAIL for 18 hrs resulted 
in enhanced cell death (Figure 21B). This reduction in cell viability with LY30-
TRAIL treatment initially appeared to be an additive effect (Figure 21B; 85% 
viability with TRAIL alone; 76% viability with LY30 alone and 50% viability with 
LY30 and TRAIL combined), however, later experiments testing for apoptotic 
characteristics in this model, demonstrated synergy in the increased death observed 
with LY30-TRAIL treated cells.  
 
5.2 Pre incubation with LY30 before TRAIL treatment synergistically 
enhances DNA fragmentation. 
DNA fragmentation of the cell is a hallmark of cellular apoptosis and HeLa cells 
treated together or separately with LY30 and TRAIL were fixed and stained with PI 
to assess for the presence of DNA fragmentation as a function of apoptosis. Whereas 
exposure to LY30 or TRAIL alone for 24h induced minimal DNA fragmentation 
(6.85% and 10.17% respectively), there was a marked synergistic increase in the 
fraction of cells in the sub-G1 phase (39.07%), indicative of DNA fragmentation, 
upon pre-treatment with LY30 and subsequent exposure to TRAIL (Figure 22). 
Prolonging the incubation with LY30 and TRAIL over 48h resulted in a complete 
shift of the profile to the sub-G1 phase (76.7%), while LY30 and TRAIL alone 
elicited moderate DNA fragmentation (24.07% and 19.7% respectively) at this time 
point (Figure 22). These data confirmed that LY30-induced increase in TRAIL 
sensitivity was a function of an increase in DNA fragmentation, thus strongly  
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Figure 21: LY30 sensitizes Hela cells to TRAIL-induced 
apoptosis. (A) Hela cells (1×105) were exposed to TRAIL (20-
100ng/ml) for 18h or (B) treated with 20ng/ml of TRAIL for 
18h in the presence or absence of a 1h pre-treatment with 25μM 
LY30. Cell viability was determined by the crystal violet assay.
Data shown are the mean±S.D. of at least three independent 
experiments performed in duplicate. 
A
B













Figure 22: LY30 sensitizes Hela cells to TRAIL-induced 
apoptosis. Hela cells (1×105) were exposed to 20ng/ml of 
TRAIL for 24 and 48h in the presence or absence of a 1h 
pretreatment with 25μM LY30. PI staining was performed 
for cell cycle analysis. The set of cell cycle profiles shown 
are representative of three independent experiments.
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pointing to a strong apoptotic response. They also indicate a synergistic enhancement 
of apoptosis by LY30 and TRAIL. 
 
5.3 LY30-TRAIL treatment reduces the colony forming ability of HeLa cells. 
In the previous study with LNCaP cells, LY30-vincristine treated cells displayed a 
marked reduction in their ability to form colonies after treatment. Here, a similar 
attempt to assess the potential of LY30-induced increase in sensitization to TRAIL on 
long-term survival/progression of tumor cells was also made by evaluating the effect 
of this combination treatment on tumor colony forming units. HeLa cells were 
exposed to 25μM LY30 for 1h before incubation with TRAIL for 8h, where no cell 
death was observed, and equal numbers of cells were seeded onto petri dishes to form 
colonies over a period of 2 weeks. There was a significant reduction in colony 
formation (20% of untreated cells) upon exposure to LY30+TRAIL, compared to 
cells treated with either LY30 or TRAIL (Figure 23A and B). 
 
5.4 LY30-induced increase in TRAIL sensitivity involves caspase dependent 
signaling. 
Intrigued by the strong sensitizing effect seen with LY30–TRAIL treatment in HeLa 
cells, as evidenced by the increased DNA fragmentation and reduction in tumor 
colony formation, the mechanism of apoptotic signaling upon treatment with a 
combination of LY30 and TRAIL was then investigated. The role of caspases in this 
system was first analyzed. As with the LY30-vincristine model in LNCaP cells,  
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results here showed that pre-treatment of HeLa cells with 25μM LY30 for 1h 
followed by exposure to 20ng/ml of TRAIL for 12h resulted in a tremendous 
amplification of caspase 2 (9X increase compared to 2X with LY30 or TRAIL alone; 
p value<0.025) and caspase 3 activity (13X increase compared to 3-4X with LY30 or 
TRAIL alone; p value<0.025) over the single agent treated cells (Figure 24A and B 
respectively). The activation of caspase 3 was further confirmed by western blot 
analysis of its truncated (active) form. Only pre-incubation of cells with LY30 
followed by TRAIL treatment could induce processing of caspase 3 as shown by the 
17kDa truncated form of the executioner caspase 3 with a concurrent reduction in the 
levels of its 32kDa pro form (Figure 25). The massive synergistic activation of 
caspases suggested that they might play a key role in mediating apoptosis in this 
model. Indeed, the role of LY30 in sensitization of cells to a caspase dependent death 
is further confirmed as preincubation with the pan-caspase inhibitor ZVAD-fmk 
before the usual LY30-TRAIL treatment for 18h, restored cell viability to the LY30-
TRAIL treated samples (Figure 26A). Furthermore, the presence of ZVAD-fmk in 
LY30+TRAIL treated cells could also abrogate the extent of DNA fragmentation 
observed over a period of 24h, from a reduction of 39.07% to 2.18% of total cells 
appearing in the apoptotic sub G1 fraction (Figure 26B).  
 
6. LY30 ENHANCES TRAIL-MEDIATED SIGNALING BY ENGAGING 
MITOCHONDRIAL DEATH PATHWAY 
 
6.1 LY30 sensitization of TRAIL induced apoptosis does not involve 
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Figure 25: LY30+TRAIL treatment in Hela cells results in 
processing of caspase 3. Hela cells (1×106) were exposed to 20ng/ml 
TRAIL in the presence or absence of a 1h pretreatment with 25μM 
LY30 for 12h. Whole cell lysates were then used to assay for caspase 3 
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Figure 26: LY30+ TRAIL mediated apoptosis in Hela cells is a 
caspase dependent process (A) Hela cells (1×105) were treated for 1h 
with the pan caspase inhibitor, ZVAD-fmk (20μM), before treatment 
with LY30+TRAIL for 18h. Cell viability was then assessed via crystal 
violet staining. Data shown are the mean±S.D. of at least three 
independent experiments performed in duplicate. (B) Hela cells (1×105) 
were treated as in (A) and stained with PI for analysis of DNA 
fragmentation by flow cytometry. The cell cycle profiles shown are 




Having shown that LY30-induced sensitization to TRAIL was a caspase dependent 
event; we next investigated if the amplification of death signaling by LY30 was a 
function of mitochondrial outer membrane permeablization (MOMP). To assess 
MOMP induction, we studied the effect of LY30 and TRAIL singly and in 
combination on ΔΨm at the pre apoptotic time points of 8 and 12h (Figure 27) using 
the lipophilic, cationic fluorescent probe DIOC6, in flow cytometry. While cells 
incubated with both LY30 and TRAIL showed a decrease in cell size, as evidenced 
by a reduction in forward scatter after incubation for 12h, either singly or in 
combination (although a greater cell size reduction was observed with combination 
treatment of LY30 and TRAIL), there was no drop in ΔΨm (shown via DIOC6 
fluorescence) for the viable cell fractions that did not show any decrease in cell size. 
Similarly at 8h, where there was no reduction in cell size for all treated samples, there 
was also no significant drop in ΔΨm, suggesting that there was no induction of 
MOMP. Many studies have shown however, that induction of MOMP is not 
necessary for the occurrence of mitochondria dependent apoptotic events.  
 
6.2 LY30 mediated sensitization to TRAIL induced apoptosis resulted in 
release of cytochrome c and Smac/Diablo. 
With that in mind, the cytosolic release of mitochondrial inter-membranous proteins, 
cytochrome c and Smac/Diablo was studied. Cytosolic and mitochondria enriched 
fractions of HeLa cells treated with LY30 and TRAIL, either singly or in 
combination, were obtained and analysed via Western blot for the abovementioned 
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Figure 27: LY30-TRAIL induced apoptosis is not preceded by a drop 
in mitochondrial transmembrane potential. Hela cells (1×105) were 
exposed to TRAIL (20ng/ml for 8hrs) in the presence or absence of a 1h 
pre-treatment with 25μM LY30. The ? Ψm of cells was assessed by DIOC6 
using flow cytometry. 100μM CICCP was used as a positive control. At 





























Figure 28: LY30 can enhance cytochrome c and Smac 
release into the cytosol. Hela cells (3×106) were exposed 
to 20ng/ml TRAIL (18hrs) after 1hr pre-treatment with 
25μM LY30. Levels of cytochrome c and Smac in the
cytosolic and mitochondrial fractions were then assayed by 
western blotting. 
 119
not induce cytosolic translocation of cytochrome c or Smac/Diablo, exposure of cells 
to LY30+TRAIL for the same time however, resulted in a virtually complete egress 
of cytochrome c from the mitochondria to the cytosol, together with a significant 
increase in cytosolic Smac/Diablo (Figure 28). Interestingly, treatment with LY30 
alone for 18h appeared to induce a slight increase in non-apoptotic (as shown by its 
minimal reduction in cell viability earlier on) cytosolic levels of cytochrome c. This 
increase in cytosolic cytochrome c by LY30 was not reflected in the corresponding 
mitochondria enriched fractions, which could be due to the fact that the cytosolic 
release of cytochrome c by LY30 was too minimal to be reflected via Western blot as 
a corresponding decrease in the mitochondria enriched fractions.  
 
6.3 Caspase 9 activation occurs in the absence of downregulation of XIAP 
and c-IAP-2 in LY30-TRAIL treated HeLa cells. 
The inactivation and downregulation of IAPs has been implicated in TRAIL 
sensitization studies and with the observed increase in cytosolic Smac in LY30-
TRAIL treated cells; the next logical step would be to question the involvement of the 
IAPs, hence, the levels of XIAP and c-IAP-2 were studied. Intriguingly, despite the 
increase in cytosolic Smac/Diablo in LY30-TRAIL treated cells, there were no 
significant changes in the levels of the apoptosis inhibitory proteins, cIAP-2 and 
XIAP (Figure 29A and B respectively). Nevertheless, analysis of caspase 9 activity, a 
classic mitochondria dependent initiator caspase, showed a significant increase in the 
enzymatic activity of caspase 9 (p value<0.05) as detected in whole cell lysates of 




(Figure 29C). Of note, the kinetics of caspase 9 activation closely paralleled the 
kinetics of caspases 2 and 3 activities (Figure 24A and B) in this system, 
suggesting a probable feedback amplification loop. Together these data indicate 
that LY30 enhanced sensitization of tumor cells to TRAIL-mediated apoptosis in 
the presence of  
cytosolic translocation of mitochondrial apoptotic amplification factors, Smac and 
cytochrome c, and downstream caspase 9 activation with minimal induction of 
MOMP. 
 
6.4 Overexpression of catalase in HeLa cells fails to revert tumor cell 
sensitization to TRAIL. 
Previous data from the LY30-vincristine model in LNCaP cells demonstrated that the 
sensitization process by LY29 and LY30 could be reverted via overexpression of 
catalase, implicating the ability of these compounds to generate intracellular H2O2 as 
a sensitization mechanism to non-lethal doses of chemotherapeutic drugs. The 
occurrence of mitochondria dependent apoptotic events in the LY30-TRAIL system 
could very well be linked to the LY30-mediated generation of intracellular H2O2 that 
could target the mitochondria in these cells. In the pursuit of a mechanistic 
explanation for the death amplifying effect of LY30, the issue as to whether the 
increase in TRAIL sensitization could be similarly linked to intracellular H2O2 
production was then studied. As with the earlier data with LNCaP cells, HeLa cells 
were successfully transiently transfected with the same catalase vector (Figure 30A). 
Cells transiently transfected with catalase or the empty vector were then first treated 
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for 1h with LY30, followed by an 18h incubation with either vincristine (1nM or 
2nM) or TRAIL (20ng/ml) (Figure 30B). It should be noted that the transfection 
process renders the cells more susceptible to death triggers thus accounting for the 
slightly higher amount of cell death observed with LY30 as compared to non-
transfected cells. Nevertheless, LY30 was able to enhance cell death in TRAIL and 
vincristine (at 2nM particularly) treated cells transfected with the empty vector. Of 
note, whereas over expression of catalase resulted in an increase in cell survival upon 
treatment with vincristine, LY30 or TRAIL alone or vincristine and LY30 in 
combination (suggestive again, of a H2O2 dependent mechanism in reduction of cell 
viability by these compounds), there was no significant effect on cell survival upon 
combination treatment with LY30 and TRAIL (Figure 30B) with the overexpression 
of catalase. These data suggest that unlike its effect on vincristine-induced apoptosis 
in LNCaP cells, LY30-induced sensitization to TRAIL mediated apoptosis in HeLa 
cells involved mechanism(s) other than or in addition to intracellular H2O2 
production. 
 
6.5 LY30 increases cell surface expression and oligomerization of DR5. 
With the data suggesting that generation of intracellular H2O2 did not play a major 
role in LY30-mediated sensitization to TRAIL-induced apoptosis unlike as previously 
shown in the LY30-vincristine model with LNCaP cells, there had to be another 
upstream death trigger that could effect the LY30-mediated sensitization to TRAIL-
induced apoptosis in HeLa cells. The mitochondria dependent apoptotic signaling 
observed has been shown to be a possible downstream signal of the receptor-mediated 
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Figure 30: Catalase over-expression fails to rescue cells from 
LY30+TRAIL-induced apoptosis (A) Hela cells (1×105) were transiently
transfected with human catalase or the empty zeocin vector. Over-
expression of the catalase protein was picked up 48hrs post-transfection by 
western blotting using anti-catalase antibody. (B) Hela cells transiently
transfected with human catalase or the empty zeocin vector were treated for 
18hrs with vincristine (1nM or 2nM) or TRAIL (20ng/ml) after 1hr pre-
incubation with 25μM LY30. Cell viability was assessed by the crystal 
violet assay. Data shown are the mean±S.D. of at least three independent 




extrinsic apoptotic pathway. Therefore, the role of the Type I pathway in LY30- 
induced TRAIL amplification was studied. To that end, the surface expression of the 
TRAIL receptors, DR5 and DR4, on the cell surface were analysed by flow 
cytometry. HeLa cells were incubated for 1h with LY30, followed by a 5 or 10min 
incubation with TRAIL, before live staining with the anti-DR5-PE or anti-DR4-PE 
conjugated antibody for flow cytometry analysis. Intriguingly enough, 1h incubation 
with 25μM LY30 resulted in a significant increase in the cell surface expression of 
DR5, compared to cells maintained in feeding medium (Figure 31). In the same 
figure, the upregulation of cell surface DR5 diminished in cells treated with LY30 
and TRAIL (for both 5 and 10min), suggestive of possible receptor internalization 
upon ligation of DR5 with TRAIL. In contrast, the cell surface levels of DR4 
remained the same upon treatment with LY30 and TRAIL, either singly or in 
combination. The total levels of DR5 in LY30 treated cells remained the same 
throughout this time (as analysed via western blot in the boxed area of Figure 32A), 
further corroborating the possibility of DR5 trafficking to the surface from the 
cytosolic pools, rather than any actual transcriptional increase in total DR5 levels. 
Oligomerization of DR5 has been shown to be necessary for ligation and successful 
signaling of TRAIL and DR5 oligomerization studies have been carried out by others 
in the presence of a non cell permeable surface cross linker, DTSSP. Here, DTSSP 
was added to the medium of cells incubated for 1h with LY30, to allow for cross-
linking of oligomerized DR5 receptors to take place. DR5 was then 
immunoprecipitated from the whole cell lysate in the presence of limiting (0.4μg) or 






























Figure 31: LY30 increases cell surface expression of DR5 but not DR4.
Hela cells (1×105) were exposed to 20ng/ml TRAIL for 5 or 10 minutes after 
1hr pre-treatment with 25μM LY30, stained with anti DR5 or DR4 -PE and 
analyzed by flow cytometry. The density plots of forward scatter and DR5 


































determined by a separate titration process). Previous studies on DR5 oligomerization 
have shown that cross linked oligomerized DR5 complexes could be pulled down 
more readily in the limiting presence of anti-DR5 as compared to non oligomerized 
DR5 or cross linked complexes made up of DR5 and other receptors. Indeed, in the 
presence of limiting anti-DR5, the cross linked DR5 could be more easily 
immunoprecipitated from whole cell lysates previously treated with LY30 as 
compared to those in medium only (Figure 32B), suggesting that there was also 
increased oligomerization of cell surface DR5 in addition to its up regulation on the 
cell surface. These data suggest a probable mechanism by which LY30 could enhance 
TRAIL responsiveness by increasing the surface expression and oligomerization of 
TRAIL receptor DR5. 
 
6.6 LY30 enhances DISC assembly and downstream caspase 8 processing. 
In order to link the effect of LY30 on surface DR5 expression/oligomerization to 
apoptotic signaling triggered by TRAIL, the next question was to establish if the 
effect of LY30 was mediated through an increase in the death initiating and signaling 
complex (DISC), a characteristic hallmark of death receptor-mediated signaling. To 
assess DISC formation, HeLa cells were first incubated for 1h in the presence or 
absence of LY30, and then treated with TRAIL for 5min. Whole cell lysates were 
then immunoprecipitated with anti-DR5 and western blot analyses were performed 
using anti-FADD or anti-caspase 8. Whereas FADD or caspase 8 were not recruited 
to DR5 in untreated lysates, LY30 or TRAIL treated cells showed an interaction 


















Figure 32: LY30 increases oligomerization of DR5. (B) Hela cells 
(1×106) were incubated for 1h with 25μM LY30. Whole cell lysates
were used to assay for total DR5 levels by western blot. (C) Hela cells 
(3×106) were exposed to LY30 for 1h before treatment with DTSSP 
for cross-linking of oligomerized DR5. The oligomerized DR5 was 
subsequently immuno-precipitated with limiting and excess amounts 
of anti-DR5 and analyzed by western blot.
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be pointed out that FADD has been previously shown to appear as a doublet upon 
western blotting (24KDa and 25Kda) in HeLa cells, which was precisely what was 
detected in the immunoprecipitated DR5 complex from cells treated with both LY30 
and TRAIL, compared to a single 25kDa band in cells treated singly with LY30 or 
TRAIL. Similarly, both forms of processed caspase 8 (43/41KDa) were detected only 
in cells treated with LY30+TRAIL (Figure 33), as compared to a 43kDa band in cells 
treated singly with LY30 or TRAIL. This suggests that in LY30-TRAIL treated cells; 
there was a stronger and more complete assembly of the DISC as compared to cells 
treated singly with either LY30 or TRAIL. In the western blot analysis for caspase 8 
in the immunoprecipitated DR5 complex, the 53kDa pro from of caspase 8, as well as 
its 18kDa truncated form was not detected. This was consistent with findings in 
current literature that only the intermediate 43/41kDa form has been shown to 
associate with the DISC. Auto processing of this intermediate form upon DISC 
association results in the 18kDa truncated form of caspase 8, which then falls off 
from the DISC, which also explains why it could not be detected in the 
immunoprecipitated DR5 complex. As a positive control, a second anti-DR5 was 
used to detect the immunoprecipitated DR5. Caspase 8 processing is an immediate 
downstream event of DISC assembly, as previously mentioned. To further 
corroborate the findings implicating DISC formation in LY30-TRAIL treated cells, 
lysates from these cells were analysed for caspase 8 processing via Western blot. 
Indeed, cells pre treated with LY30 for 1h displayed an amplified processing of 
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Figure 33: LY30 enhances DISC assembly. Hela cells (3×106) were 
exposed to 20ng/ml TRAIL for 5min with or without a 1hr pre-treatment 
with 25μM LY30. Cells were harvested and immuno-precipitated with anti-
DR5. Analysis of DISC components, FADD and caspase 8, were performed 
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Figure 34: LY30 enhances caspase 8 activation and loss of pro Bid (A)
Hela cells (1×105) were also exposed to 20ng/ml of TRAIL (3-18hrs) with 
or without 1hr pre-treatment with 25μM LY30. Whole cell lysates were 
used to assay for activation kinetics of caspase 8 using its AFC-
conjugated substrate. Data shown are the mean±S.D. of at least three 
independent experiments. (B) Cleavage of Bid was assessed by western 
blotting using anti-Bid after 12 hrs of LY30+TRAIL treatment.
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concentrations (20ng/ml) where TRAIL alone did not effect caspase 8 processing 
(Boxed area in Figure 34A). Bid processing by activated caspase 8 is another 
downstream event of DISC assembly. This was seen when treatment of HeLa cells 
with LY30 and TRAIL for 18h resulted in Bid processing by western blot analysis on 
whole cell lysates using an anti-Bid that recognizes the full-length protein (Figure 
34B). 
 
6.7 Activation of mTOR pathway in LY30 sensitized TRAIL induced 
apoptosis. 
Inactivation of the pro survival kinase, Akt has been implicated in the sensitization of 
tumor cells to TRAIL mediated apoptosis. Very recent studies by other groups have 
shown that LY30 can also inhibit cell proliferation in tumor cells by a PI3K-Akt 
independent inactivation of mTOR, a downstream kinase substrate of Akt. If this was 
a LY30 specific effect, direct inactivation of mTOR by LY30 could also account for 
its ability to sensitize HeLa cells to TRAIL induced apoptosis. Hence, the 
phosphorylation levels of mTOR and its substrate p70 S6 kinase were analysed via 
Western blot in this study. If LY30 could directly inactivate mTOR, 
dephosphorylation of mTOR would then occur at an early time, hence whole cell 
lysates of HeLa cells treated with LY30 and TRAIL either singly or in combination 
for 1h, were analyzed for mTOR phosphorylation. Contrary to expectations, not only 
did cells treated singly with LY30 and TRAIL result in phosphorylation of mTOR at 












Figure 35: LY30-TRAIL treated cells show mTOR activation.
Hela cells (3×106) were exposed to 20ng/ml TRAIL for 5min with 
or without a 1hr pre-treatment with 25μM LY30. Cells were 




treated in combination with both drugs. Concomitant with this observation, an 
increase in the phosphorylation and total levels of p70 S6 kinase at the thr 389 residue 
was also observed in HeLa cells treated with both LY30 and TRAIL together (Figure 
35).  
 
6.8 LY30 can also sensitize HT29 cells to TRAIL induced apoptosis but not 
HCT116. 
While the majority of LY30-TRAIL work has been initially performed in a TRAIL 
responsive tumor cell line, HeLa, it has been widely acknowledged that there is a 
need to revert the rapidly developing TRAIL resistant phenotypes now frequently 
found in tumor cells. To that end, the ability of LY30 to sensitize the TRAIL resistant 
colon carcinoma cell line HT29 was tested in preliminary studies. HT29 cells were 
preincubated for 1h with increasing doses of LY30 (25 to 100μM) after which they 
were again incubated with increasing doses of TRAIL (50 to 100ng/ml) for 18h. 
There appeared to be a marked synergistic reduction in cell viability for HT29 cells 
treated with 100μM LY30 and 100ng/ml TRAIL (Figure 36A). At the same time, 
similar cell viability experiments were also performed with another TRAIL 
responsive colon carcinoma cell line, HCT116. A TRAIL dose response curve for 
HCT116 cells at 18h incubation was established (Figure 36B), and two doses at 
which minimal killing was observed (0.5 and 1ng/ml) at 18h were selected for further 
cell viability experiments with HCT116 cells. HCT116 cells were first incubated with 
increasing doses of LY30 (from 25 to 100μM) for 1h, after which they were 




via crystal violet staining. Interestingly, HCT116 cells, while responsive to TRAIL 
itself (Figure 36B), were not responsive to the LY30 mediated sensitization process 
as no enhancement of cell death was observed in the cells treated with both LY30 and 
TRAIL (Figure 36C). These observations have great potential for the further 
elucidation of the exact mechanism of LY30-TRAIL induced cell death, by simply 
charting the intrinsic differences between the two colon carcinoma cell lines, HT29 
and HCT116, and comparing their responses to LY30-TRAIL combination treatment. 
Preliminary studies on the apoptotic signaling in LY30-TRAIL mediated death in 
HT29 cells appear to parallel what was observed in the HeLa cell line, albeit with 
some minor differences. Caspase activation studies for HT29 treated with 100μM 
LY30 and 100ng/ml TRAIL in a similar manner revealed robust activation of 
caspases 3, 8 and 9 (Figure 37). In particular, there was a marked increase in the 
activation of caspase 9 (10X at 12h), which was not observed previously in the LY30-
vincristine model of LNCaP cells, nor with the LY30-TRAIL model of HeLa cells. 
This suggested that the mode of action of LY30 in the cell might vary slightly 
depending on the tumor cell phenotype. In addition, analysis of the cytosolic fractions 
of HT29 cells treated with 100μM LY30 and 100ng/ml TRAIL revealed a increase in 
the levels of cytochrome c (Figure 38), an observation concomitant with the marked 
increase in caspase 9 levels, suggesting again involvement of the mitochondria 
apoptotic signaling pathway. The different responses of the different cell lines (HeLa, 
HT29, HCT116) to LY30 mediated sensitization to TRAIL did not appear to be 














Figure 38: LY30 can enhance cytochrome c release in 
TRAIL treated HT29 cells. HT29 cells (3×106) were 
exposed to 100ng/ml TRAIL (18hrs) after 1hr pre-
treatment with 25μM LY30. Levels of cytochrome c in the
cytosolic fraction was then assayed by western blotting. 
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Nevertheless, the activity of the previously unknown and inactive analogue of LY29, 
LY30, has been proven extensively in different drug model systems with different 
cell lines suggesting a potential for modification of these compounds in 
chemotherapy design as well as a warning against the use of LY29, a supposed 
specific inhibitor of PI3K, in the study of PI3K pathways, given the potency of it’s 





The bulk of this study centers on the anti tumor activity of LY30, the supposed 
inactive analogue of the commonly used PI3K inhibitor, LY29. Here, anti tumor 
activity of LY30 was first demonstrated in LNCaP cells (Poh and Pervaiz, 2005), as a 
sensitizer to vincristine induced apoptosis, via its ability to generate intracellular 
H2O2. The generation of intracellular H2O2 was first observed in LY30’s active 
cousin, LY29. Subsequent experiments revealed that LY30 could also sensitize tumor 
cells to vincristine (for LNCaP cells), and later, TRAIL induced apoptosis (for HeLa 
and HT29 cells). These observations could be explained by differing mechanisms, in 
the first study with vincristine, it was the generation of intracellular H2O2 by LY30 
that sensitized prostate carcinoma LNCap cells (and even the cervical carcinoma 
HeLa cells) to non lethal doses of vincristine, resulting in enhanced cell cycle arrest 
and eventual apoptosis. In the subsequent study with TRAIL however, overexpression 
of catalase appeared to be insufficient in protecting the cell against LY30 sensitized 
TRAIL mediated apoptosis, suggesting the presence of other non-H2O2 dependent 
apoptotic pathways acting in this system. Nevertheless, this is the first time that 
LY30, a commonly used negative control to LY29, has been demonstrated to possess 
anti tumor activity via the sensitization of tumor cells to drug induced apoptosis and 
this has been proved in two drug models, using TRAIL (receptor mediated pathway) 
and vincristine, a common anti microtubule chemotherapeutic agent involved in 
inducing cell cycle arrest and subsequent apoptosis. 
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1. SIGNIFICANCE OF INTRACELLULAR GENERATION OF H2O2 BY 
THE LY COMPOUNDS WITH RESPECT TO PI3K INHIBITION 
 
H2O2 has long been shown to play vastly different roles in the cell, where subtle 
changes in the delicate intracellular redox status could greatly affect cell physiology. 
As previously mentioned in the Introduction, depending on its concentration, H2O2 
can induce cell proliferation, mediate drug-induced apoptosis in many models 
(particularly in tumor cells), or at overwhelming levels, bring about necrotic cell 
death.  Indeed, there is a fair amount of controversy with respect to the relationship 
between PI3K signaling and H2O2 production, with data supporting both, an upstream 
or a downstream role of H2O2 in PI3K signaling. However, the ability of the LY 
compounds to generate H2O2 independent of PI3K signaling, as shown by doses of 
LY29 that did not affect PI3K activity (Figure 5), the inability of wortmannin (Figure 
6) and the ability of LY30 to generate intracellular H2O2 (Figure 7), indicates that 
inhibition of PI3K-Akt axis is not involved in the intracellular generation of H2O2.   
 
1.1 H2O2 generating abilities of the LY compounds: A result of their chemical 
structures? 
The ability of the LY compounds to generate intracellular H2O2 could perhaps be 
further understood by a closer look at their structures. The structures of the LY 
compounds were based on quercetin, a naturally occurring dietary bioflavinoid that 
was previously shown to inhibit PI3K. However, quercetin was also shown to be able 
to inhibit other kinases like PI4K and several tyrosine and serine/threonine kinases 
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(Vlahos et al., 1994), thus prompting the synthesis of the more specific PI3K 
inhibitor, LY29, in the first place. The role of quercetin in the cell is a contradictory 
one. It can induce cell cycle arrest in various cultured cell lines (Choi et al., 2001, 
Ong et al., 2004) but at the same time, protect against H2O2-induced apoptosis by 
acting as an antioxidant (Chow et al., 2005). Various studies have also suggested that 
the differential pro survival and pro apoptotic roles of quercetin could be a dose 
dependent one, like that of resveratrol, another flavinoid normally found in red wine.  
 
LY29 was synthesized using quercetin as a lead compound where the 
dihydroxyphenyl group at the 2- position of the chromone ring in quercetin was 
replaced with a morpholine moiety as seen in LY29, thus conferring upon LY29, its 
specificity in the inhibition of PI3K as it was then subsequently unable to inhibit 
PI4K, EGF receptor tyrosine kinase or other ATP requiring kinases and ATPases 
(Vlahos et al., 1994). A simple replacement of oxygen with nitrogen in the 2- position 
of the morpholine ring gave the compound LY30, which displayed a dramatic 
reduction in the ability of this compound to inhibit PI3K. LY29 inhibits PI3K to less 
than 1% of its original activity at a dose of 100μM, however, LY30 at the same dose, 
allows PI3K to retain almost all of its original activity. Although the H2O2 generated 
by both LY compounds has been shown to be functionally relevant in LNCaP cells 
treated with vincristine (Figure 18), it is probably the synergistic effect of LY29’s 
ability to inhibit PI3K effectively that results in its greater potency compared to LY30 
when it is used.  
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While the current data reported in this thesis appears to exclude the mitochondria as a 
possible source of H2O2 accumulation by these LY compounds, it does not exclude 
the possibility of the activation of other oxidase like complexes in the cell, such as 
those found in the endoplasmic reticulum or activation of the Cu/Zn superoxide 
dismutases in the cytosol itself. As the LY compounds possess structural similarity to 
quercetin, a bioflavinoid, it is perhaps not surprising that they generate intracellular 
H2O2, given the controversial nature of flavinoids to act both as an antioxidant with 
free radical scavenging properties as well as a pro-oxidant. In fact, quercetin recently 
has been shown to be able to generate low amounts of H2O2 via slow autooxidation in 
solution (Hajji et al., 2006). 
 
Regarding the relationship between inhibition of PI3K and intracellular H2O2 
production, a plausible scenario, considering the previously demonstrated ability of 
LY29 to bind to the ATP binding site of other protein kinases like the DNA-
dependent protein kinase in the nucleus (Izzard et al., 1999), could be that LY 
compounds affect transcription of intracellular redox control genes like catalase and 
superoxide dismutase. However, the burst of intracellular H2O2 generated by the LY 
compounds in LNCaP cells was detected as early as 15min after incubation, thereby 
rendering this possibility highly unlikely. 
 
1.2 Functionality of the transient overexpression of human catalase in tumor 
cells. 
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A good amount of the work done in this thesis centers around the ability of the LY 
compounds to generate H2O2. In order to prove that it was H2O2 that was generated 
and not any other types of ROS, as well as to test the functional significance of this in 
the context of tumor cell physiology, there was therefore a need to scavenge the H2O2 
generated with catalase and observe for any protective effect with the lowering of 
H2O2 levels. Exogenous addition of catalase itself to the medium of cultured cells 
(Figures 4, 5 and 8) did not always prove a feasible experimental plan as catalase is a 
large protein (~256kDa) that is unable to enter the cell and effectively scavenge the 
intracellular H2O2. It can only stay in the extracellular milieu as an antioxidant, and 
allow H2O2 to diffuse out from inside the cell and thus lowering the intracellular H2O2 
levels in this manner. However its effectiveness reduces in overnight treatment due to 
degeneration of the protein. In a search for a more effective method of lowering 
intracellular H2O2 levels, a pzeo-SV plasmid vector containing the 1.6kb human 
catalase cDNA cloned into the HindIII sites was transiently transfected into the tumor 
cells. While overexpression of the protein was consistently detected between 24 to 
48h post transfection depending on cell line (Figure 17 for LNCaP cells and Figure 30 
for HeLa cells), determining the activity of the overexpressed catalase proved a little 
trickier. Generally, cells with overexpressed catalase displayed a lower basal level of 
H2O2 as determined by DCFH-DA staining in flow cytometry (Figure 17A). 
However, catalase overexpressing cells have been reported to grow slightly slower 
than their empty vector transfected counterpart, suggesting that a lower-than-usual 
basal level of H2O2 may not necessarily be ideal for the tumorigenic growth(Arnold et 
al., 2001). It is not suprising therefore, that these tumor cells sometimes appear to 
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adapt and revert this phenotype of non-favourable growth conditions, and restore 
basal H2O2 levels to one comparable with their empty vector transfected counterpart. 
Nevertheless, while their basal H2O2 levels might differ, it is the ability of the catalase 
overexpressing cells to scavenge intracellular bursts of H2O2 that is important. DCFH-
DA analyses of catalase overexpressing cells revealed that they were still able to 
prevent LY30 induced increases in H2O2 (Figure 17B).  
 
2. PHYSIOLOGICAL SIGNIFICANCE OF LY30 MEDIATED 
GENERATION OF INTRACELLULAR H2O2 EITHER ON ITS OWN OR IN 
CONJUNCTION WITH OTHER COMPOUNDS. 
 
While it has already been demonstrated in the first part of this study that generation of 
intracellular H2O2 by the LY compounds is independent of any inhibition of the 
PI3K-Akt axis, there was also a need to establish if this generation of intracellular 
H2O2 had any physiological relevance, especially in an anti tumour context. Hence, 
after an initial screening for cytotoxicity of LNCaP cells with etoposide, daunorubicin 
and vincristine (Figure 8A), vincristine was chosen as the drug of choice to test if the 
generation of intracellular H2O2 could sensitize LNCaP to apoptosis in a 
chemotherapeutic drug model. 
 
2.1 LY30 sensitizes LNCaP cells via intracellular generation of H2O2, to 
vincristine-induced apoptosis with reduced colony forming ability and caspase 
dependent DNA fragmentation. 
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Considering the strong inhibitory effect of LY29 on PI3K activation, one could argue 
that it is not surprising that pre-incubation of tumor cells resulted in an increase in 
sensitivity to apoptosis. However, the second part of this thesis demonstrates a novel 
mechanism by which the LY compounds sensitize LNCaP prostate carcinoma cells 
expressing constitutively active Akt/PKB, to vincristine-induced apoptosis in a H2O2 
dependent manner (Figures 10 – 20). More significantly, while previous studies have 
shown that H2O2 is a mediator of vincristine-induced apoptotic cell death, the data 
presented here in this thesis show that incubation of cells with a non-lethal dose of 
vincristine did not generate H2O2 in the cell (Figure 16), an observation 
commensurate with the fact that there was no cell death observed with such low doses 
of vincristine (Figure 9). It was the pre incubation with LY compounds that 
significantly enhanced the levels of H2O2 in the cell (Figure 16), which was then 
responsible for tipping the cell towards eventual apoptosis, as shown by the ability of 
cells overexpressing catalase to reduce the increase in intracellular H2O2 levels 
(Figure 17) and thus get protected against the cytotoxic effects of LY30-vincristine 
treatment (Figure 18). The generation of H2O2 was therefore implicated as a 
mechanistic explanation for the ability of LY30 to sensitize LNCaP cells to 
vincristine induced apoptosis (Poh and Pervaiz, 2005). More importantly, discovery 
of the ability of the LY compounds to generate intracellular H2O2 meant that this 
could also be studied in other systems describing non specific PI3K independent 
effects of the LY compounds, although it should be kept in mind that generation of 
intracellular H2O2 could be a cellular stress response to the presence of the LY 
compounds rather than a direct effect attributed to the compounds themselves. 
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2.2  Physiological significance of LY30-mediated generation of intracellular 
H2O2 in relation to other published studies 
 
In recent years, other studies have shown that the LY compounds (LY29 and LY30) 
possess non-specific PI3K independent activity of their own, in a variety of biological 
systems with similarities to each other. LY29, in addition to being used to study 
tumor cell signaling, has also been used in studies of neuronal (Otaegi et al., 2006), 
cardiovascular (Browe and Baumgarten, 2006), immune (Breslin et al., 2005) and 
diabetes-related cell function (Ceolotto et al., 2004), due to the many diverse roles of 
PI3K in cellular responses. As such, it was no surprise that the non-specific effects of 
LY29 could also be linked to functions other than oncogenic signaling. With these 
recent reports (as discussed below) having demonstrated biological effects of LY 
compounds (LY29 and LY30) that are independent of its PI3K inhibitory activity, 
one might be tempted to speculate that such PI3K-independent activities of LY 
compounds could be linked to intracellular generation of H2O2 (to be discussed 
below), seeing how H2O2 can play diverse roles in the regulation of cellular 
physiology, in addition to simply mediating death and proliferation.  
 
A study of rat pancreatic β-cells by (El-Kholy et al., 2003), revealed that LY29 and 
LY30 could reversibly inhibit voltage dependent K+ (Kv) channels via a direct 
mechanism. The same study also showed that both LY compounds could potentiate 
glucose-stimulated insulin release from an insulinoma cell line, more potently that 
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what was normally observed through PI3K inhibition alone suggesting again that 
LY29 in particular, posessed non specific side effects in addition to its inhibition of 
PI3K activity via competitive inhibition of the ATP binding site on the p85α subunit. 
This observation implied that the structure of the LY compounds (LY30 in particular) 
could be used in the design of future Kv channel blockers as they could inhibit Kv 
channels but not affect PI3K activity. These results appear to be in line with results 
from this thesis implicating H2O2 as one of the functional effectors of the PI3K-
independent effects of the LY29/30. H2O2 could be directly involved in the blockage 
of Kv channels in the rat β-cell model as it has been documented to modulate K+ 
channel function in various coronary and cerebral systems. For example, 4 amino 
pyridine sensitive K+ channels was reported to contain redox sensitive thiol groups 
that could be likely targets for H2O2 mediated signaling in redox sensitive coronary 
vasodilation (Rogers et al., 2006). In fact, H2O2 has been suggested to modify the 
ROS sensitive cysteine residues in Kv channels in mouse colonic smooth muscle 
cells, resulting in a suppression of the transient outward K+ current (Prasad and 
Goyal, 2004). This was also observed in large - conductance Ca2+- sensitive Kv 
channels that could be inhibited by exogenous addition of ROS like H2O2 (Soto et al., 
2002). 
 
In addition, another group has demonstrated the ability of both LY compounds to 
inhibit monocyte chemoattractant protein-1 (MCP-1) expression by human umbilical 
vein endothelial cells at both protein and mRNA levels, indicating that this was a 
PI3K independent process as wortmannin was unable to produce a similar effect in 
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these cells (Choi et al., 2004). LY29 and LY30 also inhibited activation of the redox 
sensitive nuclear factor-kappaB (NFκB) in the same study, suggesting that LY29 
inhibits MCP-1 expression at least in part via suppression of NF-κB, independently of 
PI3K. It was then suggested that the structure of LY29 and LY30 could again be a 
novel template for development of new anti-inflammatory drugs. The lead compound 
from which LY29 and LY30 were synthesized, quercetin, has also been shown in 
earlier studies to suppress TNF-α mediated stimulation of IL-8 and MCP-1 
expression, at least in part, by inhibiting the activation of NF-κB (Nanua et al., 2006). 
Many studies have shown that NF-κB is a redox sensitive transcription factor, 
however differing schools of thought support both the activation and suppression of 
NF-κB in response to cellular accumulation of ROS. Suppression of NF-κB by ROS 
has been suggested to be linked to the direct oxidation (and inactivation) of the active 
H2O2 sensitive cysteine residues in the (IκB kinases) IΚK complex (Korn et al., 
2001), which normally functions to free NF-κB from its inactive sequestration in the 
cytoplasm by IκB. In fact, MCP-1 expression can also be regulated by activator 
protein 1 (AP-1), another redox sensitive protein. Current literature however suggests 
contrarily that H2O2 and other ROS can directly induce MCP-1 expression instead of 
inhibiting it, in inflammatory signaling in endothelial cells (Chen et al., 2004). 
 
Similarly, it has been shown that LY29 and LY30 but not wortmannin, also display 
PI3K independent effects in macrophages. The LY compounds were demonstrated to 
be able to inhibit nitric oxide (NO) production and inducible nitric oxide synthase 
(iNOS) expression in lipopolysaccharide (LPS) induced macrophage cells (Raw 
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264.7), again via suppression of the redox sensitive NF-κB (Kim et al., 2005c). 
Interestingly, a separate study has shown that ROS (O2.-, H2O2 and NO) are produced 
from Raw 264.7 cells following LPS exposure, which was shown to activate (instead 
of suppress) NF-kB, leading to the increased NO production and iNOS expression. 
NO however, was shown by the authors to be a negative feedback inhibitor of iNOS 
protein expression while H2O2 production from LPS-stimulated macrophages 
participates in the upregulation of iNOS expression via NF-κB activation (Han et al., 
2001). In fact, most studies on NF-κB dependent iNOS signaling in macrophages 
point to ROS (H2O2 in particular) as an activator of NF-κB, resulting in subsequent 
up regulation of iNOS and NO production. Nevertheless, the involvement of the 
redox sensitive NF-κB and generation of intracellular H2O2 by the LY compounds 
would warrant further study to establish if there is any connection between the two 
cellular signaling events. 
 
The results from this thesis appeared to be also corroborated to some extent by a 
study published by another group (Kristof et al., 2005) at the same time, 
demonstrating that both LY29 and LY30 could inhibit LPS and interferon-γ 
stimulated mTOR activity and mTOR dependent phosphorylation of S6K in human 
lung epithelial adenocarcinoma (A549) cells. This is perhaps also relevant to the 
abovementioned study by Kim et al., 2005, where LPS was also used to activate 
macrophage cells and the LY compounds were shown to be able to inhibit NO and 
iNOS expression in these stimulated cells. In the study by Kristof et al., 2005, they 
showed that LY30 on its own inhibited proliferation and cell cycle progression in 
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A549 cells, pulmonary artery smooth muscle cells and in an in vivo mouse xenograft 
model of human prostate adenocarcinoma tumor growth. In addition, LY30 was 
shown to directly inhibit recombinant CK2 in vitro. Again, the multi faceted role of 
H2O2 (as generated by the LY compounds) in proliferation and cell death could also 
play a role in this system although currently, various other studies have shown H2O2 
more as a direct activator of the mTOR pathway, in response to either oxidative stress 
or a mitogenic stimulus (Radisavljevic and Gonzalez-Flecha, 2004, Huang et al., 
2002).   
 
An interesting point of note is the role of LY30 as a negative control to its active 
counterpart, LY29 in current literature. Most studies do not use such low doses of 
vincristine (or any other drug) in sensitization studies. In fact, as showed in this 
thesis, slightly higher vincristine doses than what was finally used in this thesis 
(0.02μM) would have masked the effects of LY30 as it only shows a sensitizing 
ability with a sublethal dose of the chemotherapeutic drug in question. However a 
study by (Shingu et al., 2003), showed that a similar dose of LY29 (10 – 20μM) 
augmented apoptosis caused by antimicrotubule agents more significantly than that 
induced by other anticancer agents like etoposide and cisplatin in four malignant 
glioma cell lines. In fact, the study quantitatively demonstrated that LY29 
enhancement of vincristine-induced apoptosis was a synergistic one, with the use of 
similar low doses of vincristine (2 – 5nM, compared to 20nM in this thesis). The 
authors attributed the selective augmentation of anti-microtubule agent induced cell 
killing by LY39 to a distinctive relationship between the PI3K-Akt pathway and 
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tubulin-microtubule equilibrium, however, as shown in this thesis, they failed to take 
into account the possible non specificity of the LY compounds in sensitizing tumor 
cells to vincristine induced apoptosis as corroborated by the similar sensitizing ability 
of the “inactive” LY30 to vincristine, as demonstrated in this thesis. This suggests 
that the authors might have wrongly concluded a direct relationship between the 
selective augmentation of anti-microtubule agent induced cell killing and the 
inhibition of PI3K-Akt pathway. 
 
2.3 Intracellular H2O2 production: a permissive environment for 
sensitization of cells to drug induced apoptosis. 
The critical role of intracellular H2O2 in sensitization of tumor cells to apoptotic 
stimuli by creating an intracellular milieu permissive for caspase activation and death 
execution has been highlighted earlier on in the Introduction. In addition, it has been 
reported that priming of tumor cells with sub-apoptotic concentrations of H2O2 
significantly enhanced the sensitivity of tumor cells to drug-induced apoptosis 
(Pervaiz et al., 1999), and alternatively, blocking intracellular H2O2 production 
inhibited death execution(Ahmad et al., 2004b). Along the same lines, intracellular 
production of H2O2 appears to be a common denominator in drug-induced apoptosis 
of tumor cells. Generally, intracellular generation of H2O2 upon apoptotic stimuli is 
often conducive for maintenance of the death signal as shown by various reports 
where lowering these levels of intracellular H2O2 by anti oxidant measures resulted in 
protecting the cells from death. However there have been a few isolated reports 
indicating to the contrary, with one example being a study demonstrating that 
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overexpression of catalase in the cytosolic or mitochondrial compartment sensitizes 
HepG2 cells TNF-α instead with concurrent increases in the activities of caspase 3 
and 8 (Bai and Cederbaum, 2000). However, most in vitro data point towards 
production of H2O2 by apoptotic stimuli in providing an intracellular environment 
permissive towards cell death. Thus, it is logical that chemotherapeutic efficacy could 
be significantly improved in an environment made conducive for death execution by 
the presence of H2O2 (Pervaiz and Clement, 2002). Identification of compounds that 
trigger a significant increase in intracellular H2O2 and their use in conjunction with 
chemotherapy agents could therefore be an attractive strategy to enhance the 
sensitivity of tumor cells to drug therapy.  In the light of these findings, the structures 
of the LY compounds could therefore be used as a model to develop 
chemotherapeutic compounds that could trigger intracellular H2O2, which in turn 
would either sensitize tumor cells to drug-induced apoptosis or directly induce 
apoptosis itself.   
 
2.4 The role of H2O2 in LY30 mediated vincristine induced G2/M cell cycle 
arrest in LNCaP cells. 
In addition to the enhancement of apoptosis, the H2O2 generating ability of LY30 
appeared to play a role in the induction of cell cycle arrest by vincristine. Current 
literature paints a complicated picture with regards to the regulation of the cell cycle 
progression via changes in the intracellular H2O2 levels. Catalase overexpression in 
human aortic smooth muscle cells resulted in reduced proliferation (an observation 
also made in this thesis) and arrested cell cycle progression, which was associated 
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with decreased expression of cyclin D1, cyclin E, CDK2, and CDK4 and upregulation 
of p21(Cip1) and p27(Kip1) (Lin et al., 2006).  These inhibitory effects were 
observed to be mediated via downregulation of ERK1/2 and JNK phosphorylation 
and inactivation of the redox sensitive AP-1 and NF-κB. 
 
Here, this study shows that overexpression of catalase allows LNCaP cells to enter 
and stay in G2/M cell cycle arrest for a longer period of time (Figure 19), with a 
concomitant increase in p53 levels in these cells (Figure 20). It would appear that the 
LY30-mediated increased levels of intracellular H2O2 mediate the exit of LNCaP cells 
from vincristine induced G2/M arrest into apoptosis (as measured by the extent of 
DNA fragmentation in the sub G1 fraction of the cell cycle profile in Figure 19) as 
H2O2 has been shown to mediate the activation of caspases in this system. 
Inactivation of caspases either slightly by catalase overexpression (Figure 19) or 
ZVAD-fmk (Figure 14), both resulted in cells staying in the G2/M arrest for a long 
time, albeit more completely for ZVAD-fmk as it inhibited caspase activation to a 
much greater extent as compared to catalase overexpression. Interestingly, 
preliminary data from this thesis shows that lowering the intracellular levels of H2O2 
can hasten the entry into vincristine mediated G2/M cell cycle arrest with an increase 
in p53 levels (Figure 20), pointing to the need for suitably low levels of H2O2 to 
mediate normal cell cycle progression as pointed out by published data from other 
groups as well. This again reflects the many faceted roles that the varying amounts of 
H2O2 can play in cellular function.  The data at this point in time is not sufficient to 
conclude which cell cycle proteins (p53 or p21) are H2O2 sensitive as mediated by 
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LY30 and relevant to vincristine induced cell cycle arrest, although both p53 and p21 
have been shown to be redox sensitive in cell cycle regulation under oxidative stress 
in other studies. For example, there have also been studies demonstrating 
upregulation of p21 in response of oxidative stress in LNCaP cells undergoing cell 
cycle arrest (Zhong and Oberley, 2001). At the same time, quercetin, the lead 
compound from which LY29 and LY30 are synthesized has also been shown in 
various studies to induce G2/M cell cycle arrest with concomitant upregulation of p21  
(Choi et al., 2001) as also observed in here with only LY30 treated cells (Figure 20A, 
Lane 3, 18h). Although this could be attributed to its ability to block PI3K and other 
kinases non-specifically, the ability of quercetin to induce cell cycle arrest through 
other means like through the generation of intracellular H2O2 could also be taken into 
consideration. 
 
3.  OTHER ANTI TUMOR EFFECTS OF LY30 THAT ARE 
INDEPENDENT OF H2O2 GENERATION – THE TRAIL MODEL 
 
The third part of this thesis focuses on the amplification of TRAIL signaling in the 
TRAIL responsive HeLa cervical carcinoma cell line. Having established that LY30 
could sensitize LNCaP cells to non-lethal doses of vincristine, a way to strengthen the 
role of LY30 as a potential sensitizer to chemotherapeutic agents (without the side 
effects of PI3K inhibition) would be to test its effects in other drug models. The 
interest in TRAIL as a chemotherapeutic drug in recent years prompted the interest 
with regards to the testing of LY30 as a potential enhancer of TRAIL efficacy, 
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especially given the increasing reports on the development of the TRAIL resistant 
phenotype in cancer cells (Zhang and Fang, 2005, Van Geelen et al., 2004)as well as 
reports on non specific TRAIL mediated toxicity (Held and Schulze-Osthoff, 2001). 
Interestingly, the results obtained from this study showed that the sensitizing ability 
of LY30 in TRAIL treated cells, might not be as dependent on H2O2 as compared to 
the earlier LY30-vincristine model. 
 
3.1 TRAIL-mediated apoptosis is amplified upon pre-treatment with LY30 
via increased caspase dependent DNA fragmentation and reduced colony 
forming ability 
In order to determine if LY30 could act similarly as a sensitizer in TRAIL induced 
apoptosis, the TRAIL responsive cervical carcinoma HeLa cell line was first selected 
as a model cell line for the pilot study. Here, the TRAIL apoptotic sensitizing activity 
of LY30 was demonstrated with a reduction in cell viability and increased caspase 
activation, accompanied by DNA fragmentation (Figures 21 – 22, 24 – 26). The 
colony forming ability of HeLa cells after treatment (where no death was visibly 
observed) with LY30 and TRAIL was also visibly compromised  (Figure 23). 
Furthermore, LY30-induced amplification of TRAIL sensitivity as measured by a loss 
of cell viability, caspase activation and DNA fragmentation, was blocked in the 
presence of the pan-caspase inhibitor ZVAD-fmk (Figure 26). The issue of additivity 
versus synergism in the sensitization of HeLa cells to TRAIL induced apoptosis by 
LY30 is an interesting one. While the initial cell viability data as provided by crystal 
violet staining appears to show that LY30-TRAIL enhanced death is an almost 
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additive one (Figure 21), amplification of caspase activities and increased DNA 
fragmention in LY30-TRAIL treated cells is clearly synergistic (Figures 22, 24 – 25).  
 
3.2 Amplification of mitochondrial dependent death pathway. 
Results here also support the involvement of the mitochondrial death pathway in 
LY30-induced TRAIL sensitization as evidenced by the translocation of cytochrome 
c and Smac/Diablo, seen in cells incubated with both TRAIL and LY30 (Figure 28). 
Furthermore, with regards to the role of the mitochondria in TRAIL sensitization, 
there have been others reports demonstrating that drug-induced sensitization to 
TRAIL might be linked to silencing of the IAP family of proteins (XIAP, c-IAP1, c-
IAP2, survivin) (Chawla-Sarkar et al., 2004, Cummins et al., 2004, Kim et al., 2005a) 
or pro-survival kinases such as Akt (Inoue et al., 2006, Martelli et al., 2003, Puduvalli 
et al., 2005) and CK2 (Shin et al., 2005, Wang et al., 2006, Izeradjene et al., 2004). 
Results from the LY30-TRAIL treated cells however, show that despite the cytosolic 
translocation of IAP regulating protein Smac/Diablo, exposure of cells to LY30 and 
TRAIL did not affect the cellular levels of XIAP and IAP2 (Figure 29). This suggests 
that the amount of Smac/Diablo released was probably just about enough to inhibit 
activity of the IAPs (as evidenced by the robust caspase 9 and 3 activation) but not 
sufficient to reduce their total levels in the cell.  Collectively these data indicate the 
involvement of caspases and the mitochondrial pathway in the death sensitizing 
activity of LY30. Interestingly, these mitochondrial dependent death amplification 
events (cytochrome c and smac release, caspase 9 activation) appear to occur in 
independently of any significant change in MOMP (Figure 27), which could be in line 
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with reports by various groups showing that release of cytochrome c can occur 
independently of any significant MOMP. Moreover, it has been suggested that 
cytochrome c release via a slight opening of the PTP in the mitochondria can still 
occur in the absence of major MOMP as the mitochondrial electron transport chain 
can still compensate for any minor changes in the mitochondrial transmembrane 
potential (Garrido et al., 2006). 
 
3.3 Inability of LY30-sensitization to TRAIL induced apoptosis to be rescued 
by overexpression of catalase. 
Of note, although exposure to LY30 triggered intracellular H2O2 production in HeLa 
cells, unlike its effect on vincristine-induced apoptosis, the death sensitizing activity 
of LY30 on TRAIL signaling was not rescued upon transfection with the H2O2 
scavenger catalase (Figure 30).  Even more intriguing are data demonstrating the 
ability of catalase to rescue cells from either TRAIL or LY30 treatment alone (or 
LY30 with vincristine), but not upon the combination of the two agents (Figure 30B). 
The ability of catalase overexpression to rescue cells from TRAIL or LY30 treatment 
or LY30-vincristine treatment suggest that the overexpressed catalase is functional, in 
accordance with most reports demonstrating that overexpression of catalase confers 
protection against H2O2 mediated apoptotic triggers. The inability of catalase 
overexpression to protect HeLa cells from LY30-TRAIL mediated apoptosis suggests 
an involvement of death amplification pathways that may operate in parallel or 
independently of intracellular H2O2 production.             
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While intracellular H2O2 generation does not appear to be the main death inducing 
mechanism here in LY30-TRAIL treated HeLa cells, a host of other studies have 
nevertheless, implicated intracellular ROS in receptor-mediated apoptosis, be it as the 
accumulation of apoptotic inducing ROS upon TRAIL induction itself, or the 
sensitization to TRAIL by ROS generating compounds. Such ROS-assisted TRAIL-
mediated cell death has been shown to involve augmentation of pro-apoptotic factors, 
such as upregulation of TRAIL receptor(s) and release of Smac/Diablo from the 
mitochondria. In fact, like TNF-α, TRAIL induction on its own can induce oxidative 
stress in the cell and lowering of the intracellular ROS levels via preincubation with 
antioxidants can protect these cells again TRAIL induced apoptosis. Recent studies 
have shown that sulforaphane, a chemopreventive agent present in various 
cruciferous vegetables, and curcumin, a widely used spice with anti-inflammatory and 
anti cancer properties, can sensitize tumor cells to TRAIL (Kim et al., 2006). This 
was shown to occur via upregulation of both mRNA and protein levels of DR5, which 
was dependent upon an increase in intracellular levels of ROS with either 
sulforaphane or curcumin treatment. The classic uncoupler of oxidative 
phosphorylation, carbonyl cyanide m-chlorophenylhydrazone (CCCP), has also been 
shown to enhance TRAIL-induced apoptosis in TRAIL-resistant human colon 
carcinoma cell lines via the generation of intracellular ROS (Izeradjene et al., 2005). 
Generation of ROS by CCCP was responsible for TRAIL-induced Bax and caspase 
activation as scavenging ROS completely abrogated apical caspase-8 activation and 
further downstream mitochondria dependent events leading to cell death. Taken 
together, these data point strongly towards a central role of ROS in the enhancement 
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of TRAIL induced apoptosis. This makes the catalase overexpression data from the 
LY30-TRAIL model in HeLa cells even more suprising as it did not confer any 
protective effect to LY30-TRAIL mediated apoptosis on transfected cells 
overexpressing catalase. 
 
3.4 LY30 amplifies DR5 signaling and induces DISC assembly upon TRAIL 
ligation 
TRAIL-mediated apoptosis follows a pathway similar to FasL and TNFα, whereby 
ligation of the death receptors (DR4 and DR5 in case of TRAIL) is necessary to 
trigger clustering of the DISC components, caspase 8 and FADD. This brings about 
processing/activation of caspase 8, which can then drive the caspase cascade with 
(Type II) or without (Type I) the need for amplification from the mitochondria. 
Selective upregulation of genes for DR4 and/or DR5 (Kazhdan and Marciniak, 2004, 
Wen et al., 2000), caspase 8 (Platzbecker et al., 2003), FADD, BH3 protein Bid 
(Broaddus et al., 2005), or the mitochondrial protein Smac/Diablo (Bockbrader et al., 
2005) have been documented as mechanism(s) underlying increased sensitization to 
TRAIL. In the LY30-TRAIL model, LY30 pre-treatment resulted in an increase in 
sensitivity to TRAIL with a readout involving caspase activation, DNA fragmentation 
and cytosolic translocation of mitochondria derived amplification factors.  These are 
however, the downstream effectors of most apoptotic systems and do not give any 
indication as to what was the upstream transducing signal that resulting in the 
enhanced cellular response to TRAIL.  
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To decipher the upstream signal necessary for the recruitment of these pathways, the 
ability of LY30 to amplify the effect of TRAIL via its effect on death receptor 
signaling was analyzed. Notably, unlike in some other models of TRAIL-induced 
apoptosis, the total protein expression of DR5 (or DR4) did not change significantly 
upon LY30 treatment (Figure 32A). However, a selective augmentation of DR5 at the 
cell surface was observed by flow cytometry within 1h of incubation with LY30, with 
no such corresponding increase in the surface levels of DR4 (Figure 31). The 
subsequent addition of TRAIL for, as brief as 5min, resulted in an apparent 
internalization of the receptor, a mechanism consistent with death receptor-ligand 
interaction. Neither upregulation nor internalization of the death receptor was 
observed in HeLa cells stained for surface DR4, suggesting that the death signal is 
mediated primarily through DR5, which concurs with reports suggesting that DR5 
may contribute more than DR4 to TRAIL-induced apoptosis in tumor cells that 
express both death receptors (Kelley et al., 2005). As DR5 has been shown to be a 
DNA-damage inducible, p53 regulated gene (Mendoza-Rodriguez and Cerbon, 2001), 
it would seem likely that the ROS generated by LY30 could likewise induce a DNA-
damage, p53 dependent up regulation of DR5. However, the amount of time taken 
after LY30-TRAIL treatment for its up regulation at the cell surface is too short (1h) 
for any p53 dependent transcriptional and translational processes to take place, 
suggesting that the surface up regulation of DR5 could be a result of DR5 trafficking 
from the cytosolic pools to the plasma membrane. The mechanism for DR5 
trafficking to the plasma membrane has not been well documented as compared to 
that for Fas receptors, which have been shown to be sequestered within intracellular 
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pool like vesicles associated with the Golgi complex and the transgolgi network 
(Bennett et al., 1998). Fas receptors have also been shown to be able to undergo 
tyrosine phosphorylation, which can be a signal for Fas receptor membrane 
trafficking and subsequent DISC formation (Reinehr et al., 2003). Although no data 
has been shown with regards to DR5 trafficking to the membrane thus far, the ability 
of LY30 to generate oxidative stress or inhibit other kinases (like recombinant CK2 in 
vitro) could be a potential signal for DR5 trafficking to the membrane, either via 
oxidative modification of H2O2 sensitive cysteine like residues on the receptor, or via 
a (de)phosphorylation dependent process, possibly from a direct interaction with 
LY30.  
 
Furthermore, evidence is provided here that the increased cell surface expression of 
DR5 upon LY30 treatment is accompanied by increased oligomerization with DR5 
(Figure 32B). These two events could be occurring separately from each other (i.e., 
increase in cell surface DR5 is followed by oligomerization of the increased cell 
surface DR5) or alternatively, the increased cell surface DR5 detected by 
immunostaining and flow cytometry could simply be a function of receptor 
oligomerization with DR5. In any case, either scenario would explain the robust 
amplification of receptor signaling upon ligation with TRAIL. While DR5 up 
regulation upon induction by TRAIL (with or without a drug sensitizer) has been 
rather well studied with various TRAIL sensitizing compounds, the oligomerization 
of DR5 itself remains pretty much a mystery. TRAIL has been shown to bind to DR5 
as a homotrimeric complex like most receptor ligand interactions from the TNF 
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superfamily, however, it has not been conclusively established if DR5 can undergo 
homomeric assembly in the absence of TRAIL (as seen here, after incubation with 
LY30 alone). While the trimeric DR5 complex should be inactive until TRAIL 
binding to protect DR-expressing cells from ligand-independent apoptosis, it is 
nevertheless possible that pre-assembled DRs might be required for TRAIL binding. 
Studies have shown that soluble DcRs and DRs can interact homophilically and 
heterophilically in solution with affinities in the μM range, with the exception of 
interactions between soluble DR5 and DcR, which were not possible (Lee et al., 
2005). This suggests that the ability of DR5 to oligomerize upon LY30 incubation in 
the absence of TRAIL to facilitate DISC formation in the event of actual TRAIL 
binding as shown here, might be plausible after all. 
 
The precise mechanisms by which LY30 induces these changes in the cell surface 
DR5 and DISC formation are not clearly understood, but another possible target 
could be cFLIP (to be discussed in later sections); silencing of inhibitory genes 
involved in this pathway like cFLIP have been shown to promote TRAIL-mediated 
apoptosis. A second possible candidate could be intracellular H2O2 produced by 
LY30. As discussed in the previous section, ROS-induced upregulation of death 
receptors per se and more specifically DR5 during TRAIL signaling have been 
recently reported.  However, in our model, scavenging of intracellular H2O2 did not 
have any significant effect on LY30-induced increased cell sensitivity to TRAIL 
(Figure 30), arguing against the direct involvement of H2O2 in DR5 surface 
expression and DISC assembly upon LY30-induced sensitization to TRAIL. 
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Nevertheless, this does not conclusively rule out the possibility of a hitherto 
undefined alternate pathway triggered by LY30 stimulated increase in intracellular 
H2O2 in this system. 
 
With the increase in cell surface DR5 expression and an increase in its 
oligomerization, it would be reasonable to assume that DISC signaling is also 
enhanced with LY30-TRAIL treatment of the cells. Indeed, the apoptotic 
amplification effect of LY30 appears to be a function of an increased assembly of the 
DISC components, FADD and caspase 8. Following immunoprecipitation of whole 
cell lysates from LY30-TRAIL treated HeLa cells with anti-DR5, western blot 
analysis revealed an increased association of FADD and caspase 8 with DR5, 
suggesting enhanced DISC assembly with LY30-TRAIL treatment (Figure 33). As 
inhibition of DISC formation is a common alteration noted in TRAIL resistant cells, 
enhancement of the DISC formation would therefore logically lead to sensitization to 
TRAIL mediated apoptosis in tumor cells, as reported in a few studies. CK2 has been 
shown in various studies to confer resistance to TRAIL mediated apoptosis at the 
level of the DISC, with inactivation of CK2 resulting in TRAIL sensitization 
(Izeradjene et al., 2004) while LY30 has been shown to be able to inhibit recombinant 
CK2 activity in vitro (Kristoff et al., 2005). The data from these studies and this thesis 
point to a potential mechanism by which the enhanced DISC formation might be 
taking place in LY30-TRAIL treated HeLa cells, via inactivation of CK2, leading to 
enhanced clustering of the DISC assembly. However, in the study by Izeradjene et al., 
2004, inhibition of CK2 activity did not alter DR4 or 5 levels, unlike the up 
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regulation and oligomerization of DR5 shown here with LY30 mediated sensitization 
to TRAIL.  
 
In agreement with most death receptor signaling, LY30-TRAIL treatment induced 
strong activation of the upstream caspase 8 as evidenced by its proteolytic processing 
(Figure 34A), and cleavage of its substrate, the BH3 protein Bid (Figure 34B). The 
processing of caspase 8 following DISC formation is the main initiating event that 
drives downstream death execution, but selective inhibition of caspase 8 in our 
system did not completely rescue cells from LY30-TRAIL-induced apoptosis. This 
could be suggestive of the activation of a dual pathway in the amplification of 
apoptosis; up regulation of DR5 at the cell surface resulting in enhanced clustering of 
DISC components together with increased caspase 8 activation and Bid processing, as 
well as, a concomitant but probably independent increase in caspase 2, 3 and 9 
activation resulting in mitochondria-mediated amplification of apoptosis.  
 
3.5 Significance of mTOR and p70S6K early activation in LY30-TRAIL 
treated cells – preliminary data.  
Contrary to data from Kristof et al. 2005, preliminary data from this thesis shows the 
activation (phosphorylation) of mTOR and its substrate p70S6K after 1h treatment 
with LY30 and TRAIL in HeLa cells (Figure 35). Suprisingly, only one study has 
shown a link between the mTOR pathway and TRAIL sensitivity in tumor cells. 
Activation of the mTOR – p70 S6K pathway has been shown to be able to 
translationally enhance expression of FLIPs (Panner et al., 2006). Pharmacologic 
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(using rapamycin) or genetic inhibition of mTOR, or S6K1, could suppress the 
polyribosomal accumulation of FLIPs mRNA, FLIPs protein expression, thus 
overcoming TRAIL resistance in gliomablastoma multiforme (GBM), the most fatal 
form of glioma (Panner et al., 2005). In fact, these results define the mTOR pathway 
as a key limiter of tumor elimination by TRAIL-mediated mechanisms and suggest 
that this provides a means by which the TRAIL-sensitive subset of GBM can be 
identified. This and studies by others run contrary to the data shown in this thesis, 
where early activation of the pro survival/growth mTOR pathway exists in a system 
of LY30 enhanced TRAIL apoptotic signalling. This suggests that mTOR might be 
either involved in the translation of gene products that are pro apoptotic, or simply 
activated as a stress response, as it has been shown by others that H2O2 generated as a 
result of UV radiation can phosphorylate and activate mTOR independently of the 
PI3K-Akt pathway (Huang et al., 2002). In relation to this work, the large amounts of 
H2O2 generated by LY30 in this system could possibly be a mechanism by which 
mTOR is being activated. 
 
3.6 LY30 can also sensitize TRAIL resistant colon carcinoma cells HT29 to 
TRAIL. 
In order to first decide if LY30 could sensitize tumor cells to TRAIL, the bulk of the 
pilot study with LY30 and TRAIL were done on the TRAIL responsive cervical 
carcinoma cell line, HeLa. However, in recognition of the growing problem of the 
appearance of the TRAIL resistant phenotype in tumor cells, this system was also 
tested on a TRAIL resistant tumor cell line. In fact, preliminary work in this thesis 
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shows that LY30 can also similarly sensitize TRAIL resistant colon carcinoma cells, 
HT29 (Figure 36A) with a large increase in caspase 9 activation (Figure 37), 
suggesting an amplification of the mitochondrial dependent death pathway. 
Interestingly, it is the TRAIL responsive colon carcinoma cell line HCT116 that 
could not be sensitized as effectively to TRAIL by using LY30 (Figure 36C), 
suggesting a difference between the two cell lines that renders one resistant and the 
other sensitive to LY30 mediated sensitization of TRAIL. Major differences between 
the two cell lines include the p53 mutant status of HT29 and the mismatch repair 
(MMR) deficiency status of HCT116 (Chang et al., 2003, Nagasawa et al., 1995). 
TRAIL sensitization studies on HT29 have demonstrated amplification of the 
mitochondrial death pathway with release of Smac (Izeradjene et al., 2005) and XIAP 
downregulation (Shi et al., 2005). This appears to fit in with the data here showing 
sensitization of HT29 to TRAIL by LY30, as it is accompanied by massive increases 
in caspase 9 activation, much more than seen in the LY30-TRAIL model with HeLa 
cells. 
 
3.7 Involvement of other proteins in LY30 mediated signalling 
The process of chemoprevention is a complex one and it would not be suprising if 
LY30 were to significantly affect parameters other than the ones currently examined 
in this thesis. While the over expression of catalase has been shown to be unable to 
confer significant protection against the effects of LY30-TRAIL treatment, one 
cannot totally exclude the effects of ROS generated in this system. In addition to the 
up regulation of death receptors and amplification of the mitochondrial death pathway 
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as previously discussed, it would also be tempting to suggest the involvement of 
redox sensitive proteins known to affect TRAIL induced apoptosis like the 
transcription factor NF-κB. In fact, compounds like curcumin that sensitize tumor 
cells to TRAIL via ROS dependent up regulation of DR5 (Jung et al., 2005)have also 
been shown separately to inhibit NF-κB (Bharti et al., 2004). However, conflicting 
reports have also shown that in addition to Fas and FasL, NF-κB can also upregulate 
DR5, which is characteristic of NF-κB’s ability to activate transcription of both pro 
survival and pro apoptotic genes. In fact, the c-Rel subunit of the transcription Nf-κB 
has been shown to induce expression of DR4 and DR5; conversely, the RelA subunit 
of NF-κB has also been shown to increase expression of Bcl-xL, thus protecting cells 
from TRAIL (Ravi et al., 2001). This ability to induce death receptors or Bcl-xL may 
explain the dual roles of NF-kappaB as a mediator or inhibitor of TRAIL induced cell 
death. 
 
3.8 LY30 and related compounds as novel sensitizers or amplifiers of TRAIL 
signaling 
The myriad ways by which TRAIL-mediated death could be enhanced suggest that 
there are many factors mediating the effector mechanisms underlying this receptor-
dependent death signaling in tumor cells. The findings here suggest an interesting 
possibility in designing chemotherapeutic strategies aimed at enhancing the response 
of (resistant or otherwise) tumor cells to TRAIL but at the same time, reducing any 
non-specific side effects by lowering the overall dose of TRAIL used. The work in 
this thesis highlights the potential of LY30 in priming tumor cells for TRAIL-
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mediated killing, and could have implications for the design of novel strategies to 
overcome the problem of TRAIL resistance in tumor cells.   
 
4. Potential of LY30 in chemoprevention 
The ability of LY30 to sensitize tumor cells to drug induced apoptosis as shown in 
two separate drug models in this thesis, suggest potential for novel chemotherapeutic 
drug design. A possible reason that LY30 was overlooked as a potential sensitizer to 
drug induced apoptosis when used as a negative control to LY30 could be that the 
drug doses usually used in such systems are too high for any sensitizing ability of 
LY30 to be noticed. For example, the doses of vincristine used here (0.02μM) are not 
usually used in studies to induced apoptosis or even sensitization to vincristine 
induced apoptosis. However, the actual usefulness of LY30 or LY29 for that matter, 
as a sensitizing compound in chemotherapy may be limited by its insolubility in 
aqueous solutions. This could be circumvented by potentially designing soluble 
variants of the LY30 structure that can induce similar effects without affecting PI3K 
and the variety of cellular functions that it mediates as a strength of using LY30 as a 
potential chemopreventive agent is that it can sensitize tumor cells without affecting 
the function of PI3K which could play many other roles in the cell, in addition to the 
maintenance of the oncogenic phenotype. Nevertheless, the various signaling 
pathways LY30 appears to affect suggest that it could also be used as a trigger to 
further study the H2O2 dependent and independent aspects of TRAIL or vincristine 
(or other drugs) induced apoptotic signaling. At the same time, the potency of LY30 
as demonstrated in this thesis serves to highlight the potential PI3K-independent 
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effects of the widely used sister compound, the PI3K inhibitor LY29, given the 
structural similarity between these two, and acts as a reminder to those using the 
LY29 compound to study the PI3K-Akt pathway to the possible non PI3K specific 
effects of the LY compounds as a result of their intracellular generation of H2O2. In 
fact, many studies in current literature have used LY29 to study the effects of TRAIL 
mediated apoptosis with regards to the PI3K-Akt pathway without concurrent usage 




This study provides evidence for the first time, based on the prevailing hypothesis 
that moderate amounts of H2O2 can provide a permissive intracellular milieu for the 
induction of apoptosis, that what was previously known as an inactive analogue of the 
PI3K inhibitor LY29, LY30, can also demonstrate anti tumor activity in various 
cultured tumor cell lines. This was accounted for by the ability of both LY 
compounds to elevate the levels of intracellular H2O2, indicative of a hitherto as yet 
undefined ability of the LY compounds, specifically LY30, to affect cell function 
through this mechanism.  While initial studies demonstrated that LY30 had no effect 
on cultured tumor cells, later work with suitably low doses of vincristine (and 
subsequently TRAIL) showed a synergistic induction of cellular apoptosis, a process 
that appeared dependent on the generation of intracellular H2O2, in the LY30-
vincristine tumor cell model. The proven physiological significance of LY30’s (and 
LY29’s) ability to generate intracellular H2O2 in this system of drug sensitization 
could also account for the few reported PI3K independent effects of the LY 
compounds in current literature, given the ability of H2O2 to affect cellular 
physiology in a pleiotropic manner (as reviewed in Discussion), thus providing a 
common link for these reported PI3K independent effects of both LY29 and LY30. 
The ability of LY30 to sensitize tumor cells to vincristine via the generation of 
intracellular H2O2 could potentially be clinically significant in the continued efforts to 
tailor chemotherapeutic strategies to increase the apoptotic efficacy while reducing 
the non specific toxicity of anti tumor agents. The ability of the “inactive” analogue, 
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LY30 to enhance apoptosis in tumor cells has been demonstrated not only in 
conjunction with the anti microtubule agent, vincristine, but also mechanistically in 
TRAIL induced death receptor apoptosis. While this later observation appears to 
show that the generation of intracellular H2O2 might not be a crucial mediator of 
TRAIL induced apoptosis, the data offers an explanation for the sensitizing ability of 
LY30 by demonstrating that it could enhance TRAIL induced apoptosis via 
amplification of DR5 surface signaling and DISC formation. A schematic diagram 
illustrating the potential mechanisms of both H2O2 dependent and independent 
pathways studied in this thesis is shown in Figure 39. In this regard, this current study 
of LY30 would appear to be more than just simply a word of caution in wrongly 
attributing the sensitizing ability of the LY compounds (LY29 in particular) to 
chemotherapeutic agents (Shingu et al., 2003), or simply as a proof of the ability of 
H2O2 to provide a conducive intracellular milieu for the induction of apoptosis. In 
fact, the ability of LY30 to singularly amplify DR5 surface signaling could also 
provide a novel tool with which to study the relatively unknown mechanistic aspects 
of DR5 surface signaling events in a model of TRAIL induced apoptosis. While 
initial studies do not show a link between the generation of intracellular H2O2 and the 
ability of LY30 to amplify DR5 surface signaling in TRAIL induced apoptosis, 
further studies should aim to delineate more clearly any possible relationship between 
the generation of intracellular H2O2 by LY30 and amplification of DR5 signaling. 
Furthermore, given that the generation of intracellular H2O2 has been shown to be 
significant in the sensitization of tumor cells to vincristine, the exact intracellular 
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Figure 39: Schematic diagram of LY30 mediated 
effects: Both drug models (Vincristine and TRAIL) 
utilized in this study are shown, illustrating the pathways 
and mechanisms involved. Speculative effects of LY30 not 






Ahmad, K. A., Clement, M. V., Hanif, I. M. and Pervaiz, S. (2004a) Cancer Res, 64, 
1452-9. 
Ahmad, K. A., Iskandar, K. B., Hirpara, J. L., Clement, M. V. and Pervaiz, S. (2004b) 
Cancer Res, 64, 7867-78. 
Arico, S., Petiot, A., Bauvy, C., Dubbelhuis, P. F., Meijer, A. J., Codogno, P. and 
Ogier-Denis, E. (2001) J Biol Chem, 276, 35243-6. 
Arnold, R. S., Shi, J., Murad, E., Whalen, A. M., Sun, C. Q., Polavarapu, R., 
Parthasarathy, S., Petros, J. A. and Lambeth, J. D. (2001) Proc Natl Acad Sci U S A, 
98, 5550-5. 
Ashkenazi, A. (2002) Nat Rev Cancer, 2, 420-30. 
Bai, J. and Cederbaum, A. I. (2000) J Biol Chem, 275, 19241-9. 
Barnett, S. F., Defeo-Jones, D., Fu, S., Hancock, P. J., Haskell, K. M., Jones, R. E., 
Kahana, J. A., Kral, A. M., Leander, K., Lee, L. L., Malinowski, J., McAvoy, E. M., 
Nahas, D. D., Robinson, R. G. and Huber, H. E. (2005) Biochem J, 385, 399-408. 
Bellacosa, A., Testa, J. R., Staal, S. P. and Tsichlis, P. N. (1991) Science, 254, 274-7. 
Bennett, M., Macdonald, K., Chan, S. W., Luzio, J. P., Simari, R. and Weissberg, P. 
(1998) Science, 282, 290-3. 
Bharti, A. C., Takada, Y. and Aggarwal, B. B. (2004) J Immunol, 172, 5940-7. 
Bin, L., Li, X., Xu, L. G. and Shu, H. B. (2002) FEBS Lett, 510, 37-40. 
Bockbrader, K. M., Tan, M. and Sun, Y. (2005) Oncogene, 24, 7381-8. 
 174
Bolton, M. A., Lan, W., Powers, S. E., McCleland, M. L., Kuang, J. and Stukenberg, 
P. T. (2002) Mol Biol Cell, 13, 3064-77. 
Bonser, R. W., Thompson, N. T., Randall, R. W., Tateson, J. E., Spacey, G. D., 
Hodson, H. F. and Garland, L. G. (1991) Br J Pharmacol, 103, 1237-41. 
Brazil, D. P., Park, J. and Hemmings, B. A. (2002) Cell, 111, 293-303. 
Breslin, E. M., White, P. C., Shore, A. M., Clement, M. and Brennan, P. (2005) Br J 
Pharmacol, 144, 791-800. 
Broaddus, V. C., Dansen, T. B., Abayasiriwardana, K. S., Wilson, S. M., Finch, A. J., 
Swigart, L. B., Hunt, A. E. and Evan, G. I. (2005) J Biol Chem, 280, 12486-93. 
Browe, D. M. and Baumgarten, C. M. (2006) J Gen Physiol, 127, 237-51. 
Burdon, R. H. (1995) Free Radic Biol Med, 18, 775-94. 
Burdon, R. H., Gill, V. and Rice-Evans, C. (1990) Free Radic Res Commun, 11, 65-
76. 
Burgering, B. M. and Coffer, P. J. (1995) Nature, 376, 599-602. 
Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N. and Williamson, B. 
(1975) Proc Natl Acad Sci U S A, 72, 3666-70. 
Carvalho, A., Carmena, M., Sambade, C., Earnshaw, W. C. and Wheatley, S. P. 
(2003) J Cell Sci, 116, 2987-98. 
Castedo, M., Perfettini, J. L., Roumier, T., Andreau, K., Medema, R. and Kroemer, G. 
(2004) Oncogene, 23, 2825-37. 
Castillo, S. S., Brognard, J., Petukhov, P. A., Zhang, C., Tsurutani, J., Granville, C. 
A., Li, M., Jung, M., West, K. A., Gills, J. G., Kozikowski, A. P. and Dennis, P. A. 
(2004) Cancer Res, 64, 2782-92. 
 175
Ceolotto, G., Bevilacqua, M., Papparella, I., Baritono, E., Franco, L., Corvaja, C., 
Mazzoni, M., Semplicini, A. and Avogaro, A. (2004) Diabetes, 53, 1344-51. 
Cerutti, P. A. (1985) Science, 227, 375-81. 
Chang, D. K., Goel, A., Ricciardiello, L., Lee, D. H., Chang, C. L., Carethers, J. M. 
and Boland, C. R. (2003) Cancer Lett, 195, 243-51. 
Chawla-Sarkar, M., Bae, S. I., Reu, F. J., Jacobs, B. S., Lindner, D. J. and Borden, E. 
C. (2004) Cell Death Differ, 11, 915-23. 
Chen, Q., Powell, D. W., Rane, M. J., Singh, S., Butt, W., Klein, J. B. and McLeish, 
K. R. (2003) J Immunol, 170, 5302-8. 
Chen, X. L., Zhang, Q., Zhao, R. and Medford, R. M. (2004) Am J Physiol Heart Circ 
Physiol, 286, H1001-7. 
Chen, Z., Duan, R. S., Lepecheur, M., Paly, E., London, J. and Zhu, J. (2005) 
Apoptosis, 10, 499-502. 
Cheng, E. H., Sheiko, T. V., Fisher, J. K., Craigen, W. J. and Korsmeyer, S. J. (2003) 
Science, 301, 513-7. 
Cheng, J. Q., Lindsley, C. W., Cheng, G. Z., Yang, H. and Nicosia, S. V. (2005) 
Oncogene, 24, 7482-92. 
Cho, S. H., Lee, C. H., Ahn, Y., Kim, H., Ahn, C. Y., Yang, K. S. and Lee, S. R. 
(2004) FEBS Lett, 560, 7-13. 
Choi, E. K., Park, H. J., Ma, J. S., Lee, H. C., Kang, H. C., Kim, B. G. and Kang, I. C. 
(2004) FEBS Lett, 559, 141-4. 
Choi, J. A., Kim, J. Y., Lee, J. Y., Kang, C. M., Kwon, H. J., Yoo, Y. D., Kim, T. W., 
Lee, Y. S. and Lee, S. J. (2001) Int J Oncol, 19, 837-44. 
 176
Chow, J. M., Shen, S. C., Huan, S. K., Lin, H. Y. and Chen, Y. C. (2005) Biochem 
Pharmacol, 69, 1839-51. 
Clement, M. V., Hirpara, J. L. and Pervaiz, S. (2003) Cell Death Differ, 10, 1273-85. 
Clement, M. V. and Stamenkovic, I. (1996) Embo J, 15, 216-25. 
Connor, K. M., Subbaram, S., Regan, K. J., Nelson, K. K., Mazurkiewicz, J. E., 
Bartholomew, P. J., Aplin, A. E., Tai, Y. T., Aguirre-Ghiso, J., Flores, S. C. and 
Melendez, J. A. (2005) J Biol Chem, 280, 16916-24. 
Cory, S. and Adams, J. M. (2002) Nat Rev Cancer, 2, 647-56. 
Cross, M. J., Stewart, A., Hodgkin, M. N., Kerr, D. J. and Wakelam, M. J. (1995) J 
Biol Chem, 270, 25352-5. 
Cummins, J. M., Kohli, M., Rago, C., Kinzler, K. W., Vogelstein, B. and Bunz, F. 
(2004) Cancer Res, 64, 3006-8. 
D'Amours, D., Desnoyers, S., D'Silva, I. and Poirier, G. G. (1999) Biochem J, 342 ( 
Pt 2), 249-68. 
Danial, N. N. and Korsmeyer, S. J. (2004) Cell, 116, 205-19. 
de la Pena, L., Burgan, W. E., Carter, D. J., Hollingshead, M. G., Satyamitra, M., 
Camphausen, K. and Tofilon, P. J. (2006) Mol Cancer Ther, 5, 1504-10. 
Djavaheri-Mergny, M., Amelotti, M., Mathieu, J., Besancon, F., Bauvy, C., Souquere, 
S., Pierron, G. and Codogno, P. (2006) J Biol Chem. 
El-Kholy, W., Macdonald, P. E., Lin, J. H., Wang, J., Fox, J. M., Light, P. E., Wang, 
Q., Tsushima, R. G. and Wheeler, M. B. (2003) Faseb J, 17, 720-2. 
Esposito, F., Chirico, G., Montesano Gesualdi, N., Posadas, I., Ammendola, R., 
Russo, T., Cirino, G. and Cimino, F. (2003) J Biol Chem, 278, 20828-34. 
 177
Ferby, I. M., Waga, I., Hoshino, M., Kume, K. and Shimizu, T. (1996) J Biol Chem, 
271, 11684-8. 
Foyouzi-Youssefi, R., Arnaudeau, S., Borner, C., Kelley, W. L., Tschopp, J., Lew, D. 
P., Demaurex, N. and Krause, K. H. (2000) Proc Natl Acad Sci U S A, 97, 5723-8. 
Franke, T. F., Hornik, C. P., Segev, L., Shostak, G. A. and Sugimoto, C. (2003) 
Oncogene, 22, 8983-98. 
Franke, T. F., Yang, S. I., Chan, T. O., Datta, K., Kazlauskas, A., Morrison, D. K., 
Kaplan, D. R. and Tsichlis, P. N. (1995) Cell, 81, 727-36. 
Fruman, D. A., Meyers, R. E. and Cantley, L. C. (1998) Annu Rev Biochem, 67, 481-
507. 
Garrido, C., Galluzzi, L., Brunet, M., Puig, P. E., Didelot, C. and Kroemer, G. (2006) 
Cell Death Differ. 
Gills, J. J. and Dennis, P. A. (2004) Expert Opin Investig Drugs, 13, 787-97. 
Gottlieb, T. M., Leal, J. F., Seger, R., Taya, Y. and Oren, M. (2002) Oncogene, 21, 
1299-303. 
Gozuacik, D. and Kimchi, A. (2004) Oncogene, 23, 2891-906. 
Green, D. R. and Kroemer, G. (2004) Science, 305, 626-9. 
Guan, B., Yue, P., Clayman, G. L. and Sun, S. Y. (2001) J Cell Physiol, 188, 98-105. 
Hail, N., Jr. (2005) Apoptosis, 10, 687-705. 
Hajji, H. E., Nkhili, E., Tomao, V. and Dangles, O. (2006) Free Radic Res, 40, 303-
20. 
Halliwell, B., and Gutteridge, J.M.C. (1999) Free Radicals in Biology and Medicine, 
Clarendon Press, Oxford, London. 
 178
Hamasaki, A., Sendo, F., Nakayama, K., Ishida, N., Negishi, I. and Hatakeyama, S. 
(1998) J Exp Med, 188, 1985-92. 
Han, D., Hanawa, N., Saberi, B. and Kaplowitz, N. (2006) Free Radic Biol Med, 41, 
627-39. 
Han, Y. J., Kwon, Y. G., Chung, H. T., Lee, S. K., Simmons, R. L., Billiar, T. R. and 
Kim, Y. M. (2001) Nitric Oxide, 5, 504-13. 
Held, J. and Schulze-Osthoff, K. (2001) Drug Resist Updat, 4, 243-52. 
Hengartner, M. O. (2000) Nature, 407, 770-6. 
Hennessy, B. T., Smith, D. L., Ram, P. T., Lu, Y. and Mills, G. B. (2005) Nat Rev 
Drug Discov, 4, 988-1004. 
Hideshima, T., Catley, L., Yasui, H., Ishitsuka, K., Raje, N., Mitsiades, C., Podar, K., 
Munshi, N. C., Chauhan, D., Richardson, P. G. and Anderson, K. C. (2006) Blood, 
107, 4053-62. 
Huang, C., Li, J., Ke, Q., Leonard, S. S., Jiang, B. H., Zhong, X. S., Costa, M., 
Castranova, V. and Shi, X. (2002) Cancer Res, 62, 5689-97. 
Huang, H. L., Fang, L. W., Lu, S. P., Chou, C. K., Luh, T. Y. and Lai, M. Z. (2003) 
Oncogene, 22, 8168-77. 
Ide, T., Tsutsui, H., Kinugawa, S., Utsumi, H., Kang, D., Hattori, N., Uchida, K., 
Arimura, K., Egashira, K. and Takeshita, A. (1999) Circ Res, 85, 357-63. 
Inoue, T., Shiraki, K., Fuke, H., Yamanaka, Y., Miyashita, K., Yamaguchi, Y., 
Yamamoto, N., Ito, K., Sugimoto, K. and Nakano, T. (2006) Anticancer Drugs, 17, 
261-8. 
 179
Itoh, N., Yonehara, S., Ishii, A., Yonehara, M., Mizushima, S., Sameshima, M., Hase, 
A., Seto, Y. and Nagata, S. (1991) Cell, 66, 233-43. 
Izeradjene, K., Douglas, L., Delaney, A. and Houghton, J. A. (2004) Clin Cancer Res, 
10, 6650-60. 
Izeradjene, K., Douglas, L., Tillman, D. M., Delaney, A. B. and Houghton, J. A. 
(2005) Cancer Res, 65, 7436-45. 
Izzard, R. A., Jackson, S. P. and Smith, G. C. (1999) Cancer Res, 59, 2581-6. 
Jezek, P. and Hlavata, L. (2005) Int J Biochem Cell Biol, 37, 2478-503. 
Jimenez, C., Jones, D. R., Rodriguez-Viciana, P., Gonzalez-Garcia, A., Leonardo, E., 
Wennstrom, S., von Kobbe, C., Toran, J. L., L, R. B., Calvo, V., Copin, S. G., Albar, 
J. P., Gaspar, M. L., Diez, E., Marcos, M. A., Downward, J., Martinez, A. C., Merida, 
I. and Carrera, A. C. (1998) Embo J, 17, 743-53. 
Jin, Z., McDonald, E. R., 3rd, Dicker, D. T. and El-Deiry, W. S. (2004) J Biol Chem, 
279, 35829-39. 
Jung, E. M., Lim, J. H., Lee, T. J., Park, J. W., Choi, K. S. and Kwon, T. K. (2005) 
Carcinogenesis, 26, 1905-13. 
Kazhdan, I. and Marciniak, R. A. (2004) Cancer Gene Ther, 11, 691-8. 
Kelley, R. F., Totpal, K., Lindstrom, S. H., Mathieu, M., Billeci, K., Deforge, L., Pai, 
R., Hymowitz, S. G. and Ashkenazi, A. (2005) J Biol Chem, 280, 2205-12. 
Kerr, J. F., Wyllie, A. H. and Currie, A. R. (1972) Br J Cancer, 26, 239-57. 
Kim, E. H., Kim, S. U. and Choi, K. S. (2005a) Oncogene, 24, 838-49. 
Kim, H., Kim, E. H., Eom, Y. W., Kim, W. H., Kwon, T. K., Lee, S. J. and Choi, K. 
S. (2006) Cancer Res, 66, 1740-50. 
 180
Kim, H., Kim, Y. N. and Kim, C. W. (2005b) Oncogene, 24, 1252-61. 
Kim, Y. H., Choi, K. H., Park, J. W. and Kwon, T. K. (2005c) Immunol Lett, 99, 45-
50. 
Kirchhoff, S. R., Gupta, S. and Knowlton, A. A. (2002) Circulation, 105, 2899-904. 
Klee, M. and Pimentel-Muinos, F. X. (2005) J Cell Biol, 168, 723-34. 
Klippel, A., Kavanaugh, W. M., Pot, D. and Williams, L. T. (1997) Mol Cell Biol, 17, 
338-44. 
Knowling, M., Blackstein, M., Tozer, R., Bramwell, V., Dancey, J., Dore, N., 
Matthews, S. and Eisenhauer, E. (2006) Invest New Drugs, 24, 435-9. 
Kohn, A. D., Kovacina, K. S. and Roth, R. A. (1995) Embo J, 14, 4288-95. 
Korn, S. H., Wouters, E. F., Vos, N. and Janssen-Heininger, Y. M. (2001) J Biol 
Chem, 276, 35693-700. 
Korsmeyer, S. J. (1999) Cancer Res, 59, 1693s-1700s. 
Kristof, A. S., Pacheco-Rodriguez, G., Schremmer, B. and Moss, J. (2005) J 
Pharmacol Exp Ther, 314, 1134-43. 
Kwon, J., Lee, S. R., Yang, K. S., Ahn, Y., Kim, Y. J., Stadtman, E. R. and Rhee, S. 
G. (2004) Proc Natl Acad Sci U S A, 101, 16419-24. 
Lacasse, C. and Rola-Pleszczynski, M. (1991) J Leukoc Biol, 49, 245-52. 
Lakhani, S. A., Masud, A., Kuida, K., Porter, G. A., Jr., Booth, C. J., Mehal, W. Z., 
Inayat, I. and Flavell, R. A. (2006) Science, 311, 847-51. 
Lassus, P., Opitz-Araya, X. and Lazebnik, Y. (2002) Science, 297, 1352-4. 
 181
Laurent, A., Nicco, C., Chereau, C., Goulvestre, C., Alexandre, J., Alves, A., Levy, 
E., Goldwasser, F., Panis, Y., Soubrane, O., Weill, B. and Batteux, F. (2005) Cancer 
Res, 65, 948-56. 
Lavrik, I. N., Golks, A., Baumann, S. and Krammer, P. H. (2006) Blood. 
Lebedeva, I. and Stein, C. A. (2001) Annu Rev Pharmacol Toxicol, 41, 403-19. 
Lee, H. W., Lee, S. H., Ryu, Y. W., Kwon, M. H. and Kim, Y. S. (2005) Biochem 
Biophys Res Commun, 330, 1205-12. 
Lee, M. W., Park, S. C., Yang, Y. G., Yim, S. O., Chae, H. S., Bach, J. H., Lee, H. J., 
Kim, K. Y., Lee, W. B. and Kim, S. S. (2002) FEBS Lett, 512, 313-8. 
Lee, Y. J., Lee, K. H., Kim, H. R., Jessup, J. M., Seol, D. W., Kim, T. H., Billiar, T. 
R. and Song, Y. K. (2001) Oncogene, 20, 1476-85. 
Lens, S. M. and Medema, R. H. (2003) Cell Cycle, 2, 507-10. 
Leslie, N. R., Bennett, D., Lindsay, Y. E., Stewart, H., Gray, A. and Downes, C. P. 
(2003) Embo J, 22, 5501-10. 
Li, L., Thomas, R. M., Suzuki, H., De Brabander, J. K., Wang, X. and Harran, P. G. 
(2004) Science, 305, 1471-4. 
Li, N. and Oberley, T. D. (1998) J Cell Physiol, 177, 148-60. 
Li, N., Ragheb, K., Lawler, G., Sturgis, J., Rajwa, B., Melendez, J. A. and Robinson, 
J. P. (2003) Free Radic Biol Med, 34, 465-77. 
Liang, C., Feng, P., Ku, B., Dotan, I., Canaani, D., Oh, B. H. and Jung, J. U. (2006) 
Nat Cell Biol, 8, 688-99. 
Liang, X. H., Jackson, S., Seaman, M., Brown, K., Kempkes, B., Hibshoosh, H. and 
Levine, B. (1999) Nature, 402, 672-6. 
 182
Liang, X. H., Kleeman, L. K., Jiang, H. H., Gordon, G., Goldman, J. E., Berry, G., 
Herman, B. and Levine, B. (1998) J Virol, 72, 8586-96. 
Lin, S. J., Shyue, S. K., Shih, M. C., Chu, T. H., Chen, Y. H., Ku, H. H., Chen, J. W., 
Tam, K. B. and Chen, Y. L. (2006) Atherosclerosis. 
Liston, P., Fong, W. G. and Korneluk, R. G. (2003) Oncogene, 22, 8568-80. 
Liu, X., Dai, S., Zhu, Y., Marrack, P. and Kappler, J. W. (2003) Immunity, 19, 341-
52. 
Liu, Z., Lu, H., Shi, H., Du, Y., Yu, J., Gu, S., Chen, X., Liu, K. J. and Hu, C. A. 
(2005) Cancer Res, 65, 1647-54. 
Lockshin, R. A. and Zakeri, Z. (2004) Int J Biochem Cell Biol, 36, 2405-19. 
Lu, B., Wang, L., Stehlik, C., Medan, D., Huang, C., Hu, S., Chen, F., Shi, X. and 
Rojanasakul, Y. (2006) J Immunol, 176, 6785-93. 
Lucken-Ardjomande, S. and Martinou, J. C. (2005) C R Biol, 328, 616-31. 
Lum, J. J., DeBerardinis, R. J. and Thompson, C. B. (2005) Nat Rev Mol Cell Biol, 6, 
439-48. 
Mandal, M., Borowski, C., Palomero, T., Ferrando, A. A., Oberdoerffer, P., Meng, F., 
Ruiz-Vela, A., Ciofani, M., Zuniga-Pflucker, J. C., Screpanti, I., Look, A. T., 
Korsmeyer, S. J., Rajewsky, K., von Boehmer, H. and Aifantis, I. (2005) J Exp Med, 
201, 603-14. 
Manero, F., Gautier, F., Gallenne, T., Cauquil, N., Gree, D., Cartron, P. F., Geneste, 
O., Gree, R., Vallette, F. M. and Juin, P. (2006) Cancer Res, 66, 2757-64. 
Martelli, A. M., Tazzari, P. L., Tabellini, G., Bortul, R., Billi, A. M., Manzoli, L., 
Ruggeri, A., Conte, R. and Cocco, L. (2003) Leukemia, 17, 1794-805. 
 183
Martinon, F. and Tschopp, J. (2004) Cell, 117, 561-74. 
Matsui, T. A., Sowa, Y., Yoshida, T., Murata, H., Horinaka, M., Wakada, M., 
Nakanishi, R., Sakabe, T., Kubo, T. and Sakai, T. (2006) Carcinogenesis. 
Mendoza-Rodriguez, C. A. and Cerbon, M. A. (2001) Rev Invest Clin, 53, 266-73. 
Meylan, E., Martinon, F., Thome, M., Gschwendt, M. and Tschopp, J. (2002) EMBO 
Rep, 3, 1201-8. 
Meylan, E. and Tschopp, J. (2005) Trends Biochem Sci, 30, 151-9. 
Mills, K. R., Reginato, M., Debnath, J., Queenan, B. and Brugge, J. S. (2004) Proc 
Natl Acad Sci U S A, 101, 3438-43. 
Minagawa, N., Kruglov, E. A., Dranoff, J. A., Robert, M. E., Gores, G. J. and 
Nathanson, M. H. (2005) J Biol Chem, 280, 33637-44. 
Miyazaki, T. and Reed, J. C. (2001) Nat Immunol, 2, 493-500. 
Mizrahi, A., Berdichevsky, Y., Ugolev, Y., Molshanski-Mor, S., Nakash, Y., Dahan, 
I., Alloul, N., Gorzalczany, Y., Sarfstein, R., Hirshberg, M. and Pick, E. (2006) J 
Leukoc Biol, 79, 881-95. 
Morgan, W. F., Hartmann, A., Limoli, C. L., Nagar, S. and Ponnaiya, B. (2002) 
Mutat Res, 504, 91-100. 
Nagasawa, H., Li, C. Y., Maki, C. G., Imrich, A. C. and Little, J. B. (1995) Cancer 
Res, 55, 1842-6. 
Nagata, S. (2000) Exp Cell Res, 256, 12-8. 
Nanua, S., Zick, S. M., Andrade, J. E., Burgess, J. R., Lukacs, N. W. and Hershenson, 
M. B. (2006) Am J Respir Cell Mol Biol. 
 184
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., 
Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A. and et al. (1995) 
Nature, 376, 37-43. 
Nigg, E. A. (2001) Nat Rev Mol Cell Biol, 2, 21-32. 
Oberley, L. W. (2005) Biomed Pharmacother, 59, 143-8. 
Oberley, L. W. and Buettner, G. R. (1979) Cancer Res, 39, 1141-9. 
Ong, C. S., Tran, E., Nguyen, T. T., Ong, C. K., Lee, S. K., Lee, J. J., Ng, C. P., 
Leong, C. and Huynh, H. (2004) Oncol Rep, 11, 727-33. 
Orlinick, J. R. and Chao, M. V. (1998) Cell Signal, 10, 543-51. 
Otaegi, G., Yusta-Boyo, M. J., Vergano-Vera, E., Mendez-Gomez, H. R., Carrera, A. 
C., Abad, J. L., Gonzalez, M., de la Rosa, E. J., Vicario-Abejon, C. and de Pablo, F. 
(2006) J Cell Sci, 119, 2739-48. 
Panner, A., James, C. D., Berger, M. S. and Pieper, R. O. (2005) Mol Cell Biol, 25, 
8809-23. 
Panner, A., Parsa, A. T. and Pieper, R. O. (2006) Cell Cycle, 5, 147-50. 
Pervaiz, S., Cao, J., Chao, O. S., Chin, Y. Y. and Clement, M. V. (2001) Oncogene, 
20, 6263-8. 
Pervaiz, S. and Clement, M. V. (2002) Biochem Biophys Res Commun, 290, 1145-50. 
Pervaiz, S., Seyed, M. A., Hirpara, J. L., Clement, M. V. and Loh, K. W. (1999) 
Blood, 93, 4096-108. 
Pitti, R. M., Marsters, S. A., Ruppert, S., Donahue, C. J., Moore, A. and Ashkenazi, 
A. (1996) J Biol Chem, 271, 12687-90. 
Platzbecker, U., Ward, J. L. and Deeg, H. J. (2003) Br J Haematol, 122, 489-97. 
 185
Poh, T. W. and Pervaiz, S. (2005) Cancer Res, 65, 6264-74. 
Prasad, M. and Goyal, R. K. (2004) Am J Physiol Cell Physiol, 286, C671-82. 
Puduvalli, V. K., Sampath, D., Bruner, J. M., Nangia, J., Xu, R. and Kyritsis, A. P. 
(2005) Apoptosis, 10, 233-43. 
Radisavljevic, Z. M. and Gonzalez-Flecha, B. (2004) J Cell Biochem, 91, 1293-300. 
Ramanarayanan, J., Hernandez-Ilizaliturri, F. J., Chanan-Khan, A. and Czuczman, M. 
S. (2004) Br J Haematol, 127, 519-30. 
Ramaswamy, M., Efimova, E. V., Martinez, O., Mulherkar, N. U., Singh, S. P. and 
Prabhakar, B. S. (2004) Oncogene, 23, 6083-94. 
Ravi, R., Bedi, G. C., Engstrom, L. W., Zeng, Q., Mookerjee, B., Gelinas, C., Fuchs, 
E. J. and Bedi, A. (2001) Nat Cell Biol, 3, 409-16. 
Reinehr, R., Schliess, F. and Haussinger, D. (2003) Faseb J, 17, 731-3. 
Renz, H., Gong, J. H., Schmidt, A., Nain, M. and Gemsa, D. (1988) J Immunol, 141, 
2388-93. 
Rogers, P. A., Dick, G. M., Knudson, J. D., Focardi, M., Bratz, I. N., Swafford Jr, A. 
N., Saitoh, S., Tune, J. D. and Chilian, W. M. (2006) Am J Physiol Heart Circ 
Physiol. 
Ross, A. J., Waymire, K. G., Moss, J. E., Parlow, A. F., Skinner, M. K., Russell, L. D. 
and MacGregor, G. R. (1998) Nat Genet, 18, 251-6. 
Ruggero, D. and Sonenberg, N. (2005) Oncogene, 24, 7426-34. 
Samel, D., Muller, D., Gerspach, J., Assohou-Luty, C., Sass, G., Tiegs, G., 
Pfizenmaier, K. and Wajant, H. (2003) J Biol Chem, 278, 32077-82. 
 186
Sarbassov dos, D., Ali, S. M. and Sabatini, D. M. (2005) Curr Opin Cell Biol, 17, 
596-603. 
Sato, T., Machida, T., Takahashi, S., Iyama, S., Sato, Y., Kuribayashi, K., Takada, K., 
Oku, T., Kawano, Y., Okamoto, T., Takimoto, R., Matsunaga, T., Takayama, T., 
Takahashi, M., Kato, J. and Niitsu, Y. (2004) J Immunol, 173, 285-96. 
Scaffidi, C., Fulda, S., Srinivasan, A., Friesen, C., Li, F., Tomaselli, K. J., Debatin, K. 
M., Krammer, P. H. and Peter, M. E. (1998) Embo J, 17, 1675-87. 
Scheid, M. P. and Woodgett, J. R. (2003) FEBS Lett, 546, 108-12. 
Schneider-Brachert, W., Tchikov, V., Neumeyer, J., Jakob, M., Winoto-Morbach, S., 
Held-Feindt, J., Heinrich, M., Merkel, O., Ehrenschwender, M., Adam, D., Mentlein, 
R., Kabelitz, D. and Schutze, S. (2004) Immunity, 21, 415-28. 
Schultz, R. M., Merriman, R. L., Andis, S. L., Bonjouklian, R., Grindey, G. B., 
Rutherford, P. G., Gallegos, A., Massey, K. and Powis, G. (1995) Anticancer Res, 15, 
1135-9. 
Schulze-Osthoff, K., Ferrari, D., Los, M., Wesselborg, S. and Peter, M. E. (1998) Eur 
J Biochem, 254, 439-59. 
Shi, R. X., Ong, C. N. and Shen, H. M. (2005) Cancer Res, 65, 7815-23. 
Shin, S., Lee, Y., Kim, W., Ko, H., Choi, H. and Kim, K. (2005) Embo J, 24, 3532-
42. 
Shingu, T., Yamada, K., Hara, N., Moritake, K., Osago, H., Terashima, M., Uemura, 
T., Yamasaki, T. and Tsuchiya, M. (2003) Cancer Res, 63, 4044-7. 
Shinoura, N., Yamamoto, N., Asai, A., Kirino, T. and Hamada, H. (2000) Jpn J 
Cancer Res, 91, 1044-50. 
 187
Shiraishi, T., Suzuyama, K., Okamoto, H., Mineta, T., Tabuchi, K., Nakayama, K., 
Shimizu, Y., Tohma, J., Ogihara, T., Naba, H., Mochizuki, H. and Nagata, S. (2004) 
Biochem Biophys Res Commun, 322, 197-202. 
Siegel, R. M. (2006) Nat Rev Immunol, 6, 308-17. 
Siegel, R. M., Muppidi, J. R., Sarker, M., Lobito, A., Jen, M., Martin, D., Straus, S. 
E. and Lenardo, M. J. (2004) J Cell Biol, 167, 735-44. 
Sinicrope, F. A. and Penington, R. C. (2005) Mol Cancer Ther, 4, 1475-83. 
Slee, E. A., Adrain, C. and Martin, S. J. (2001) J Biol Chem, 276, 7320-6. 
Soto, M. A., Gonzalez, C., Lissi, E., Vergara, C. and Latorre, R. (2002) Am J Physiol 
Cell Physiol, 282, C461-71. 
Staal, S. P. and Hartley, J. W. (1988) J Exp Med, 167, 1259-64. 
Suzuki, M., Youle, R. J. and Tjandra, N. (2000) Cell, 103, 645-54. 
Tafani, M., Karpinich, N. O., Serroni, A., Russo, M. A. and Farber, J. L. (2006) J Cell 
Physiol. 
Thorburn, J., Moore, F., Rao, A., Barclay, W. W., Thomas, L. R., Grant, K. W., 
Cramer, S. D. and Thorburn, A. (2005) Mol Biol Cell, 16, 1189-99. 
Trauth, B. C., Klas, C., Peters, A. M., Matzku, S., Moller, P., Falk, W., Debatin, K. 
M. and Krammer, P. H. (1989) Science, 245, 301-5. 
Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., 
McLaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., Alnemri, E. S., 
Williams, W. V. and Doyle, M. L. (2000) J Biol Chem, 275, 23319-25. 
Tsuruta, F., Sunayama, J., Mori, Y., Hattori, S., Shimizu, S., Tsujimoto, Y., 
Yoshioka, K., Masuyama, N. and Gotoh, Y. (2004) Embo J, 23, 1889-99. 
 188
Urbano, A., Lakshmanan, U., Choo, P. H., Kwan, J. C., Ng, P. Y., Guo, K., 
Dhakshinamoorthy, S. and Porter, A. (2005) Embo J, 24, 2815-26. 
Vakifahmetoglu, H., Olsson, M., Orrenius, S. and Zhivotovsky, B. (2006) Oncogene. 
Van Geelen, C. M., de Vries, E. G. and de Jong, S. (2004) Drug Resist Updat, 7, 345-
58. 
Vaux, D. L. and Silke, J. (2005) Nat Rev Mol Cell Biol, 6, 287-97. 
Venkataraman, S., Jiang, X., Weydert, C., Zhang, Y., Zhang, H. J., Goswami, P. C., 
Ritchie, J. M., Oberley, L. W. and Buettner, G. R. (2005) Oncogene, 24, 77-89. 
Vivanco, I. and Sawyers, C. L. (2002) Nat Rev Cancer, 2, 489-501. 
Vlahos, C. J., Matter, W. F., Hui, K. Y. and Brown, R. F. (1994) J Biol Chem, 269, 
5241-8. 
Wajant, H., Gerspach, J. and Pfizenmaier, K. (2005) Cytokine Growth Factor Rev, 
16, 55-76. 
Wajant, H. and Scheurich, P. (2001) Int J Biochem Cell Biol, 33, 19-32. 
Wang, G., Ahmad, K. A. and Ahmed, K. (2006) Cancer Res, 66, 2242-9. 
Wang, M., Kirk, J. S., Venkataraman, S., Domann, F. E., Zhang, H. J., Schafer, F. Q., 
Flanagan, S. W., Weydert, C. J., Spitz, D. R., Buettner, G. R. and Oberley, L. W. 
(2005) Oncogene, 24, 8154-66. 
Wen, J., Ramadevi, N., Nguyen, D., Perkins, C., Worthington, E. and Bhalla, K. 
(2000) Blood, 96, 3900-6. 
Weydert, C. J., Waugh, T. A., Ritchie, J. M., Iyer, K. S., Smith, J. L., Li, L., Spitz, D. 
R. and Oberley, L. W. (2006) Free Radic Biol Med, 41, 226-37. 
 189
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C. P., Nicholl, J. K., 
Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A. and et al. (1995) Immunity, 
3, 673-82. 
Willis, S. N. and Adams, J. M. (2005) Curr Opin Cell Biol, 17, 617-25. 
Winters, Z. E., Ongkeko, W. M., Harris, A. L. and Norbury, C. J. (1998) Oncogene, 
17, 673-84. 
Woo, S. H., Park, I. C., Park, M. J., An, S., Lee, H. C., Jin, H. O., Park, S. A., Cho, 
H., Lee, S. J., Gwak, H. S., Hong, Y. J., Hong, S. I. and Rhee, C. H. (2004) Int J 
Cancer, 112, 596-606. 
Yonehara, S., Ishii, A. and Yonehara, M. (1989) J Exp Med, 169, 1747-56. 
Yoshikawa, R., Kusunoki, M., Yanagi, H., Noda, M., Furuyama, J. I., Yamamura, T. 
and Hashimoto-Tamaoki, T. (2001) Cancer Res, 61, 1029-37. 
Yu, L., Wan, F., Dutta, S., Welsh, S., Liu, Z., Freundt, E., Baehrecke, E. H. and 
Lenardo, M. (2006) Proc Natl Acad Sci U S A, 103, 4952-7. 
Zha, J., Weiler, S., Oh, K. J., Wei, M. C. and Korsmeyer, S. J. (2000) Science, 290, 
1761-5. 
Zhang, C., Hein, T. W., Wang, W., Ren, Y., Shipley, R. D. and Kuo, L. (2006) J Mol 
Cell Cardiol, 40, 247-57. 
Zhang, L. and Fang, B. (2005) Cancer Gene Ther, 12, 228-37. 
Zhong, W. and Oberley, T. D. (2001) Cancer Res, 61, 7071-8. 
Zong, W. X., Ditsworth, D., Bauer, D. E., Wang, Z. Q. and Thompson, C. B. (2004) 
Genes Dev, 18, 1272-82. 
Zong, W. X. and Thompson, C. B. (2006) Genes Dev, 20, 1-15. 
